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ABSTRACT 
 
 
In this study we investigated the role of unfolded proteins as a toxic insult for 
cardiomyocytes in idiopathic dilated cardiomyopathy (DCM). 
We first confirmed the presence of amyloid fibers in DCM cardiomyocytes by 
histological and ultrastructural analysis, showing their preferentially intracellular 
distribution. These molecular species seem to coexist with low-complexity β-folded 
precursors (oligomers) which in our experiments could promote increase of systolic 
Ca2+ in normal cardiomyocytes and alterations of contractility.  
Our results suggest that these molecular species trigger the overexpression of UPR 
components such as GRPs, Chop and Caspase 12. In addition we demonstrated the 
presence of interactions between presenilins (PS) and Serca2a, suggesting a 
regulatory role of these Alzheimer’s-related proteins on the Ca2+ pump. The genetic 
analysis of the presenilin genes in DCM samples identified two undescribed 
mutations in the promoter of PS1, which appeared to inhibit the expression of the 
protein.  The quantification of the presenilin levels showed a considerable decrease of 
PS2 associated with an increase of PS1.  
In order to characterize the protein(s) involved in the aggregasomes, we developed a 
series of purification protocols, which, unfortunately, did not identify a single protein 
species. As an alternative approach, we focused on the identification of transcripts 
differentially expressed in iDCM. Our study introduces an innovative three-group 
analysis in which we used amyloid samples to eliminate the interference related to the 
accumulation of unfolded peptides and deriving from the progression of HF. 
Interestingly we recognized a limited number of iDCM-specific genes, including 
nestin and DSCR1, which are normally correlated to neural development. 
In conclusion, our findings open intriguing perspectives to increase our knowledge of 
the etiology and progression of DCM. However further investigation is required to 
identify the protein(s) involved in the formation of the aggregasomes and the role of 
these molecular structures in the etiology of the disease. 
 
 8
 
 9
 
 
 
ACKNOWLEDGMENTS 
 
 
 
This work would not have been possible without the supervision of Dr. del Monte at 
Harvard Medical School, who always represented a model both as a person and as a 
scientist.  Although my presence in her laboratory was concomitant with important 
changes in her carrier, she always contributed with extraordinary effort and guidance 
in helping my development as the scientist I am today. 
 
I also owe my deepest gratitude to my supervisor at Imperial College, Prof. Harding, 
for the strong support and encouragement she offered even in the most difficult 
moments of my program.  
 
I would like also to express my gratitude to Dr. Fulci and Dr. Esteves for the valuable 
and wise advices they provided. 
 
Lastly, I’d like to thank my family for the financial support during these years and, in 
particular, my wife Erika for her strong support and for understanding the difficulties 
that often were present during the completion of my program. 
 
 
 
Davide Gianni 
 10
 11
TABLE OF CONTENTS 
 
 Page 
 
Title 1 
  
Declaration of Originality  5 
  
Abstract 7 
  
Acknowledgments 9 
  
Table of Contents 11 
  
Index of Figures  17 
  
Index of Tables 21 
  
Chapter 1: Introduction 
1.1. Heart Failure 
1.1.1 Definition 
1.1.2 Causes of Heart Failure            
1.1.3 Clinical characteristics 
1.1.4 Progression of heart failure 
 
1.2. Dilated Cardiomyopathy 
1.2.1 Definition 
1.2.2 Genetic Causes of Dilated Cardiomyopathy 
1.2.3 Clinical Characteristics of Dilated Cardiomyopathy 
1.2.4 Progression 
1.2.5 Animal Models of Dilated Cardiomyopathy 
25 
27 
27 
33 
33 
35 
 
36 
36 
38 
40 
41 
42 
 12
1.3. Heart Disease and Protein Folding 
1.4. Protein Folding 
1.4.1 The Endoplamic Reticulum: Principal Functions 
1.4.2 Response to the Accumulation of Unfolded Peptides 
1.4.3 Amyloid Aggregation and Effects of the Unfolded Proteins 
on Cell Function 
 
1.5. Systemic Amyloidosis 
1.5.1 Definition 
1.5.2 Causes of Amyloidosis 
1.5.3 Clinical Characteristics of Systemic Amyloidosis 
1.5.4 Amyloidosis in the Heart 
 
1.6. Alzheimer Disease 
1.6.1 Definition 
1.6.2 Clinical Characteristics 
1.6.3 Pathological Characteristics  
1.6.4 Proteins Involved 
Amyloid Precursor Protein (APP) 
APP Processing 
γ-Secretase 
 
1.6.5 Causes of AD 
1.6.6 Ca2+ Alteration in AD 
1.6.7 Vascular Defects Associated to AD 
 
1.7.Aims 
 
43 
45 
50 
53 
60 
 
 
66 
66 
68 
69 
69 
 
71 
71 
72 
73 
75 
75 
76 
78 
80 
83 
84 
 
86 
 
Chapter 2: Materials and Methods 
2.1 Human Samples 
2.2 Congo Red Staining 
2.3 Thioflavin-S Staining 
91 
93 
94 
94 
 13
2.4 Electron Microscopy 
2.5 Immunofluorescence    
2.6 Immunogold staining 
2.7 Laser Capture Microdissection 
2.8 Sarcoplasmic reticulum isolation 
2.9 Western blot 
2.10 Immuno-precipitation 
2.11 DADT/PAGE 
2.12 Agarose gel for protein separation 
2.13 Detergent extraction of amyloid fibers  
2.14 Oligomer immunoprecipitation and PAGE separation 
2.15 Differential sedimentation of unfolded structures 
2.16 Mass spectrometry 
2.17 Oligomer in-vitro production 
2.18 Cardiomyocyte isolation 
2.19 Cardiomyocyte contractility analysis 
2.20 Genetic analysis 
2.21 PSEN1 Promoter variant expression level evaluation  
2.22 Population analysis 
2.23 RNA Purification 
2.24 cRNA Preparation  
2.25 Hybridization 
2.26 Microarray Analysis 
2.27 Statistical Analysis and Selection of Differentially Expressed 
Probes 
2.28 Clustering and Self Organizing Maps 
2.29 Functional Analysis 
2.30 Data Validation 
2.31 Statistical analysis 
 
 
95 
95 
97 
97 
98 
99 
99 
100 
101 
102 
103 
104 
105 
105 
106 
107 
107 
109 
112 
112 
113 
115 
116 
116 
 
117 
117 
117 
119 
 
 14
Chapter 3: Identification of Protein Aggregates and Activation of the 
Unfolded Protein Response in Idiopathic Dilated 
Cardiomyopathy 
3.1 Introduction 
3.2 Results 
3.2.1 Detection of Protein Aggregates 
3.2.2 Evaluation of the Levels of AD-Related Proteins 
3.2.3 Genetic Analysis of PSEN1 and PSEN2  
3.2.4 Population Analysis 
3.2.5 Effects of Oligomers on Cardiomyocyte Function 
3.2.6 Evaluation of UPR-Component Levels 
 
3.3 Discussion 
3.3.1 Limitations 
 
 
121 
 
 
123 
126 
126 
129 
136 
139 
141 
145 
 
148 
154 
Chapter 4: Isolation and Identification of Unfolded Peptides in 
Idiopathic Dilated Cardiomyopathy 
4.1 Introduction 
4.2 Results 
4.2.1  High molecular weight protein-optimized gel separation 
4.2.2 Laser Capture Microdissection (LCM) 
4.2.3 Differential Sedimentation 
4.2.4 Detergent Extraction of Amyloid Fibers 
4.2.5 Oligomer Immunoprecipitation 
 
4.3 Discussion 
 
 
 
 
157 
 
159 
162 
162 
163 
164 
165 
167 
 
169 
 15
 
 
 
 
 
 
 
 
 
 
Chapter 5: Gene Expression Profiling of Dilated Cardiomyopathy 
5.1.Introduction 
5.2.Results 
5.2.1 RNA Extraction 
5.2.2 Microarray Preparation 
5.2.3 Microarray Analysis 
5.2.4 Group Comparison  
5.2.5 PCR Validation 
5.2.6 Gene Ontology Analysis 
 
5.3.Discussion 
5.3.1 Limitations 
 
 
 
177 
179 
182 
184 
184 
185 
187 
199 
201 
 
204 
214 
Chapter 6: Final Considerations 
6.1 Limitations and Future Directions 
 
219 
226 
Cited Literature 233 
  
  
 16
 
 
 
 
 
 17
INDEX OF FIGURES 
 
  Page 
1.1 Major modification of the contractile apparatus in HF. 30 
1.2 Principal modification in the Ca2+ handling in HF myocytes. 31 
1.3 Calcium sparks non-failing and failing cardiomyocytes. 32 
1.4 Schematic representation of the membrane depolarization in 
failing and non-failing cardiomyocytes and main ion current 
alterations. 
32 
1.5 Chest X-ray of non-failing and failing subjects. 34 
1.6 Macroscopic anomalies in DCM. 37 
1.7 Histological anomalies in failing hearts. 37 
1.8 Anatomic anomalies of DCM by echocardiography.  41 
1.9 Landscape theory of protein folding. 46 
1.10 Chaperones and chaperonines. 47 
1.11 GroES/HSP60-mediated folding. 47 
1.12 Chaperonines-mediated folding of nascent proteins. 49 
1.13 Sensor of ER stress: IRE1, PERK, ATF6. 54 
1.14 Transcriptional regulation upon ER stress. 55 
1.15 Translational regulation upon ER stress. 56 
1.16 Mechanism of action of the calreticul/mannosidase on the 
control of the protein folding in the ER. 
57 
1.17 Proteasome-mediated degradation of ubiquitinated proteins. 58 
1.18 Apoptosis mediated by UPR signaling. 59 
1.19 Xray diffraction and computer-based reconstruction of amyloid. 61 
1.20 Different aggregation states of unfolded peptides.  63 
1.21 Wnt/GSK3b Pathway and activation of b-catenin induced genes.  65 
1.22 Apoptosis cascade following the activation of p53 by the 
interaction with amyloid structures. 
65 
1.23 Classification of the different forms of amyloid based on the 
mechanisms of aggregation. 
67 
 18
1.24 Congo red staining of amyloidosis myocardium in polarized 
light. 
69 
1.25 Echocardiography and MRI images of hearts in amyloidosis 
patients. 
70 
1.26 In vivo imaging of AD. 73 
1.27 Silver staining of AD brain sample. 74 
1.28 Amyloid plaques in AD brain. 74 
1.29 Silver stain detection of accumulation of hyperphosphorylated 
tau in neurons showing the typical flame shape. 
75 
1.30 Schematic processing pathways of APP operated by  and 
 secretases. 
76 
1.31 Structure of PS1 and localization of APP-NFT in the catalytic 
site located between transmembrane helices 6 and 7 that contain 
two critical aspartate residues in position 257 and 385. 
78 
1.32 The -secretase complex and domains involved in the processing 
of APP. 
79 
1.33 Mechanism of action of different APOE isoforms on the 
clearance of extracellular amyloid. 
82 
1.34 Proposed effects of PS mutation on the InsP-3 pathway. 84 
   
2.1 Map of pGL2-basic. 110 
   
3.1 Molecular structure of Congo Red and Thioflavin-S. 126 
3.2 Congo red staining of non-failing, amyloid and DCM samples. 127 
3.3 Thioflavin-S staining. 128 
3.4 Electron microscopy analysis of DCM samples. 129 
3.5 Electron microscopy of biopsies from DCM patients. 130 
3.6 Detection of Serca2a following immunoprecipitation of PS1 131 
3.7 Presenilin1 and 2 levels in SR preps from DCM and non-failing 
hearts. 
131 
   
 19
3.8 Immunofluorescence detection of PS1 and PS2 in Non-failing, 
Alzheimer and DCM heart sections. 
132 
3.9 APP levels in non-failing and DCM hearts. 134 
3.10 Immunofluorescence detection APP on Non-failing, Alzheimer 
and DCM heart slices. 
135 
3.11 Immunodetection of Aβ in DCM samples. 136 
3.12 Analysis of the two novel mutations identified in the PS1 
promoter. 
138 
3.13 Analysis of PS1 levels in DCM samples. 139 
3.14 Immunodetection of Aβ in patients carryng mutations in the 
Presenilin genes. 
140 
3.15 Oligomer immunofluorescence. 142 
3.16 Electron microscopy analysis of DCM samples. 143 
3.17 Effects of oligomers on murine isolated cardiomyocytes. 144 
3.18 Analysis of UPR-related protein content in DCM and non-failing 
samples. 
146 
3.19 Schematic representation of the mechanisms described. 149 
   
4.1 Agarose gel electrophoresis of protein extracts. 162 
4.2 DADT-PAGE. 163 
4.3 LCM of Thioflavin-stained cardiac tissue on Leika LMD 6000. 165 
4.4 Density-based separation on sucrose gradients. 166 
4.5 Detergent extraction of amyloid material. 168 
4.6 Isolation of soluble unfolded aggregates (oligomers) by 
immunoprecipitation 
169 
4.7 Ankyirin repeat domain-containing protein 18A aminoacidic 
sequence and location of the peptide recognized by MS. 
171 
   
5.1 Bioanalyzer profiles of a representative RNA sample. 184 
5.2 Bioanalyzer profile of a representative cRNA sample before and 
after fragmentation. 
185 
 20
5.3 Amount of probe sets in each microchip image considered 
present or absent. 
186 
5.4 Distribution of altered probes in 2-group comparisons. 187 
5.5 Representation of the rationale behind the use of our three-
group analysis 
187 
5.6 Hierarchical clustering of DCM-, amyloidosis- and failing 
specific genes in the 17 samples analyzed. 
188 
5.7 qRT-PCR validation of the microchip results. 200 
5.8 Biological processes associated to the failing-specific genes 
according to the Database for Annotation, Visualization and 
Integrated Discovery (DAVID). 
203 
5.9 Biological processes associated to the amyloid-specific genes 
according to the Database for Annotation, Visualization and 
Integrated Discovery (DAVID). 
206 
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 21
INDEX OF TABLES 
 
  Page 
1.1 Main classification methods for heart failure. 27 
1.2 Molecular defects in heart failure. 29 
1.3 Gene involved in familiar forms of DCM. 39 
1.4 Human diseases related to protein unfolding. 64 
1.5 Genes mutated in the familial forms of AD. 80 
1.6 Genes considered risk factors for AD (sporadic form). 81 
  
 
 
2.1 Commercial antibodies and conditions. 96 
  
 
 
3.1 Presenilin mutations detected in iDCM patients. 137 
3.2 Population analysis of the mutations detected in DCM samples. 141 
  
 
 
4.1 Comparison between different slides for LCM applications. 164 
4.2 Aggregation index of the Thioflavin-S bands isolated from the 
linear sucrose gradient-based separation. 
167 
  
 
 
5.1 Clinical data of the samples used for the microarray analysis. 183 
5.2 Number of probes altered in each 2-group comparison. 186 
5.3 List of genes significantly different in DCM vs AMY and non-
failing samples. 
189 
5.4 List of genes showing significant difference in AMY versus DCM 
and non-failing samples. 
190 
5.5 List of genes showing significant and similar difference both in 
amyloidosis and DCM versus non-failing samples. 
192 
 22
5.6 List of biological processes and pathways associated to the 
failing process according to DAVID, Kyoto encyclopedia of 
genes and genomes (KEGG) and biocarta databases. 
202 
5.7 List of biological processes associated to DCM according to 
DAVID database. 
204 
5.8 List of biological processes and pathways associated to 
amyloidosis according to DAVID, KEGG and biocarta 
databases. 
205 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 23
 
 24
 
Introduction 
 
 
 25
 
 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 26
Introduction 
 
 
 27
 
1.1 Heart Failure 
 
1.1.1 Definition 
Cardiovascular diseases (CDV) are currently one of the most frequent causes of 
mortality in Western countries. In the UK alone every year nearly 238,000 people die 
of heart and circulatory diseases, representing about one third of the total deaths. 
Congestive heart failure (HF), in particular, is officially recorded as the cause of death 
in 11,500 cases/year. However, this number is considered a large underestimate of the 
actual deaths mainly because of the current guidelines on death certificates, which 
explicitly discourage from recording HF as the underlying cause of death  (2001).  
 
Heart failure is the end stage of several conditions of different etiologies leading to 
abnormal hemodynamics with low cardiac output and accumulation of blood 
upstream to the heart. In the long term these defects lead to a progressive deterioration 
of cardiac function and premature cardiomyocyte death.  
 
Different clinical classifications for HF have been proposed based on the diverse 
hemodynamic characteristics (Table 1.1).  
 
Table 1.1. Main classification methods for heart failure.
Criteria Classification 
Localization of the defect •  myocardial 
•  cardiac (includes valve defects) 
•  circulatory (includes hypertension, 
stenosis, anemia, hepatic and liver 
diseases) 
Localization of the ventricular dysfunction  
(only for HF due to defects within the heart) 
•  Left 
•  Right 
Type of defect •  Forward: impaired capacity of 
pumping the blood 
•  Backward: impaired filling of the 
chambers 
Alteration of the ejection fraction (EF) •  Diastolic: EF>45%  
•  Systolic: EF<45% 
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A first classification is based on the localization of cause of the inadequate cardiac 
output. According to this classification it is possible to identify three different 
categories of HF: myocardial failure, heart failure (which includes valve genetic 
defects inducing the regurgitation of blood from the ventricles to the atria) and 
circulatory failure (which derives from hypertension, anemia, aortic stenosis, fluid 
retention secondary to renal or hepatic diseases) (Braunwald, 1996).  
When the cause of the failure is within the heart, a clinical distinction is usually made 
to identify the ventricle producing the abnormal function. In most cases HF is 
determined by dysfunctions originating in the left ventricle. Right ventricle failure, 
instead, is usually secondary to the presence of congenital heart diseases or to 
conditions affecting the lung (e.g., multiple emboli, chronic lung diseases or 
pulmonary hypertension). However, the distinction between left and right failure is a 
simplification of the disease: the two ventricles work as two pumps in series, so 
impairment of one inevitably affects the correct function of the second.  
A further distinction in the HF group is related to the type of defect causing the 
dysfunction. According to what was proposed by James Hope back in 1832, a failing 
condition is referred as forward if the insufficient cardiac output is due to the 
incapacity of the ventricle to pump the blood out of the cavity or backward if the low 
output is due to defects leading to an incomplete filling of the chamber (e.g., valve 
anomalies or ventricle hypertrophy associated with reduced ventricular volume 
(Hope, 1832). 
A last classification of HF is instead based on the evaluation of the ejection fraction 
(EF). EF is defined as the ratio between stroke volume and telediastolic volume. 
According to this definition, HF is considered diastolic when the EF is preserved or 
systolic when the EF is lower than 45%. In this last case the failing condition is 
usually due to increased diastolic volume rather than reduced stroke volume.    
 
Despite the different classification proposed, HF is characterized by a series of 
common molecular defects leading to a decreased contractility of the cardiomyocyte 
including alterations in the energetic metabolism, in the contractile apparatus and in 
the molecules involved in the homeostasis of the cell (Table 1.2). Failing 
cardiomyocytes are characterized by significantly decreased contents of ATP and  
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phospocreatine, i.e., the molecule allowing a rapid diffusion of the energy produced in 
the mitochondria (Taha and Lopaschuk, 2007). The processes leading to the reduction 
of ATP include decreased capillary density and, in hypertrophy-related HF, increased 
diameter of the cardiomyocyte. These characteristics generate limited capacity of 
oxygen and nutrients to reach all the mitochondria of the cell and, therefore, produce 
impairment in the production of ATP. The effects of the decreased availability of ATP 
on the cardiomyocyte mainly affect high energy demanding processes of the cell such 
as the contractile function and homeostasis. In this condition cardiomyocytes switch 
Category Alterations 
Contractile apparatus  - Decreased  Ca2+-dependent Mg2+ ATPase activity 
- Reduction of cross bridges and slower cycling 
- Reduction of relative amount of myofibrils 
- Isoform changes (TnT, Myosin light chain) 
-  Change of phosphorylation states (TnI)  
-  Increased Ca2+ sensitivity (debated) 
Energetics -  Reduced fatty acid oxidation 
-  Increased glycolysis 
-  Decreased phosphocreatine:ATP ratio 
-  Decreased and structurally abnormal mitochondria 
-  Reduced expression of th electron transport chain components
Calcium homeostasis -  Increased cytosolic Ca2+ concentration during diastole 
-  Prolonged Ca2+ transient 
-  Progressive decrease of Ca2+ in cellular storage  
-  Decrease of L-type Ca2+ channels 
-  Impaired coupling between L-type Ca2+ and Ryanodine 
receptor 
-  Increased activity of the sarcolemmal Na+/Ca2+ exchanger 
-  Increased phospohrylation of PLN kinase 
Signal transduction -  Decrease in β-adrenoceptor 
-  Decreased activity of the adenylyl cyclase-cAMP-PKA 
pathway 
-  Increased desentization of in β-adrenoceptor 
-  Increased levels of inhibitory G-proteins 
Table 1.2. Molecular defects in heart failure. 
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their energy source from high efficiency -oxidation of fatty acids to anaerobic 
glycolysis, leading to the accumulation of lactate and, consequently, to acidosis. The 
molecular changes in the contractile apparatus affect different proteins, mainly 
causing isoform shifts leading to altered Ca2+ sensitivity and eventually depressed 
contractility (Del Monte and Hajjar, 2008). These proteins include myosin light and 
heavy chains, actin, troponin T and many cytoskeletal proteins such as titin, -actinin, 
myosin binding protein C and fibronectin. In particular, failing cardiomyocytes 
present increased content of myosin heavy chain  combined with decreased level of 
the isoform . This is associated with diminished velocity of contraction (Figure 1.1) 
(Nakao et al., 1997). 
Additional anomalies of failing cardiomyocytes involve the ion transport systems 
(Figure 1.2) (Del Monte and Hajjar, 2008). In the sarcoplasmic reticulum (SR) the 
molecules affected by the failing condition are mainly the sarco/endoplasmic 
reticulum Ca2+ ATPase (SERCA) and the ryanodine receptor (RYR). Both the 
proteins show decreased content in HF (Go et al., 1995, Currie and Smith, 1999). 
However RYR is also characterized by an impaired activity (Terentyev et al., 2008). 
This effect is probably delivered by increased distance between the cisternae and the 
T-tubule in the dyadic space, leading to a decreased sensitivity to the Ca2+ released by 
Slow MHC
Fast MHC
TnT1
TnT2
  
Figure 1.1. Major modification of the contractile apparatus in HF. HF samples show ~20% 
decrease in myofibrillar proteins, including the myosin light chain kinase (MLCK) and reduction of 
the ATPase activity. HF is also characterized by isoform transition in the myosin heavy chain 
(MHC, leading to reduced cross-bridge cycling) and troponin T (TnT, leading to decrease Ca2+ 
sensitivity). (Picture: courtesy of Dr. del Monte)  
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the L-type channels during the depolarization of the membrane (Cannell et al., 2006). 
The decreased content in SERCA is further aggravated by the action of 
phospholamban (i.e., the inibitor of SERCA), which appear increased in HF (Kiss et 
al., 1995). The combination of these events lead to impaired Ca2+ handling 
characterized by progressive decrease of the ion content in the SR reticulum 
combined to increased levels in the cytosol. According to recent studies, these 
alterations can produce effects on the calcium sparks including increased duration and 
width of the event, leading to increased RYR activity (Lindner et al., 2002). However, 
the reduced levels of Ca2+ stored in the SR counterbalance this increase leading to a 
general impairment of the E-C coupling (Figure 1.3). 
T-Tubule
Ca+2
L-Type
Ca+2 Channels
Ca+2 pump
ATP Na+
Ca+2
ATP
Ca+2 3 Na+ 2K+
Longitudinal
SR
Ryanodine
Receptors
Junctional SR
Mitochondria
Phospholamban Serca 2a
Myosin
Actin
Z Line
CSCR
PCr/ATP
Phosphatase
AC
cAMP
1 receptor
PDE
ATP
Gs Gi
K+
Transient outward
K+ channel
K+
ARK
P
 
Figure 1.2. Principal modification in the Ca2+ handling in HF myocytes. HF cardiomyocytes 
show significant alteration of many proteins related to the regulation of the Ca2+ homeostasis. In 
particular the levels of Serca2a on the sarcoplasmic reticulum, β1 receptor and K+ channels on the 
sarcolemma appear decreased. Phospolamban phosphatase, β adrenergic receptor kinase (βARK) and 
the Na+/Ca2+ exchanger are increased. Of note the dyadic space between the ryanodine receptor and 
the voltage-sensitive L-type channels is increased, leading to a decreased release of sarcoplasmatic 
Ca2+ following the arrival of action potentials. (From: del Monte, 2003) 
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Other molecular alterations in HF are related to the modification of proteins of the 
sarcolemma and, in particular, molecules involved in the ion transport system such as 
the channels Kv4.2 and Kv4.3 (Wickenden et al., 1998). The reduction of these 
channels is associated to defects in the repolarization of the membrane causing the 
prolongation of the action potential (Figure 1.4).       
Figure 1.3. Calcium sparks non-failing 
(left) and failing (right) cardiomyocytes. 
Failing cardiomyocytes are characterized 
by altered depolarization of the cell 
membrane (a and b). This defect is related 
to altered Ca2+ current in the cells and, in 
particular, to decrease amplitude of the 
incoming current (c and d) mainly due to 
different temporal distribution of Ca2+ 
sparks (e,g  and f,h).  (From: Lindner, 
2002) 
 
 
Figure 1.4. Schematic representation of the membrane depolarization in failing and non-failing 
cardiomyocytes and main ion current alterations. 
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1.1.2 Causes of Heart Failure 
 
HF is caused by diseases or other factors that affect the cardiac function. The most 
common cause of HF is coronary artery disease (He et al., 2001). This disease is 
characterized by the progressive accumulation of atheromatous plaques within the 
coronary arteries producing a total or partial block of the blood supply to the cardiac 
muscle with deleterious effects on the cardiomyocyte metabolism in the affected 
region. Depending on the extension of the region affected, the myocardial infarction 
might have a lethal outcome or it might produce permanent damage to the 
myocardium, decreasing the efficiency of the heart in the long term. 
Alternatively, in about 30% of cases, HF arises from recognizable etiologies including 
hibernating myocardium, hypertension, cardiac hypertrophy, myocarditis, congenital 
valvular defects (congenital or acquired), genetic and amyloidosis (Hare, 2004). 
 
In the remaining cases HF develops without a recognizable cause and the heart 
function progressively deteriorates and is accompanied by morphological changes of 
the heart with dilatation of the chambers and altered geometry towards a more 
spherical shape. These cases are classified as idiopathic dilated cardiomyopathy 
(DCM) and will be discussed in detail in chapter 1.2.  
 
 
1.1.3 Clinical Characteristics 
 
The different forms of HF share similar signs and symptoms despite the diverse 
etiologies that might be involved. A physical exam of HF patients shows gaining of 
weight and presence of higher body temperature (<38° C) ascites, hepatomegalia, pale 
skin, diminished pulse, systemic venous hypertension, signs of increased adrenergic 
activity such as cyanosis of the digits due to vasoconstriction and, in the heart, 
cardiomegaly, systolic murmurs, pulse alternans and gallop sounds (Braunwald, 
1996). 
 
Introduction 
 
 
 34
HF patients present respiratory problems ranging from lung congestion to pulmonary 
edema that develop as a consequence of the increased pressure in the pulmonary 
veins. This abnormality produces an increase in pressure in the alveolar capillary 
circulation that supports fluid diffusion into the extracellular space. In physiological 
conditions the excess of extracellular fluid is removed via the lymphatic vessels. 
However, when the capacity of the lymphatic system is saturated, the fluid starts 
accumulating (Figure 1.5), with consequent impairment in the O2-CO2 exchange. The 
formation of edema in the lungs is therefore associated to dyspnea that exacerbates 
during the night’s sleep: spending hours in horizontal position, in fact, induces the 
reabsorption of fluids in particular from the lower limbs, where they have been 
confined by gravity during the normal daily activities.  
 
A second characteristic of HF consists in the occurrence of fatigue and weakness. In 
the past these symptoms were related to decreased perfusion of the skeletal muscles 
associated to the decreased cardiac output. However recent reports showed the 
presence of a more complex mechanism involving a myopathy condition related to the 
accumulation of lactic acid deriving from glycolysis. According to this theory, the 
inflammation process and, in the most severe cases, apoptosis have a considerable 
role in limiting the muscular activity (Katz, 1990). 
 
Figure 1.5. Chest X-ray of non-failing and failing subjects. HF patients (right) show evidence of 
pulmonary edema due to the increase of the lung capillary pressure. (From: Davies, 2000 (left 
panel), http://ehalth.gov.mt//impaedcard/issue/issue2/0310/031 (right panel)) 
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In the most severe cases, HF can induce cerebral symptoms in addition to the 
anomalies previously mentioned (Heckman et al., 2007). Symptoms such as headache, 
confusion, memory impairment, delirium and disorientation can arise especially in 
patients affected by HF and showing the presence of cerebral arteriosclerosis plaques 
that further limit the blood flow in the central nervous system.  
 
1.1.4 Progression of heart failure 
 
HF is commonly described as a chronic disease that gradually tends to become worse, 
leading to serious impairment of the vital activities and, eventually, death.  
It is generally agreed that cardiac cells lack significant proliferative capacity due to 
their terminally differentiated nature. In fact, only a limited pool of cells with 
proliferative capacity have been identified in specific areas of the heart (Messina et 
al., 2004, Urbanek et al., 2006), which, however are not sufficient to replace the 
defective fibers and restore the original architecture and function of the organ. 
Therefore, cardiomyocytes have evolved different solutions to contrast the decreased 
cardiac output. 
 
A first group of responses is related to modifications of the geometry and structure of 
the organ to pump more blood and provide more pressure (Braunwald, 1996). In the 
first phases of heart failure the heart usually enlarges assuming either an eccentric or a 
concentric shape. The first is commonly associated with a faster degeneration of the 
organ function, while the latter provides a short-term improvement of the cardiac 
condition since it is associated to an increase in cardiomyocyte size and, therefore, to 
the increase of the contracting muscular mass of the ventricle. In the long term, 
though, the heart is not able to sustain the continuous hypertrophic stimulation and 
starts a maladaptive process involving muscle degeneration and weakening (Katz, 
1990).  
At a cellular level the progression of HF is normally associated with changes in the 
components of the extracellular matrix. During the first phases of HF there is an 
increased production of collagen III that enhances the elasticity of the tissue. When 
the condition becomes chronic the collagen III is replaced by collagen I, which is 
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characterized by a higher mechanical resistance. This response provide a stronger 
support for the contraction on one side but on the other the deposition of fibrotic 
material in the extracellular space can damage the cardiomyocytes or interfere with 
the conduction of the action potential (Weber et al., 1987, Chapman et al., 1990, 
Marijianowski et al., 1995). 
Other molecular alterations that have been related to the progression of HF are instead 
related to the neurohormonal regulation system of the heart. In fact, several groups 
reported sensitive reduction of specific adrenergic receptors (β1) in correlation with 
the severity of the disease (Engelhardt et al., 1996). This characteristic is usually 
associated with a general desensitization of the β-adrenergic cascade, which lead to 
attenuation of the stimulatory effects of the PKA signaling pathway (Ungerer et al., 
1993).  
 
Additional responses to HF are instead mediated by the circulatory system. In fact 
adequate pressure and perfusion of vital organs can be delivered by general 
vasoconstriction and by partially diverting the blood flow form less critical tissues 
(Braunwald, 1996). These mechanisms may produce beneficial effects in the short 
term; however their action in the long term is considered deleterious since they induce 
a continuous and progressively increasing need of correction by the adaptive 
mechanisms.  
  
 
1.2 Dilated Cardiomyopathy 
 
1.2.1 Definition 
 
Dilated Cardiomyopathy (DCM) consists of a group of diseases of different 
etiologies, which can affect the function of one or both ventricles. Regardless of the 
cause, DCM is characterized by ventricular dilatation, contractile dysfunction and 
often symptoms of congestive HF. DCM can arise as a consequence of coronary 
artery disease, viral and bacterial infections, genetic mutations, excessive and chronic 
alcohol consumption, prolonged exposure to toxic substances and, in some cases, 
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from pregnancy (Braunwald, 1996). In about 30% of the patients, though, the specific 
noxa cannot be identified. In these cases the condition is referred as idiopathic. 
  
DCM generally becomes manifest with a gradual and eccentric dilatation of the left 
ventricle that becomes more spherical with consequent alteration of the 
hemodynamics properties (Figure 1.6) These characteristics are usually associated 
with anomalies of the walls that become thinner and lose stiffness. In some patients 
the walls may present increased thickness compared to normal individuals. However 
this form of hypertrophy is not proportional to the severe enlargement observed in the 
ventricular cavity (Vikstrom et al., 1998).   
 
At the cellular level the major anomalies 
consists of the presence of large areas of 
interstitial and perivascular fibrosis, necrosis 
and, occasionally, cell infiltration. The 
cardiomyocytes appear in part hypertropic 
and in part atrophic (Figure 1.7) (Seidman 
and Seidman, 2001).  
 
Molecular analysis of late stage DCM-
affected hearts revealed abnormalities in 
Figure 1.7. Histological anomalies in 
failing hearts. Failing hearts present large 
areas characterized by fiber disorganization, 
necrosis and deposition of fibrotic material.    
Figure 1.6. Macroscopic anomalies in 
DCM. DCM hearts (right) present 
enlarged ventricles characterized by 
thinner walls and eccentric shape 
compared to non-failing hearts (left). 
(From: http://hubpages.com/hub/ 
Heart-Failure-Congestive-Heart-Failure 
(left panel), courtesy of Dr. del Monte 
(right panel). 
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Ca2+ handling and changes in the expression level and function of key regulatory 
proteins for excitation-contraction coupling (Davidoff and Gwathmey, 1994). More 
specifically, DCM is characterized by a deficient Ca2+ reuptake into the SR during 
relaxation that leads to a persistent high concentration of Ca2+ in the cytosol and to a 
progressive decrease of the Ca2+ stocks in the SR. This condition is further 
aggravated by the switch from the highly efficient fatty acid metabolism to 
glycolysis, that produce a decrease of the ATP produced in the cells and, therefore, 
to an impairment of the active transport of Ca2+ across the SR membrane operated 
by SERCA2a. In addition to the impairment of contractility, high levels of Ca2+ in 
the cytosol can produce activation of several critical pathways including apoptosis. 
 
1.2.2 Genetic Causes of Dilated Cardiomyopathy 
 
Genetic DCM is commonly inherited as a dominant autosomal trait, even if other 
forms of inheritance might occur (Karkkainen and Peuhkurinen, 2007). This condition 
is usually characterized by high mortality, late onset and incomplete penetrance; 
therefore in the past it has been remarkably difficult to obtain large families to 
identify candidate genes. 
The known genetic mutations related to DCM are grouped in two major categories 
depending whether the failing condition is inherited in association with other 
disorders. Most of the mutations not having a phenotype limited to the heart are 
related to skeletal muscle diseases, but also associations to hematologic, skin or 
hearing disorders exist. 
 
Familial DCM has been associated to different classes of genes by linkage analysis. 
These include genes codifying for cytoskeletal, sarcomeric, calcium handling and 
energetic-related proteins. A small portion including tafazin and EYA4 still has 
unknown biological function and, therefore, have not been classified in any of the 
categories mentioned above (Schonberger et al., 2005, Philipp et al., 2007) (Table 
1.3). 
Alterations of cytoskeletal molecules impair the capability of the cell to efficiently 
transfer the contractile force produced by the sarcomeres to the adjacent cells and to 
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the extracellular matrix. This category includes proteins such as the cardiac muscle 
LIM protein (encoded by CLP), cipher (LBD3), -sarcoglycan (SGCD) desmoplakin 
(DSP), dystrophin (DMD), telethonin (TCAP), vinculin (VCL) and desmin (DES) 
(Norgett et al., 2000, Itoh-Satoh et al., 2002, Sylvius et al., 2003, Arimura et al., 2004, 
Chang and Potter, 2005, Shimizu et al., 2005). The later, in particular, seems to be 
related to the formation of intracellular amyloid bodies when mutated.  
 
Gene Symbol Locus Additional phenotype
Lamin A/C LMNA 1p1-q21 Conduction disease, skeletal myopathy 
Cardiac troponin T2 TNNT2 1q32   
Titin TTN 2q31 Conduction disease 
Desmin DES 2q35 Skeletal myopathy 
δ-Sarcoglycan SGCD 5q33 Skeletal myopathy 
Desmoplakin DSP 6p23-q4 Wooly  hair, keratoderma 
Phospholamban PLN 6q22.1   
Metavinculin MVCL 10q22-q23 Mitral valve prolapse 
Cypher LDB3 10q22.3-
q23.2 
Left ventricular noncompaction 
Cardiac myosin 
binding protein C 
MYBPC3 11p11.2   
Cardiac muscle LIM 
protein 
CLP 11p15.1   
ATP-sensitive K 
channel 
ABCC9/SUR2 12p12.1 Arrhythmias  
β myosin heavy 
chain 
MYH7 14q12   
Cardiac actin ACTC 15q14   
α-tropomyosin TMP1 15q22   
Dystrophin DMD Xp21 Skeletal myopathy 
Tafazzin TAZ Xq28 Skeletal myopathy 
Eye absent 
homolopgus 4 
EYA4 6q23-q24 Skeletal myopathy, sensrineural hearing loss 
Teletonin TCAP 17q12 Limb girdle muscular dystrophy 
Cardiotrophin CTF1 16p11   
Potassium inwardly-
rectifying channel 
KAPT 11q24 Arrhythmias  
Unknown   2q14-q22   
Unknown   6q12-q16   
Unknown   9q13-q22   
Unknown   9q22-q31   
Unknown   19q13.2 Conduction disease 
 
Table 1.3. Gene involved in familiar forms of DCM 
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Other forms of genetic-inherited DCM are related to mutations of sarcomeric proteins. 
In particular mutations producing alterations of the Ca2+ sensitivity or of the 
mechanical properties of the sarcomere have been described in titin (TNN), cardiac 
actin (ACTC), tropomyosin (TPM1) and myosin heavy chain (MYH7) (Tesson et al., 
2000, Daehmlow et al., 2002, Chang and Potter, 2005). 
Genetic mitochondrial syndromes represent an additional cause of cardiomyopathy 
due to the high demand of energy related to the cardiac activity. This category of 
mutations have been described in genes encoding proteins such as SUR2a and KATP 
(Bienengraeber et al., 2004), i.e., two components of a K+ channel that seems to be 
related to the susceptibility to Ca2+ overload.  
 
A last category of DCM-related mutations includes the control of the calcium in the 
cytosol; in particular mutations in phospholamban (PLN) have been reported to be 
associated with a decreased sensitivity to -adrenergic phosphorylating stimuli and, 
therefore, with a decrease control on the dissociation of PLN from SERCA2a, with 
consequent increased inhibition of the activity of the pump (Schmitt et al., 2003, 
DeWitt et al., 2006, Medin et al., 2007). However, the role of PLN in the etiology 
DCM is still under debate since recent contrasting reports have appeared suggesting 
the presence of a delicate equilibrium in the fine regulation of the reuptake of Ca2+ in 
the SR. In fact, on one side the ablation of the molecule activity mediated by negative 
dominant mutants such asK3E/R14E and V49A or by small interfering RNA has been 
shown to produce enhanced contractility and capacity of rescuing from the failing 
phenotype (He et al., 1999, Minamisawa et al., 1999, Suckau et al., 2009), while on 
the other mutations such as L39stop, R14del or R9C have been related to the 
development of DCM (Haghighi et al., 2003, Schmitt et al., 2003). 
 
 
1.2.3 Clinical Characteristics of Dilated Cardiomyopathy 
 
The clinical manifestations of dilated cardiomyopathy are generally related to the 
development of HF (Chapter 1.1.3) 
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In many cases DCM can develop for months or even years in an asymptomatic form, 
but when the left ventricular function becomes severely impaired the patients are 
affected by sense of fatigue, weakness and pulmonary congestion as observed in HF. 
 
A physical examination of DCM patients usually reveals the presence of systemic 
embolism concentrated in particular in the legs and a diminished stroke volume that 
manifests as low systolic pressure and narrow pulse pressure. The auscultation of the 
heart shows gallop sounds often associated to systolic murmurs due to the 
regurgitation of the mitral valve and, in some cases, arrhythmias (Braunwald, 1996). 
Echocardiography is considered the most reliable way 
to diagnose DCM currently available. In this exam the 
heart ventricle clearly shows spherical eccentric shape 
and thin walls (figure 1.8); according to Henry et al., 
DCM is diagnosed if the following criteria are met 
(Henry et al., 1980): 
 Ejection fraction <45%; 
 Fractional shortening <25%; 
 Left ventricle end diastolic volume >112% 
compared to the average corrected for the 
age and body surface. 
 Exclusion of different ethiologies (CAD, 
alcohol consumption, congenital defects, 
etc.) 
 
 
1.2.4 Progression 
 
Dilated Cardiomyopathy is a chronic disease consisting of a progressive deterioration 
of the cardiac structure and function. The lethality of DCM is extremely high: about 
one third of the patients affected dies within 1 year from the diagnosis while the 
survival rate at 5years drops to 25% (Keogh et al., 1990). Surprisingly, the prognosis 
Figure 1.8. Anatomic anoma-
lies of DCM by 
echocardiography. (From 
http://www.drmarcelonogueira.
med.br/exames/EXAMES.htm 
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and the mortality of DCM are not associated to the ventricular function, probably 
because of the different etiologies involved in the disease.   
 
The only effective treatments currently available for DCM consist of the implantation 
of a left ventricle assisting device (temporarily) or in surgical transplant. The later, in 
particular, triples the survival rate at 5 years. However, cardiac transplant is an option 
not always available due to the difficulty of finding compatible donors. 
 
 
1.2.5 Animal Models of Dilated Cardiomyopathy 
 
The study of animal models represents an interesting opportunity for better 
understanding the molecular mechanisms associated with complex diseases and to test 
new potential therapeutic approaches. As mentioned above, DCM can develop in 
asymptomatic form for many years. Therefore the condition usually presents late 
stage features at the time of diagnosis. The high mortality rate within one year from 
diagnosis and the difficulties in obtaining patient consent further compromise the 
possibility of acquiring a significant number of samples for research purposes. 
These problems can be partially solved by focusing part of the research on animal 
models. Many animal models for DCM have been identified in the past, including 
spontaneous and transgenic/induced. 
DCM can arise spontaneously in some dog breeds such as Boxers, Doberman 
Pinschers and English Cocker Spaniels (Tidholm and Jonsson, 2005). Canine DCM 
can present two different histological phenotypes respectively characterized by fat 
infiltration in the myocardium or by the presence of wavy muscular fibers. This 
feature has been typically observed in humans as a consequence of ischemia and only 
occasionally of DCM. In some cases the canine form is characterized by the presence 
of both the histological characteristics.  
However, the use of large animals is often considered ineffective due to the 
combination of high housing costs and the long time before the disease becomes 
manifest. These reasons increase the interest of investigators towards the development 
of models that are easier to study such as rodents. Many genetic murine models of 
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DCM are currently available. Most of them have been developed after identifying the 
homolog genetic defect in humans. In other instances, instead, the molecular defect 
has been first studied in the mouse and then confirmed in patients (e.g., desmin, -
sarcoglycan, LIM). However, no clear correlations between murine and human 
defects have been yet reported for some mutations (Ross, 2002).  
 
Somatic gene transfer represents a valid alternative to obtain the expression of a 
certain gene/mutation in the heart when transgenic or knockout mice for a specific 
protein are not available. The most efficient method currently available for the in vivo 
transfer is the use of viral vectors such as adonoviral, adeno-associated, lentiviral and, 
in general, viral vectors with capacity of infecting non-dividing cells as the 
cardiomyocytes (Lyon et al., 2008). Many different delivery routes have been tested 
in the past, including systemic or intramyocardial injection. However, the most 
efficient seems to be intracoronary injection. This procedure is based on the injection 
of the viral vector downstream to the aortic valve in conjunction with temporal 
occlusion of the ascending aorta tract. A permeabilizing agent such as adenosine is 
usually administered in combination with the virus in order to facilitate the diffusion 
of the viral particles from the capillary vessels (Wright et al., 2001).   
 
A different approach for generating DCM models in rodents consists of increasing the 
afterload by creating a surgical constriction of the ascendant aortic tract. This process 
usually leads to the development of a compensating hypertrophy in the short term 
(about 3 months after the procedure) that progressively degenerates to dilated 
cardiomyopathy in about 6 months (Kleinman et al., 1978).  
 
 
1.3 Heart Diseases and Protein Folding 
 
In the last few years increasing interest has developed in the involvement of protein 
folding defects in cardiac diseases.  
In particular, data obtained in Dr. Robbins’ lab showed that mutations in genes 
encoding proteins such as desmin and A-crystallin (CryAhave dementrial effects 
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on the cardiac activity. Desmin is a protein belonging to the intermediate filaments 
involved in the architecture of the cytoskeleton. Its role in muscular cells is related to 
forming a scaffold around the Z-disks in order to connect these structures with the 
sarcolemmal cytoskeleton and with the myofibrils (Bar et al., 2004).  CryA, instead, 
is the most abundant small heat shock protein in the heart (Longoni et al., 1990). This 
molecule is focused on the maintenance of the integrity of the cytoskeleton by 
controlling the structural conformation of desmin (Wang et al., 2002, Wang et al., 
2003). Although overexpression of desmin and/or CryA has not been related to any 
pathological phenotype, mutations in the coding sequences of these proteins have 
been associated with accumulation of insoluble electron-dense cytoplasmic deposits 
composed primarily by desmin and CryAbut also involving other cytoskeletal 
proteins such as tubulin, vimentin and dystrophin. These aggregatescan lead to 
restrictive, hypertrophic or dilatative cardiomyopathies in the long term (Wang et al., 
2002). In particular, the substitution of an arginine residue with a glycine in position 
120 of CryAseems to produce a dominant autosomal syndrome characterized by 
evidences of HF and, eventually, premature death in transgenic mice. As 
confirmation, the abrogation of the expression of CryAR120G decreases the content of 
desmin aggregates and improves the viability of the animals (Sanbe et al., 2005). 
Additional studies also showed that these transgenic mice as well as other models of 
desmin-related myopathies are characterized by alterations of the unfolded protein 
response and of the ubiquitin-mediated protein degradation (Chen et al., 2005, Liu et 
al., 2006).  
 
Similar anomalies were also observed in some familiar forms of hyperthrophic 
cardiomyopathy (FHCM): recent reports showed that some of the FHCM-related 
cardiac myosin binding protein-C (MYBP-c3) mutations induce preferential 
degradation of the aberrant protein by the proteasome (Sarikas et al., 2005, Bahrudin 
et al., 2008, van Dijk et al., 2009). This process seems associated with changes in the 
conformational state of the protein. In fact Bahrudin et al showed that the preference 
of the proteasome for the mutated protein can be drastically altered only when a single 
amino acid located in a critical region is replaced with another with significantly 
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different chemical properties (Bahrudin et al., 2008). According to the author the 
whole process leads to saturation of the proteasome system with the aberrant 
polypeptide and to consequent accumulation of all the other cellular proteins needing 
proteosomal degradation. 
 
Interestingly, the hypothesis of the impaired proteosome activity has been validated in 
animal models of other cardiovascular diseases such as pressure-overload (Tsukamoto 
et al., 2006) and myocardial ischemia (Powell et al., 2005). 
 
A detailed picture of the quality control of protein folding and of the toxicity deriving 
from the accumulation of aberrant proteins will be discussed in detail in the next 
section. 
 
 
1.4 Protein folding  
 
The structural and catalytic functions of proteins are performed by creating 
sophisticated three-dimensional structures in which specific chemical groups interact 
with each other and with the surrounding environment. Differently from nucleic acids 
(in which the biological function is solely depending on the nucleotide sequence), 
protein function is related to both their amino acidic sequence and their conformation. 
In fact, the specificity of a particular region in interacting with a particular molecule 
derives from the compatibility between the sterical structure and the chemical 
properties.  
 
The process of folding is totally dependent on the thermodynamic properties of the 
polypeptidic chains involved with no participation of kinetics (Govindarajan and 
Goldstein, 1998). The final (and active) three-dimensional structure of a protein, in 
fact, is solely related to the lower and most stable energy level possible for the 
polypeptide, which is generally reached when compatible groups are interacting with 
each other. For example, hydrophobic residue-enriched regions (i.e., mainly 
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composed by aa such as leucine, valine, methionine and phenylalanine) have the 
tendency to fold inwards the centre of the protein to maximize their distance from the 
aqueous environment. Instead, charged residues and the amino and carboxyl unpaired 
groups at the two ends of the polypeptide chain are usually external and interacting 
with water. It has been calculated that for a 100 aa peptide the total number of energy 
states is in the 105 range, even if the total number of configuration patterns related to 
biological activity have been estimated to be 103-104 (Lehninger, 1993). Small 
proteins can usually assume independently their correct folding. Large polypeptides, 
instead, can fold during the translation process assuming intermediate structures that 
may be thermodynamically stable, although they do not represent the lowest energy 
state possible (Young et al., 2004). The recovery of the functional conformation 
normally requires an energy-consuming step to unfold the molecule. Therefore these 
states are called energy pits (Figure 1.9). In order to prevent dissipation of large 
amounts of ATP to resolve energy pits, eukaryotic cells and prokaryotic organisms 
have developed a class of proteins responsible for the control of the protein folding 
called chaperones. Chaperones are defined as “a family of unrelated classes of 
proteins that mediates the correct assembly of other polypeptides, but are not 
themselves components of the final functional structure” (Ellis and van der Vies, 
1991).  
Figure 1.9. Landscape 
theory of protein folding. 
Different energetic 
conformation are available in 
proteins. The functional is 
usually characterized by the 
lower and most stable energy 
content. (From: Herczenik, 
2008) 
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Figure 1.11. GroES/HSP60-
mediated folding. Incorrectly 
folded proteins are isolated from the 
cytosol and refolded in the lumen of 
the chaperon. The dissolution of the 
incorrect folding requires energy 
that is provided by ATP hydrolysis. 
(From: Alberts, Molecular biology 
of the cell, 4th Ed.) 
 
 
These proteins are grouped into two families respectively called molecular chaperones 
and chaperonins and related to two different functions.  Chaperonins are directly 
involved in folding polypeptide chains; instead molecular chaperones seem to be 
related to the stabilization of the high energy intermediates of nascent proteins and to 
the prevention of energy pits (Figure 1.10)(Horwich et al., 2007).  
Chaperonins are structurally characterized by the presence of two identical monomers 
forming a barrel-like structure (Carrascosa et al., 2001, Young et al., 2004). This can 
accommodate the unfolded protein in the lumen and promote the correct folding by 
isolating the protein from the external environment. The energy required for this 
process is delivered by the hydrolysis of a molecule of ATP. Examples of chaperonins 
are heat shock protein (Hsp) 60 in eukaryotes and GroEL in the prokaryotes (Figure 
1.11).  
Molecular chaperones are instead mostly represented by the Hsp70 family. These 
Figure 1.10. Chaperones and 
chaperonins. Chaperones 
(Hsp70) have an important role 
in stabilizing the nascent 
peptides inhibiting the 
formation of three-dimensional 
incorrect conformations. 
Chaperonins (TCiP), instead, 
promote the folding of the 
protein by isolating the 
unfolded peptide in their lumen. 
Both chaperone and 
chaperonins activities are ATP-
dependent. (From: Lodish, Cell 
biology, 4th Ed.) 
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proteins are characterized by the presence of hydrophobic regions which are exposed 
following the hydrolysis of ATP into ADP+Pi. These regions bind unfolded peptides 
at high specificity and promote folding into their functional state. The correctly folded 
peptides are then released following a structural re-arrangement of the chaperone 
caused by the substitution of ADP with ATP (Saibil, 2008).  
A third group of chaperone proteins has been identified in relationship to the control 
of the architecture of the cytoskeleton rather than of the folding process. These 
peptides include -B crystallin and Hsp27, which respectively stabilize the actin-
desmin interaction and the aggregation of filaments of actin (Dillmann, 1999).    
Chaperones have an important role in determining the kinetics of the reaction besides 
adjuvating the folding of proteins into the most thermodynamically favorable energy 
state: if the folding process were merely associated to a combinatorial event, the 
correct folding for a 100 aa protein would require up to several hours. Instead in the 
cells chaperones reduce the duration of this process to micro- or milliseconds 
(Lehninger, 1993). 
  
Chaperones are highly conserved proteins that are largely distributed throughout the 
entire cell and its organelles. Their activity is highly important in several 
physiological processes (Ellis and van der Vies, 1991) such as: 
1. Protein synthesis: during the elongation of the polypeptidic chain, the free 
amino-terminal region can fold in non-efficient structures. 
2. Protein transport between cellular compartments: the protein involved in the 
biochemical and structural functions in the organelles (with the exception of 
few peptides that are locally produced in the mitochondria) are produced in the 
cytosol and then transported through the lipid membrane of the organelles. 
The translocation of the protein is usually achieved if the protein has a linear 
structure. After the transport, the protein requires the presence of local 
chaperons to re-estabilish the correct folding structures. 
3. Stress response: extreme variations in pH, temperature, ion concentration or 
the presence of free radicals produce conditions that can irreversibly alter the 
conformation of the proteins. 
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4. Protein-protein interaction. During normal physiological reactions, some 
oligomeric complexes change their structure and transiently expose some 
domains normally involved in protein-protein interaction. 
 
In some cases the correct folding for particular proteins is achieved through the 
interaction of different chaperones and co-chaperones. In particular the activity of 
Hsp70 is usually performed in combination with a different chaperone called Hsp90  
(Figure 1.12) (Young et al., 2001, Pearl and Prodromou, 2006). Hsp90 is a 
homodimer in which each subunit is characterized by an ATP-binding site on the 
The immunophilin 52-kDa FK506-binding protein (FKBP52) functions in HSP90-dependent 
steroid-receptor folding, together with the HSP90 co-chaperone p23. UNC-45 functions with 
HSP90 in myosin folding. CDC37 is unrelated to the TPR-clamp cofactors and works with HSP90 
in the folding of certain kinases. TPR-clamp interactions also recruit HSC70 and HSP90 for protein 
sorting. Some mitochondrial precursor proteins are delivered by HSC70 and HSP90 to the import 
receptor 70-kDa translocase of the outer mitochondrial membrane (TOM70) for import into the 
organelle. The U-box ubiquitin-ligase CHIP (carboxyl terminus of HSC70-interacting protein) 
contacts HSC70 or HSP90 to attach polyubiquitin onto substrate polypeptides, which results in 
these substrates being targeted to the proteasome for degradation. Finally, the HSC70-regulatory 
co-chaperone BCL2-associated athanogene-1 (BAG1) can assist in targeting the HSC70-bound 
polyubiquitylated polypeptides to the proteasome. Ub, ubiquitin. (From: Young, 2004) 
Figure 1.12. Chaperonins-
mediated folding of nascent 
proteins. Newly synthesized 
polypeptides are bound by the 
70-kDa heat-shock cognate 
protein (HSC70), which 
works together with its 40-
kDa heat-shock protein 
(HSP40 or HDJ1) or HDJ2 
cofactor. Some polypeptides 
fold with the assistance of 
HSC70, whereas others are 
passed to the 90-kDa heat-
shock protein (HSP90). The 
tetratricopeptide repeat 
(TPR)-clamp co-chaperone 
Hsp-organizing protein 
(HOP) organizes the transfer 
of animal steroid-receptor 
proteins from HSC70 onto 
HSP90 and might function 
similarly for other substrate 
polypeptides. Other TPR-
clamp co-chaperones (shaded 
pink) help HSC70 and HSP90 
in various functions.  
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amino terminus. The presence of binding produces conformational rearrangements of 
the structure of Hsp90 that promote the retention of unfolded proteins and the 
conversion of their three-dimensional conformation. The mechanism involved in the 
activity of Hsp90 is not completely understood, but it seems to involve the co-
participation of different co-chaperones such as HOP (that allows Hsp90 interaction 
in the Hsp70 machinery), p23, (that stabilizes the Hsp90 homodimer), and Hsp40  
(that participates in the interaction between HSC70 and the unfolded protein).  
The activity of the Hsp70-90 complex can be modulated by interaction with several 
co-chaperones. For example, mitochondrial proteins are relocated into the 
mitochondria by the cytosolic Hsp70-90 complex only when linked to TOM70, i.e., a 
protein located on the external membrane of the organelle acting as an import receptor 
(Young et al., 2004).  
In other cases the Hsp70-90 complex is involved in the degradation of the unfolded 
protein by promoting its ubiquitination and the consequent proteolysis in the 
proteasome. The co-chaperones involved in this activity are CHIP and BAG1 
(Hohfeld and Jentsch, 1997, Connell et al., 2001).     
 
 
1.4.1 The endoplasmic reticulum: principal functions 
 
The endoplasmic reticulum (ER) consists of an extensive network of tubules and 
cisternae, which is present in all the eukaryotic cells and extends throughout the 
cytosol forming a series of convolutions supported by the cytoskeleton (Wolfe, 1993). 
The main role of ER consists in the production and post translational modification of 
protein for the ER itself, the cytosolic membrane, the cytoplasmic organelles 
(including the Golgi apparatus, lysosomes, endosomes, secretory vesicles) and for 
secretion. It has been calculated that about one third of the total proteins produced in 
an average cell are processed in the ER. In order to undergo the post-translational 
modification and, ultimately, to perform their function, all the proteins entering the 
ER need to assume a correct three-dimensional conformation. This step is monitored 
by complex mechanisms of control. The most common process involves the action of 
a class of proteins called lectins, including calreticulin and calnexin (Ellgaard and 
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Helenius, 2003). These chaperones are specialized in folding glycosylated protein. 
Two distinct forms of glycosylation are available in the cell, O-glycosylation and N-
glycosylation, even if only the latter is processed in the ER. During this process a 
preformed precursor oligosaccharide (composed of N-acetylglucosamine, mannose, 
and glucose and containing a total of 14 sugars) is transferred to the amide group of 
aspargine by the oligosaccharyl transferase. This enzyme is located on the internal 
side of the ER membrane and directly glycosylates peptides during the ribosomal 
synthesis and translocation through the membrane. This reaction is facilitated by a 
molecule of dolichol lipid anchoring the oligosaccharide in its activated form (i.e., 
linked through a high-energy phosphate bond) to the membrane in proximity of the 
oligosaccharyl transferase.  
After N-glycosylation the polysaccharide chains are trimmed in different steps leading 
to complex glycosylation patterns. This step, in particular, seems to be related to the 
lectin-mediated control of the correct folding. Initially the precursor oligosaccharide 
terminates with three residues of glucose. During the maturation, these molecules are 
progressively removed. If the protein is not correctly folded, it is retained in the ER 
by calnexin and calreticulin and one molecule of glucose is added to the 
polysaccharide chain by the (UDP)-glucose:glycoprotein glucosyltransferase 
(UGGT). This procedure promotes a new folding attempt.  
 
The lectin complex can perform its folding assistance activity only on glycosylated 
proteins. The folding of most of the other peptides in the ER, instead, is processed by 
by GRP78 and GRP94, respectively the analog of the cytoplasmatic Hsp70 and Hsp90 
(Argon and Simen, 1999, Ni and Lee, 2007).  
Different proteins including Grp170 and the co-chaperone ERdj3 seem to be involved 
in the formation of the Grp78-94 complex (Meunier et al., 2002, Ni and Lee, 2007). 
However the specific molecular mechanisms are still unclear. 
A third folding pathway in the ER is associated to the activity of the small heat shock 
protein hsp47 and is specifically involved in the processing of procollagen (Hirayoshi 
et al., 1991, Natsume et al., 1994). 
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In many proteins the stability of the three-dimensional structure after folding is 
significantly increased by the oxidative environment of the ER lumen and by the 
action of protein disulfide isomerase (Weissman and Kim, 1993). This enzyme 
catalyzes the oxidation of the sulfhydryl groups present on cysteines and form strong 
covalent bonds between two non-adjacent residues.  
 
All the processes described to this point involving the translocation and the folding of 
the proteins and are generally confined to the rough ER. The portion of the ER 
lacking ribosomes, instead, is called smooth ER and is specialized in different 
activities. The smooth ER is mainly related to the export of the mature proteins to 
their relative final location by a system based on vesicles. Moreover it is a critical 
location for production and exportation of membrane lipids such as phospholipids, 
cholesterol and ceramide (Wolfe, 1993). 
 
In particular cell types the smooth endoplasmic reticulum acquires specific functions 
related to the activity of the cell. For example, organs that produces large amounts of 
steroid hormones such as the testis and ovaries are characterized by a significantly 
extended ER network. In hepatocytes, instead, the ER has a major role in producing 
proteins secreted in the blood. In addition the ER of hepatocytes is specialized in the 
metabolism of lipids, including the detoxification of potentially harmful lipophilic 
molecules through the cytochrome P450 pathway. 
Myocytes, instead, contain a specialized form of endoplasmic reticulum called 
sarcoplasmic reticulum (SR). The SR is the most important Ca2+ storage in the cell. 
When a contraction signal reaches the cell, the SR is triggered to release large 
amounts of the ion into the cytosol. This allows the interaction of the actin and 
myosin fibers and, consequently the contraction.     
 
It is interesting to observe that most of the chaperones operating in the ER are 
sensitive to oscillations of the Ca2+ concentration. In normal conditions the total 
concentration of Ca2+ in the myocyte SR is in the mM range, but it can change 
significantly during the contraction/relaxation cycles. In order to maintain the Ca2+ 
concentration always at a level compatible with the correct function of the proteins in 
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the lumen, the calcium cycling activity and the post-transaltional modification 
machinery are located in different regions of the SR (Papp et al., 2003). In addition 
the SR evolved molecular buffers such as calsequestrin, which bind the cation and 
keeps the level of free Ca2+ constant. 
 
 
1.4.2 Response to the accumulation of unfolded peptides      
 
In normal conditions about one third of the protein translocated into the ER cannot 
acquire a correct folding. Therefore in an average cell large amounts of proteins are 
exposing domains normally not present on the protein surface. In some cases these 
domains may be able to unspecifically interact with functionally correct proteins, 
leading to interference to the normal activities of the cell.  
For this reason, the control of the level of unfolded proteins is an issue of considerable 
importance. In the SR/ER this function is achieved through the combination of three 
different pathways activated by three different sensors/effectors: the activating 
transcription factor 6 (ATF6), the inositol-requiring enzyme 1 (IRE1) and the PRK-
associated kinase (PERK) (Zhang and Kaufman, 2006). The events triggered by the 
activation of these three peptides are commonly referred to as unfolded protein 
response (UPR). The UPR consists is a series of modifications in different cellular 
compartment leading to alterations of the nuclear transcription, alteration of the 
protein synthesis, increased catabolism of the proteins and, when the excess of 
unfolded proteins cannot be resolved, to apoptosis (Zhao and Ackerman, 2006).   
ATF6, IRE1 and PERK are transmembrane molecules located across the ER 
membrane. In absence of unfolded proteins, the luminal domains of these proteins 
bind Grp78, preventing the activation of the UPR (Figure 1.13). Several events can 
trigger the dissociation of Grp78 from the UPR molecular sensors, including large 
presence of newly synthesized peptides or the persistence of conditions inducing the 
denaturation of existing peptides (e.g., temperature increase, altered ion 
concentration). Grp78 binds the unfolded peptides immediately after the separation 
from IRE1, ATF6 and PERK, protecting the hydrophobic domains and inhibiting their 
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export of the polypeptidic chains from the ER. This process leads to the 
homodimerization of IRE1 and PERK and their concomitant activation achieved by 
autophosphorylation. ATF6, instead, is translocated to the Golgi apparatus where it is 
processed into its active form.  
 
The IRE1 pathway is the best characterized of the three, mainly because of several 
studies conducted on its yeast homolog, Ern1p (Zhang and Kaufman, 2006). The 
cytosolic domain of IRE1 is characterized by an intrinsic RNAse activity that is 
activated after the ER-stress induced-homodimerization and phosphorylation (Figure 
1.14) (Shamu and Walter, 1996). The active molecule specifically recognizes the 
mRNA for XBP1 (HAC1 in yeast) and induces splicing of a 26 nucleotide-long 
internal sequence (Yoshida et al., 2001, Calfon et al., 2002, Back et al., 2005). This 
event produces a translational frame shift of the 3’ region of the mRNA that leads to 
the production of the active XBP1 molecule. XBP1 has been characterized as a potent 
transcription factor acting at nuclear level. After the cytosolic synthesis, the molecule 
is translocated to the nucleus of the cell where it binds a sequence commonly found in 
the promoters of UPR activated genes and, in particular, of ER-specific chaperones 
such as calreticulin, GRP94 and Grp78. This sequence, called ERSE (endoplasmic 
reticulum stress response element), is characterized by a minimal core 
(CCAAT(N9)CCACG) that interacts with XBP1, allowing the assembly of the 
transcription apparatus (Yoshida et al., 1998).   
Figure 1.13. Sensor of ER stress: 
IRE1, PERK, ATF6. IRE1, PERK, 
ATF6 are transmembrane proteins 
located on the membrane of the 
endoplasmic reticulum. In absence of 
unfolded proteins these molecule are 
kept in inactive form by binding 
BiP/GRP78. (From Zhang, 2004) 
 
 
Introduction 
 
 
 55
 
ERSE sequences represent a target also for ATF6 (Yoshida et al., 1998). ATF6 is 
normally present in the SR/ER membrane as a 90 kDa (ATF6α) or 110 kDa (ATF6β) 
inactive protein (Figure 1.14) (Haze et al., 1999). The dissociation of Grp78 allows 
the relocation of the molecule to the Golgi apparatus through vesicular trafficking, 
where it is cleaved by site-1 protease (S1P) and site-2 protease (S2P). This event 
induces the release of a 50 kDa cytosolic fragment that migrates to the nucleus, where 
it combines with the transcription factor NF-Y (Yoshida et al., 2000). This complex 
recognizes ERSE sequence in the genome, producing activation of genes encoding ER 
chaperones and other proteins related to the maturation and degradation of peptides. 
Of note, recent studies reported that in some cases the transcription of ATF6 is 
regulated by the activity of XBP1, and, indirectly, by IRE1 (Lee et al., 2003).  
 
The activation of the IRE1 and ATF6-mediated responses requires the transcription 
and translation of new sets of proteins. It has been shown that the whole process may 
require up to one or two hours. PERK activity, instead, is mainly achieved through 
Figure 1.14. Transcriptional 
regulation upon ER stress. 
Upon accumulation of 
unfolded protein in the ER 
lumen, BiP release from 
IRE1 permits dimerization to 
activate its kinase and RNase 
activities to initiate XBP1 
mRNA splicing. Spliced 
XBP1 mRNA encodes a 
potent transcription factor 
that binds to UPRE or ERSE 
sequences in many UPR 
target genes. BiP release from 
ATF6 permits ATF6 
transport to the Golgi 
compartment where full-
length ATF6 (90kDa) is 
cleaved by S1P and S2P 
proteases to yield a cytosolic 
fragment (50kDa) that 
migrates to the nucleus to 
activate transcription of UPR 
responsive genes. U-Pr, 
unfolded protein. (From 
Zhang, 2006) 
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modulation of the protein synthesis apparatus in the cytosol, producing effects within 
minutes (Kaufman, 2004). 
The activation of PERK is achieved similarly to what observed in IRE1: after the 
dissociation of Grp78, two molecules of PERK combine forming a homodimer in 
which they activate each other by autophosphorylation (Figure 1.15) (Bertolotti et al., 
2000). The cytosolic domain of active PERK interacts with the soluble protein 
elongation factor eIF2α, inducing its phosphorylation. In the non-phosphorylated form 
eIF2α is a key protein in the initiation of the translation process since it stabilizes the 
ribosome-tRNAmet-methionine interaction (Kaufman, 2004). The phosphorylation of 
eIF2α on Ser51 mediated by PERK produces a general destabilization of the protein 
synthesis apparatus, leading to a reduced protein production (Harding et al., 2000a, 
Harding et al., 2000b). However, a limited group of proteins can be translated 
efficiently in presence of phosphorylated eIF2α (P-eIF2α). These proteins are usually 
characterized by the presence of multiple 5’ untranslated open reading frames (uORF) 
on the mRNA sequence. uORFs prevent the translation of the codifying ORF in 
normal conditions by inducing the release of the ribosome from the nucleic acid. In 
ER stress conditions, instead, the P-eIF2α promotes the activity of the ribosome on 
these ORF (Kaufman, 2004). An example of this complex regulation mechanism 
derives from the activating transcription factor 4 (ATF4) that is transported in the 
nucleus after translation (Harding et al., 2000b). Here it induces the transcription of 
genes involved in the amino acid metabolism and transport, oxidation-reduction 
reactions and ER-stress induced apoptosis (Harding et al., 2003). 
Figure 1.15. Translational 
regulation upon ER stress. Upon 
accumulation of unfolded protein 
in the ER lumen, PERK is 
released from BiP, thus permitting 
its dimerization and activation. 
Activated PERK phosphorylates 
eIF2  to reduce the frequency of 
the mRNA translation initiation in 
general. However, selective 
mRNAs, such as GCN4 or ATF4 
mRNA, are preferentially 
translated in the presence of 
phosphorylated eIF2 . U-Pr, 
unfolded protein. (From Zhang, 
2006)
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A second mechanism included in the UPR consists in the activation of the catabolic 
pathway. This process is called ER-associated degradation (ERAD) and is mediated 
by several proteins expressed under the control of the IRE1-XBP1 pathway (Werner 
et al., 1996, Zhao and Ackerman, 2006). In particular the ERAD is generally triggered 
when continuous accumulation of unfolded and partially folded proteins is not 
balanced by a proportional increase of chaperones to stabilize their unfolded state.  
Several mechanisms are involved in the recognition of the aberrant proteins to be 
degraded, including the recognition of exposed hydrophobic pathways, unpaired 
cysteines or immature glycan chains. 
Immature glycoproteins are addressed to the ERAD by the α-mannosidase, which acts 
on the oligosaccaridic chains removing the terminal four sugars (Molinari et al., 2003, 
Oda et al., 2003) (Figure 1.16). This enzyme doesn’t have specificity for unfolded 
proteins; in facts it interacts stochastically with any protein present in the ER (Wang 
and Hebert, 2003). Therefore the probability of a particular protein to be processed by 
α-mannosidase is directly proportional to the duration of its stay in the ER, which is 
usually prolonged in proteins incurring multiple folding attempts. After this step the 
protein binds calnexin and the endoplasmic reticulum degradation-enhancing 1,2 
mannosidase-like protein (EDEM). This complex is then translocated across the 
Figure 1.16. Mechanism of action of the calreticul/mannosidase on the control of the protein 
folding in the ER. Unfolded glycopeptides are kept in the ER by the calreticulin (CRT)/ glucose 
transferase (UGGT) system until they reach the correct conformation. In particular conditions, i.e. 
when all the glucose on the oligosaccharide chain are removed, the glycoprotein becomes substrate 
of the a-mannosidase. The removal of a molecule of mannose induce the binding of the peptide 
with EDEM and the export to the cytoplasm. (From: http://www.bijvoet-center.nl/cpc/ 
research/CNX) 
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membrane with a process that involves a channel –probably Sec61 operating in 
reverse (Sitia and Braakman, 2003) mode or derlin-1- with the co-participation of p97 
ATPase (Ye et al., 2004) (which provides the energy necessary for the complete 
unfolding of the protein) and other proteins that prevent the backsliding of the 
polypeptide into the ER (UBX (Schuberth and Buchberger, 2005), Rad23p (van Laar 
et al., 2002) and Dsk2p (Medicherla et al., 2004)). The protein sequence entering the 
cytosol is immediately covalently linked to preformed chains of ubiquitin by the 
ubiquitin protein ligase E3 (Glickman and Ciechanover, 2002). The ubiquitinated 
polypeptide is then delivered to the cytosolic apparatus for protein degradation, i.e., 
the proteasome. 
The proteasome is a large cytosolic complex (2 MDa) composed by two multimeric 
subunits, 19S and 20S, respectively involved in the regulation of the proteasome 
function and in the proteolytic activity (Voges et al., 1999) (Figure 1.17). The 20S 
complex is formed by 28 subunits encoded by 14 different genes and arranged in four 
axially stacked heptameric rings. The central lumen of the cylindrical structure of the 
20S represents the active site and it is delimited by two copies of each of the 
proteolytic subunits (Groll and Huber, 2003) (β1, β2, β5). All the substrates reach this 
region through two 13 Å pores located at both the ends of the barrel (Lowe et al., 
1995). The activity of the 20S subunit is regulated by the presence of one or two 19S 
subunits that work as gates for the catalytic site (Goldberg, 2003). The 19S complex is 
Figure 1.17. Proteasome-mediated 
degradation of ubiquitinated proteins. 
Ubiquitinated proteins interact with the 
19S subunit of the proteasome inducing the 
opening of the lid of the complex and the 
linearization of the peptide. This allows the 
degradation of the protein in the 20S 
subunit lumen. (From Hermann, 2007) 
 
20 S
19 S
19 S
Ubiquitinated
proteins
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formed by 20 subunits responsible for different activities including binding the 
incoming protein, dissociating the ubiquitin chain, opening the catalytic core, 
dissolving the three-dimensional structure.  
 
In some cases the combination of the control of the transcription and the ERAD-
mediated proteolysis is insufficient to resolve the ER-stress induced by the overload 
of unfolded proteins (Zhao and Ackerman, 2006). Consequently the cell activates 
three different apoptotic pathways respectively initiated by IRE1, caspase 12 and 
PERK (Figure 1.18) (Nakagawa et al., 2000, Schroder and Kaufman, 2005, Xu et al., 
2005). IRE1 can bind the c-Jun-N-terminal inhibitory kinases (JIK) upon dissociation 
form Grp78. This allows the recruitment of the cytosolic adapter TRAF2 to the 
Figure 1.18. Apoptosis mediated by UPR signaling. Upon ER stress, activated IRE1 can recruit 
JIK and TRAF2 to activate ASK1 and JNK, leading to activation of mitochondria/Apaf1-dependent 
caspases. Upon activation of the UPR, c-Jun-N-terminal inhibitory kinase (JIK) release from 
procaspase-12 permits clustering and activation of procaspase-12. Caspase-12 activates procaspase-
9 to activate procaspase-3, the executioner of cell death. Activated PERK phosphorylates eIF2 , 
that enhances translation of ATF4 mRNA. ATF4 induces transcription of the pro-apoptotic factor 
CHOP, that can inhibit expression of apoptotic suppressor BCL2. CSP, caspase; CYTO C, 
cytochrome C. (From: Zhang, 2006)  
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external side of the ER membrane. This molecule activates the apoptosis-signaling 
kinase 1 (ASK1) that induce the activation of the JNK protein kinase and of the 
mitochondria/APAf1-dependent caspase cascade (Nishitoh et al., 2002).  
Caspase 12, instead, is present in the cell as a transmembrane protein of the ER that is 
activated directly by ER stress. Active caspase 12 induces activation of the cytosolic 
caspase 3 (i.e., the actual effector of the apoptotic process) by activating caspase 9 
(Morishima et al., 2002). 
The third apoptotic cascade induced by ER-stress is related to the action of ATF4, a 
transcription factor induced by the PERK/eIF2α pathway (Harding et al., 2000a, 
McCullough et al., 2001, Ma et al., 2002). ATF4 induces the transcription of CHOP, a 
strong proapoptotic transcription factor that opposes the antiapoptotic activity of Bcl2 
by inhibiting its transcription (Maytin et al., 2001).  
 
   
1.4.3 Amyloid aggregation and effects of the unfolded proteins on cell function 
 
Unfolded proteins have a tendency to aggregate forming structures with different 
levels of complexity. Three main different models have been proposed to represent 
the mechanics of this process: the cross spine, the end to end and the domain 
swapping models (Bennett et al., 2006).  
 
The end to end mechanism is characterized by the capacity of preserving the 
functional folding of the protein. The aggregates progressively form sequentially to 
the establishment of hydrogen bounds between the monomers. In general this event is 
triggered by a single point mutation that alters the properties of the surface of the 
protein. Typical examples of polypeptides aggregating following the end to end model 
include superoxide dismutase 1 (Elam et al., 2003), hemoglobin (Marenduzzo et al., 
2006) and transthyretin (Correia et al., 2006), leading respectively to amyotrophic 
lateral sclerosis, sickle cell anemia and transthyretin-related amyloidosis. 
 
Domain swapping has been mainly related to proteins characterized by two 
structurally different regions interacting with each other and separated by a random-
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coiled loop. Domain swapping consists in the formation of aggregates deriving from 
the interaction of a domain with the complementary domain of an adjacent molecule 
of the same protein (Bennett et al., 2006). This process can be limited to two 
molecules swapping the domains to each other (close end domain swapping) or can 
involve a series of molecules forming a chain (open end domain swapping). The 
process is generally not related to any modification of the molecular interactions 
between the subunits of the protein and doesn’t require any formation of new 
hydrogen bonds or hydrophobic interactions.  
 
The cross spine model, instead, induces the formation of the highly ordered structure 
that aggregates forming macroscopical deposits called amyloid plaques. In this model 
adjacent -sheets belonging to different polypeptidic chains are linked by 
intermolecular hydrogen bonds. Electron microscopy analysis of these structures 
revealed a long unbranched filament pattern with a diameter ranging from 65 to 130 Å 
(Sipe and Cohen, 2000). In addition X-ray crystallographic diffraction studies showed 
that the structure is characterized by the presence of 2 main reflection signals deriving 
respectively from the interstrand and the intersheet distances, respectively 
corresponding to about 4.8 Å and 10.7 Å (Stromer and Serpell, 2005) (Figure 1.19). 
Although the orientation of adjacent β-sheets (parallel vs. antiparallel) is still debated, 
the β-sheeted structure is recognized as a common feature of all the amyloidogenic 
 Figure 1.19. Xray diffraction and computer-based reconstruction of amyloid. 
Cristallography studies (a) shows the presence of different spots (4.7 and 10 A) respectively 
representing the interstrand and the intersheeet distances (b). (From: Fowler, 2007) 
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proteins despite of their primary sequence and their functional conformation. 
From the molecular point of view, amyloid is composed by small oligomers (i.e., -
sheeted structures formed by a limited number of proteins) that progressively 
aggregate forming increasingly complex structure such as protofibers and amyloid 
fibers (Dobson, 2003). The aggregation seems to be a process related to the amino 
acid composition of the peptide, although no specific patterns have been yet 
identified. 
The process of amyloid formation follows two different models depending on the 
kinetics and thermodynamics of the reaction. In thermodynamically unfavorable 
reactions the initial polymerization is characterized by a long lag phase during which 
a core of unfolded protein is built. After the formation of the nucleus, the 
polymerization occurs rapidly. This model is referred as nucleated polymerization. In 
other cases, instead, the aggregation in complexes is thermodynamically favorable 
and the formation of the complex follows linear kinetics. This second polymerization 
pathway seems to be the most common in cells, since the amyloid structure represents 
a significantly stable protein conformation. 
Regardless of the kinetics of the reaction, the aggregation is characterized by a two 
step-model called docking-locking model (Esler et al., 2000, Dobson, 2003, Glabe 
and Kayed, 2006). The docking step consists of the aggregation in complexes of 
oligomers and protofibers. At this stage the transition from one state to another is 
regulated by a thermodynamic equilibrium, making the process reversible. The 
locking phase, instead, consists in the terminal and irreversible deposition of fibers 
that is sustained by the continuous production of the amyloidogenic protein (Figure 
1.20). 
      
The first report related to the deposition of filaments following the cross spine model 
was published in 1906, when Alois Alzheimer described the presence of deposits of 
unknown nature in the brain of patients affected by dementia. Afterward the presence 
of these deposits has been observed in different diseases including neurological 
disorders such as Parkinson and Creuzfelt-Jacobs disease and non neurological 
conditions such as systemic amyloidosis and diabetes (Zhao and Ackerman, 2006) 
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(Table 1.4). In these diseases the deposits of amyloid are mainly composed by one 
protein.  
 
As previously mentioned, protein function is a direct consequence of correct folding. 
Therefore, the accumulation of unfolded and misfolded protein in the cell can lead to 
a significantly diminished activity of the proteins involved in the deposits (Dobson, 
2003). For example, cystic fibrosis is a severe disease resulting from the deletion of 
an aa in the polypeptidic sequence of a chloride channel located on the cell 
membrane. This mutation produces general instability in the three-dimensional 
conformation of the protein that leads to the retention of the immature peptide in the 
ER with consequent loss of the activity of the channel. 
In other cases misfolded proteins gain toxic functions due to the acquisition of a three-
dimensional structure favoring unwanted interaction with other proteins of the cell. 
Although this last aspect of the effects of amyloid has been widely studied, it is still 
debated which state of the amyloid aggregation process is producing damage to the 
cell (Glabe, 2008). In particular two major hypotheses have been formulated. 
Experimental data obtained from the study of Alzheimer’s amyloid  (A show that 
Figure 1.20. Different aggregation states of unfolded peptides. (From http://talaga.rutgers.edu/ 
research/images/Amyloid%20Mechanisms-2-tm.jpg) 
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the administration of exogenous A fibers induces cell death and neuronal loss in 
vitro and in vivo (Yankner et al., 1989, Koh et al., 1990, Kowall et al., 1991, Reyes et 
al., 2004). Other reports, instead, showed that oligomers are the principal mediators of 
toxicity (Lashuel et al., 2002a, Lashuel et al., 2002b, Walsh et al., 2002, Caughey and 
Lansbury, 2003, Baglioni et al., 2006, Novitskaya et al., 2006). 
 
The toxicity deriving from the accumulation of unfolded proteins seems to involve 
two different cellular pathways: Wnt and apoptosis. 
Wnt signaling represents an important pathway in development, oncogenesis 
(Coombs et al., 2008) as well as in neurodegenerative disorders such as autism and 
schizophrenia (De Ferrari and Moon, 2006). The principal modulator of the Wnt 
pathway is GSK-3(Chong et al., 2005)(Figure 1.21)This protein is regulated by 
the interaction of soluble extracellular Wnt with a membrane receptor called frizzled. 
The process induces the activation of the aberrant protein that inhibits the activity of 
GSK-3and, eventually, promotes the increase of intracellular -catenin. -catenin 
Table 1.4.  Human diseases related to protein unfolding 
Disease Protein(s) involved 
Cystic fibrosis CFTR 
Marfan Syndrome Fibrillin 
Nephrogenic Diabetes Insipidus Amylin 
Systemic Amyloidos Light Ig chain, SAA, TTR, b2 microglobulin 
Amyothrophic Lateral Sclerosis SOD1 
Alzheimers’s Disease Beta Amyloid 
Creutzfeldt-Jacob Disease PrP 
Parkinson’s Disease a-Synuclein, Parkin 
Marinesco-Sjogren syndrome SIL1 
Pelizaeus-Merzbacher disease PLP1 
Batten disease PPT1 
Huntington disease huntintin 
Bipolar disease XBP1 
Spinocerebellar ataxia SCA3 
Sporadic inclusion body myositis APP 
Wolcott-Rallison syndrome PERK 
Wolfram syndrome WSF1 
Hereditary tyrosinemia FAH 
Diabetes mellistus (type 2) Amylin 
Familial hypercholesterolemia LDLR 
Z α1-antitripsin deficiency A1AT 
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translocates to the nucleus where it combines with other nuclear factors to modify 
transcription. The activation of GSK-3 produces phosphorylation of -catenin and its 
proteasome-mediated degradation. Several experiments showed that the 
administration of substances inhibiting GSK-3 such as lithium induced an increased 
resistance of cells to the effects of Asuggesting that intracellular fiber aggregation 
produces effects related to the decrease of -catenin (Hedgepeth et al., 1997, Inestrosa 
et al., 2005).   
 
The second pathway involved in the 
A-mediated cell death is related to 
direct activation of the apoptotic 
pathway. Recent reports show that the 
administration of A produces 
unbalance between the proapoptotic 
and antiapoptotic proteins interacting 
with p53 (Esposito et al., 2004) 
(Figure 1.22). In particular, cells 
exposed to A present higher levels 
of bax and diminished bcl2, inducing 
activation of p53 and of the caspase-3 
mediated apoptosis. This process 
Figure 1.21. Wnt/GSK3b 
Pathway and activation of b-
catenin induced genes.  
The presence of aberrant 
proteins induces the release of 
β-catenin that translocate to the 
nucleus and modulates the 
transcription patterns by 
combining with other nuclear 
factors. In absence of aberrant 
proteins, β-catenin is 
phosphorylated by GSK-3β and 
transported to the proteasome 
for degradation. (From: 
http://www.anatomy.unimelb.e
du.au/researchlabs/deIongh/proj
ects.html  
 
Figure 1.22. Apoptosis cascade following the 
activation of p53 by the interaction with 
amyloid structures. (From: http://www. 
weizmann.ac.il/home/ligivol/apoptosis_project/ap
optotic_pathways.html) 
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seems to be related to altered homeostasis of Ca2+ that is direct and immediate 
consequence of the administration of A. Different hypotheses have been proposed to 
explain the correlation between Ca2+ dysregulation and A One of the most attractive 
theories suggests that A fibers directly inserts within the cellular membranes, 
producing destabilization of the lipid layer, formation of cation conducing pores, 
activation of receptors and oxidative stress (Demuro et al., 2005).  
 
Some studies also suggested a role for activation of the necrotic pathways following 
the presence of  in the cells with consequent cytosolic vacuolization, Golgi 
apparatus disorganization and absence of DNA damage. However, the specific 
mechanisms involved in the A-mediated necrosis are still unclear (Behl et al., 1994).  
 
 
 
1.5 Systemic Amyloidosis 
 
1.5.1 Definition 
 
Amyloidosis consists of a group of pathologies characterized by deposition of protein 
material deriving from the aggregation of a specific protein. The polypeptide involved 
usually loses the functional folding and acquires a -sheeted three-dimensional 
structure, which is associated with decreased solubility and with formation of 6.5-13 
nm thick fibrils of indefinite length (Hirschfield, 2004).  
The different forms of amyloidosis can be grouped in two main categories depending 
on the localization of the protein deposits: if the fibers are located in one specific 
organ, the amyloidosis is referred as localized. Instead if the fibers are transported in 
the blood and deposit in several organs, the amyloidosis is called systemic (Selkoe, 
2003). 
A second classification of the forms of amyloidosis is based on the molecular event 
that produces the fiber agglomeration (Buxbaum, 2004). According to this definition 
type I amyloidosis is related to the aggregation of a protein physiologically in 
equilibrium between amyloigenic and soluble form (Figure 1.23). This typically 
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occurs in transthyretin  amyloidosis (Kelly et al., 1997). Type II and III amyloidosis 
are respectively due to incomplete digestion of a soluble precursor or to the formation 
of insoluble peptides from the physiological cleavage of a precursor. Instead, Type IV 
amyloidosis is essentially due to specific mutations that destabilize the functional 
folding of a protein (e.g., PrP in prion disease (Prusiner, 1998)). 
The accumulation of a non-functional and non-compliant material in a metabolic 
active tissue or organ has been shown to be sufficient to induce a pathologic condition 
even in absence of an inflammatory response (Sousa et al., 2001). Although the 
specific cellular mechanism inducing toxicity has still to be elucidated, many studies 
reported the activation of the apoptotic pathway through the activation of NF-κB 
(Bales et al., 1998). 
At the moment no effective therapies for systemic amyloidosis are available. However 
survival rate for these patients has been increasing in the last few years thanks to 
novel therapeutic approaches decreasing the production of the amyloidogenic peptide 
and to the recent advances in organ transplantation for the most severe cases.  
 
 
 
 
 
 
 
Figure 1.23. Classification of 
the different forms of amyloid 
based on the mechanisms of 
aggregation. Amyloid fibers 
can derive from different 
aggregation processes including 
aggregation of proteins in 
thermodynamic equilibrium 
between a functional and an 
amyloigenic form (type I), 
aggregation of fragments 
derived from proteolysis (type 
II) or degradation (type (III) or 
aggregation of proteins 
containing mutations (type IV). 
(From: Buxbaum, 2004) 
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1.5.2 Causes of amyloidosis       
 
Amyolidosis can arise from different causes including genetic mutations, chronic 
infections (e.g., tuberculosis, osteomyelites), chronic inflammatory diseases, aging 
and presence of neoplasias such as multiple myeloma. At the moment, about 25 
different amyloigenic peptides have been recognized. Of these, 12 can lead to the 
systemic form of the disease (Buxbaum, 2004).  
The most common systemic amyloidosis is represented by the immunoglobulin light 
chain amyloidosis (AL). This condition is usually secondary to multiple myelomas or 
malignant lymphomas, in which the uncontrolled expansion of B lymphocyte clones 
results in the overproduction of light immunoglobulin chains (Hirschfield, 2004). 
These peptides are then secreted into the plasma where they aggregate in amyloid 
fibers and reach all the peripheral organs through the vascular system.  
       
Amyloid A (AA) is another common form of amyloidosis especially in the developing 
countries, where the occurrence of untreated chronic infections is still high. AA is 
considered a type II amyloidosis since it caused by the deposition of protein 
fragments derived from the degradation of the serum amyloid A; during inflammation 
the degradation rate of this peptide fail to meet the actual need, leading to a 
progressive accumulation of toxic products (Buxbaum, 2004). 
      
Transthyretin amyloidosis (ATTR) is instead a condition originating in the liver since 
this organ is the major producer of serum albumin. ATTR is usually not related to 
overexpression of transthyretin but it is associated to the presence of point mutations 
that induce structural modifications of the protein. TTR is normally secreted in the 
serum as a homotetramer (Saraiva, 2002). However the presence of just one molecule 
carrying amyloidogenic mutations produces structural changes affecting the whole 
quaternary structure of the protein and, eventually, the formation of amyloid deposits.  
In addition TTR seems to participate in other forms of amyloidosis; in fact the 
amyloid senile deposits (which are commonly found in almost all the individuals over 
80 years old especially in the atria, in the aorta and occasionally around the 
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vasculature of lung and other organs) contain large amount of this protein 
(Westermark et al., 2003).  
 
   
1.5.3 Clinical characteristics of systemic amyloidosis 
 
Amyloid deposits can occur in all the organs, even if the most commonly involved are 
kidneys, heart, gastrointestinal (GI) tract, peripheral nerves, and liver. 
At a first examination, patients show peripheral edema as a result of heart and 
nephrotic failure, hepatomegalia and purpura, which derives from the accumulation of 
amyloid fibers in the subendothelium of the capillary leading to increased fragility of 
the vessels. For this reason bleeding is a frequent complication of amyloidosis. This is 
further aggravated in AL since light chains seem able to bind and inhibit the 
coagulation factor X (Enjeti et al., 2005).    
As mentioned, the nervous system is a frequent target of the deposition of amyloid. 
This leads to weakness and sensorimotor peripheral neuropathy.  
Occasionally systemic amyloidosis also manifests with localized aggregates of light 
chains in the skin, in the lungs, in the respiratory tract and in the urinary system.  
 
 
 
1.5.4 Amyloidosis in the heart 
 
The heart is one of the most sensitive targets for 
systemic amyloidosis (Figure 1.24).  Amyloid 
infiltration in the cardiac tissue is initially 
clinically undetectable. However the 
progression of the deposition in the long term 
produces different non-specific effects including 
congestive heart failure, orthostatic hypotension, 
impaired conduction and restrictive 
cardiomyopathy, which is characterized by 
Figure 1.24. Congo red staining of 
amyloidosis myocardium in 
polarized light. Due to its capacity of 
binding β-sheeted structures, Congo 
red is used for diagnosis of 
amyloidosis, giving a green signal in 
polarized light.  
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peripheral edema and stiffness of the myocardium leading to improper filling of the 
chambers. When the failing condition becomes symptomatic the average survival is 
usually no longer than one year, although improvements can derive from heart 
transplant (Van Geluwe et al., 2006).  
Echocardiography and pathological observation of the amyloidosis-affected heart 
shows a mild atrial enlargement usually not associated by significant ventricular 
dilatation. An increased thickness of the walls is instead a common feature due to the 
interstitial amyloid deposition (Figure 1.25). 
Occasionally some patients present deposits in the coronary arteries that can cause 
anginal symptoms similar to what is observed in coronary artery disease (Mesquita et 
al., 2005, Neben-Wittich et al., 2005). 
 
 
 
 
 
 
 
 
 
 
Figure 1.25. Echocardiography (left) and 
MRI images (right) of hearts in 
amyloidosis patients. The heart presents 
lower elasticity that leads to a limited 
ejection fraction as shown by the MMode in the echocardiogram and by the diastolic and 
systolic diameter of the chambers by MRI. (From: http://www.medison.ru/uzi/eho404.htm (left 
panel), Van Geluwe, 2006 (right)). 
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1.6 Alzheimer’s Disease 
 
1.6.1 Definition 
 
“A. reports a case of illness, which was observed at the asylum in Frankfurt/Main and 
which was submitted for the examination of the central nervous system by director 
Sioli. The case has clinically presented such an aberrant picture, that it was 
impossible to classify it according to known diseases. It shows anatomically a picture, 
which differed from all other findings, known so far. […] She is temporally and 
locally completely disoriented. From time to time she says that she does not 
understand the whole matter, does not find her way. She greets the doctor as if he 
visits her and apologizes for not having finished her work, she shouted, he will slit her, 
or she turns him away, using phrases, which indicate that she thinks he could say 
something against her female honor. […] From time to time she is completely lunatic, 
carries her bedclothes around, cries for her husband and her daughter and seems to 
suffer from acousma. […]  Her memory is extremely disordered. If you show her some 
objects, she names them correctly, but shortly after she has forgotten everything. […] 
Her gait is normal, she uses her hands equally. The patellar reflexes exist. The pupil 
reacts.[…] The autopsy reveals an atrophic brain without macroscopical focuses. The 
major brain vessels are arteriosclerotically modified. With the help of preparations, 
which are made by Bielschowsky's silver stain, very strange changes of neurofibrils 
appear. In the inside of a cell, which seems otherwise to be normal, one or more 
fibrils stand out due to their special thickness and their feature to impregnate. Further 
on, many parallel-running fibrils appear modified in the same way. Then they affiliate 
to close bundles [tangels] and appear gradually on the surface. Finally the nucleus 
and the cell itself break down, and only an unfurled bundle of fibrils shows the 
position, where a ganglion cell has lain before.[…]”  
With these words in 1906 Alois Alzheimer presented an unusual case of psychiatric 
illness and specific histomorphological alteration observed in the brain of a 51 year-
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old woman, Augusta D. This is the first report regarding a neurodegenerative disease 
which was later classified as Alzheimer’s disease (AD). 
AD is a major cause of dementia in the Western countries, representing about 45% of 
the total amount of the diagnosed cases and affecting a total of about 700,000 
individuals in the UK. In general AD has minimal incidence below the fifth decade, 
but it gradually increases with aging. AD cases can be classified as early (≤65 years 
old) or late onset (≥65 years old) depending on the age the patients show the first 
symptoms. The development of AD is usually a sporadic event, although most of the 
cases of early onset AD have been associated to Mendelian transmission of the 
disease (familiar AD or FAD, 5-10% of the total). 
 
 
1.6.2 Clinical characteristics  
 
The presence of plaques in the brain is a clear indication of AD. However it is 
pratically impossible to obtain a biopsy of brain tissue from living patients; therefore 
diagnosis of AD is usually performed on clinical observation aimed to the 
identification of behavioral and neurological profiles that can be associated with the 
neuropathy.  
The most common sign correlating to early stage AD consists in a progressive decline 
of the mnemonic functions characterized by a tendency to forget name and events and 
to reveal personal preserved information. Over time, the patients also gradually show 
difficulties in learning deriving from short term memory impairment. 
In addition, the patients present general alteration of different neurological functions 
including executive functions, language and visual-spatial abilities. These 
characteristics progressively degenerate to a severe form of dementia in which the 
patient has difficulties in naming objects, produces empty fluent speech and 
experience a relevant spatial disorientation. 
AD usually develops with a long course that can range between years and decades. 
However, the disease becomes clinically manifest only when the brain presents severe 
and irreversible damages. This characteristic produced increasing efforts in the 
possibility of diagnosing AD at very early stages. In particular, imaging technologies 
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a b
Figure 1.26. In vivo imaging of AD. Panel a shows the MRI scan of a suspected AD case 
characterized by unilateral tempoparietal atrophy. Panel b, instead, shows the activity of different 
cerebral area detected by sPET in a normal (up) and a diseased brain (down). (From: 
http://www.radgray.com/mri-articles/alzheimer-disease (left)) 
have been very useful in developing new diagnostic tools. For example a common 
alteration in the brain of AD patients consists in significant focal atrophy of the 
medial temporal lobe structures. This anomaly can be observed by MRI in preclinical 
stages of the disease (Figure 1.26a). Further alterations are associated to a bilateral 
hypoperfusion of the nervous system especially localized in the temporal and parietal 
lobes and, occasionally, in the frontal lobes, which can be detected by single photon 
emission computed tomography (Figure 1.26b). 
 
1.6.3 Pathological characteristics  
 
AD brains show evidence of diffuse neuronal degeneration in specific regions of the 
brain during post mortem analysis. In particular, hippocampus and temporal cortex 
generally present marked cytostructural alteration even at early stages of the disease. 
These regions are characterized by proteinaceus plaques that progressively induce 
atrophy and that gradually deposit in the surrounding areas of the brain. In the long 
term this results in marked degeneration of the tempo-parietal cortex combined to 
decreased cholinergic projections to the frontal cortex, to the hippocampus and to the 
amigdala (DeKosky et al., 1985, Zubenko et al., 1989).  
  
From the histological point of view AD is characterized by formation of plaques and 
tangles in the cortical areas associated to a progressive loss of cortical neurons. At the 
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moment, post mortem histological analysis 
represents the only available method for a 
precise diagnosis of the disease (Figure 
1.27). 
 
Senile plaques consist of 20-200 m 
extracellular deposition of amyloid 
material. The neurons surrounding these 
aggregates are usually characterized by 
alteration of their typical shape, although it 
is still not clear whether they maintain normal activity (Rogers et al., 1996). 
The senile plaque core is composed by fibers of A, i.e., a 40-42 aa long peptide 
deriving from the posttranslational cleavage of the amyloid precursor protein (APP). 
Aaggregates can be divided in two major groups, classic and diffuse, depending on 
the presence of neuronal degeneration in the surrounding area. In addition, senile 
plaques are usually present in combination with an inflammatory response mediated 
by the microglia. (Figure 1.28)    
 
Tangles, instead, consist of intracellular agglomerates of filaments. These deposits are 
mainly localized in the cytoplasm and around the nucleus of the neuron, although 
occasionally they diffuse into the dendrites (Figure 1.29). Ultrastructural evaluation of 
the tangles revealed a double helix structure with a diameter of 20-24 nm. Each helix 
 
Figure 1.27. Silver staining of AD brain 
sample. Post-mortem analysis of AD brain 
tissue by silver staining shows the presence 
of extracellular plaques and intracellular 
tangles. (From: www.ladulab.anat.uic.edu) 
a b c
 
Figure 1.28. Amyloid plaques in AD brain. Panel a shows a high magnification image of an 
amyloid plaque detected by silver stain. Panel b illustrates the structure of the amyloid fibers by 
electron microscopy. Panel c, instead, shows the presence of microglial cells on the border of the 
plaques and of neurons (MG in blue). (From: Nagele, 2003) 
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is formed by 4-8 protofilaments of tau, a 55 kDa cytoskeletal protein highly expressed 
in the brain. This protein is normally related to the assembly of the microtubules of 
the cell. However it can form insoluble intracellular deposits especially in the 
hippocampal and in the cortical neurons when hyperphosphorylated, 
 
 
1.6.4 Proteins involved 
 
Amyloid precursor protein (APP) 
 
APP is a single pass transmembrane glycoprotein with a molecular weight of 110-130 
kDa. This protein is encoded by a large gene (over 170 kBp) mapping on 
chromosome 21q21 (Korenberg et al., 1989); the gene contains 19 exons that can be 
alternatively spliced to give three main isoforms. APP695 is the shortest isoform and is 
created by assembling exons 1-6 and 9-18 with the exclusion of 13a. APP751 and 
APP770, instead, contain a serine protease inhibitor domain called serpin domain and 
encoded in exon 7. These two isoforms are respectively obtained by the combination 
of exons 1-7+9-18 without 13a and 1-18 without 13a (Tanaka et al., 1988). 
Expression of APP has been detected in a broad number of tissues, even if the brain 
shows the most abundant levels (Tanzi et al., 1988). In particular APP695 is mainly 
present in neurons while APP751 and APP770 are more expressed in glial cells.  
 
The biological function of APP is still 
unknown although different theories have 
been formulated including a potential role in 
cell adhesion and in neuroprotection (Priller et 
al., 2006). According to some hypotheses APP 
present a domain resembling the serin-
protease inhibitor. This region may be 
involved in the inhibition of the coagulation 
pathway by specifically blocking the activity 
Figure 1.29. Silver stain detection of 
accumulation of hyperphosphorylated 
tau in neurons showing the typical 
flame shape (arrow). (From: http:// www. 
oumedicine.com/body.cfm?id=2881) 
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Figure 1.30. Schematic processing pathways of 
APP operated by  and  secretases. 
(From: LaFerla, 2002) 
of XIa factor, i.e., a serin-protease involved in the process. Nishimoto et al, instead, 
suggested a hypothetic role for APP in signal transduction: a specific mutation of 
APP, in fact, seems to alter the activation of a G0 protein leading to an increased 
release of Ca2+ from the cell storages (Nishimoto et al., 1993). An additional theory 
associates APP to vesicle trafficking along the axon due to its capacity of binding 
chinesine-I, an ATPase belonging to the molecular motor class and related to 
anterograde transportation in the cell (Kamal et al., 2001). 
Some investigators attempted to clarify the biological function of APP by developing 
knockout mice. However these models failed to show increased lethality or pathologic 
conditions, probably due to the presence of amyloid precursor like protein 1 and 2 
(APLP1 and APLP2). These two proteins are characterized by high sequence 
homology with APP and, apparently, seem to be able to partially replace it. Indeed, 
triple deficient mice for APP, APLP1 and APLP2 are not viable (von Koch et al., 
1997, Heber et al., 2000).  
  
APP processing 
 
In physiological conditions, APP is matured through several post-translational 
proteolytic steps operated by the secretase complexes (Figure 1.30). The first phase of 
the process occurs during the transport of the molecule to the membrane and involves 
the α-secretase, i.e., a protease 
belonging to the A disintegrin and 
metalloproteases (ADAM) family. α-
secretase cleaves a large portion of 
the N terminus of the peptide (called 
s-APPα) and releases it in the 
vesicular lumen or in the extracellular 
space. s-APPα seems related to a 
neuroprotective activity; In fact this 
fragment is apparently able to 
significantly decrease the toxic effects 
Introduction 
 
 
 77
of high intracellular Ca2+ content subsequential to cellular damage or, in hippocampal 
neurons, to glutamate stimulation (LaFerla, 2002).   
The remaining portion of APP after α-secretase-mediated cleavage consists in an 83 
aa transmembrane peptide called CTF. This fragment can be further processed by a 
different enzymatic complex γ-secretase. This enzyme produces a proteolytic 
cleavage in the transmembrane domain releasing a 3 kDa peptide called p3, which is 
commonly present in the amyloid plaques even if not directly involved in the 
aggregation process. 
Alternatively, full length APP can be processed by β-secretase, a transmembrane 
glycoprotein usually located on the membrane of the Golgi apparatus or on the 
cellular membrane. Two different forms of the enzyme have been identified, named β-
site APP cleaving enzyme (BACE) 1 and 2, which are respectively characterized by 
specific tissue distribution. β-secretase cleaves APP into a soluble fragment (s-APPβ) 
and a 99 residue transmembrane peptide (CTFβ). Similarly to what observed for CTF, 
the latter can be further processed by γ-secretase. This event leads to the pro 
production of β-amyloid (Aβ), a 4 KDa peptide that has amyloidogenic properties. γ-
secretase processing can cleave CTF in two different positions (711 and 713) 
producing respectively a 42 aa and a 40 aa fragments called Aβ42 and Aβ40. In normal 
conditions the balance between production and degradation of these molecules is 
achieved mainly through the insulin degrading enzyme pathway and, in part, the 
proteasome system (Schmitz et al., 2004). In AD, instead, the content of Aβ40 and 
Aβ42 are significantly increased. Although both the fragments are involved in the 
formation of amyloid plaques, it seems that Aβ42 is the main responsible for the 
aggregation. This represents a result of the marked hydrophobicity of the molecule 
conferred by the presence of two extra highly hydrophobic residues (Haass et al., 
1992, Shoji et al., 1992, Yoshiike et al., 2003).  
In addition recent reports showed the presence of an alternative processing pathway of 
CTFβ involving a different secretase (ε-secretase) that cleaves and releases the 
intracellular domain of APP (AICD). The functional role of this peptide is still 
unknown but it seems to be related to the calcium homeostasis through the regulation 
of the inositol triphosphate pathway (Leissring et al., 2002). 
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γ-secretase 
 
γ-secretase represents a particular group of endoproteases that catalyzes the cleavage 
of target sequences in transmembrane domains. The catalytic region of the γ-secretase 
complex is formed by presenilin 1 (PS1) or presenilin 2 (PS2) (Tolia and De Strooper, 
2008). These two proteins are mainly localized in the ER and in the Golgi apparatus, 
although recent reports showed their presence in the cytoplasmic, in the nuclear and in 
the endosomial membranes (Walter et al., 1996, Cupers et al., 2001).  
PS1 and PS2 are encoded in two different genes (PSEN1 and PSEN2) located 
respectively on 14q24.3 and 1q32-q42. The translation of these genes produces two 
proteins of 463 and 448 aa characterized by high amino acid homology (67%) and a 
series of structural analogies. PS1 and PS2 are 8-pass transmembrane proteins with a 
molecular weight of 49 and 50 kDa, which present cytoplasmic N and C termini. The 
catalytic core of the proteins is located in a highly conserved large cytoplasmic loop 
between the transmembrane domain 6 and 7, corresponding to the sequence included 
between aa 378 and 406 (Figure 1.31). In particular this region contains 2 aspartic 
 
Figure 1.31. Structure of PS1 (blue) and localization of APP-NFT (green) in the catalytic site 
located between transmembrane helices 6 and 7 that contain two critical aspartate residues in 
position 257 and 385 (yellow). The proteolysis sites of both proteins are marked by scissor 
simbols. The amino acids marked in red represent some of the mutation described as related to AD. 
(From: Hardy, 2002)
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acid residues (Asp257 and Asp385) that are directly responsible of the cleavage of Aβ 
(Wolfe et al., 1999).  
Full length PSs require a activation step in order to perform their physiological 
function. This process consists in the cleavage of the protein in the catalytic loop most 
probably mediated by autocatalysis with the co-partecipation of co-factors (Takasugi 
et al., 2003). The proteolysis of PS produces a 30 kDa N terminal fragment (NTF) and 
a 20 kDa C terminal fragment that dimerize to form the γ-secretase core. 
γ-secretase, though, is a high molecular weight enzymatic complex (150-250 kDa) 
composed by several other proteins with accessory function, including Pen-2, 
nicastrin, Aph-1, δ- and β-catenin (Figure 1.32) (De Strooper, 2003, Capell et al., 
2005). In particular Pen-2 seems to be related to the correct assembly of the γ-
secretase complex, while the other elements of the enzyme have a role in stabilizing 
the structure of PS (Steiner et al., 2002, Tolia and De Strooper, 2008). Nicastrin, for 
example, is a transmembrane glycoprotein that binds the N and the C termini of the 
presenilin stabilizing its structure and its interaction with APP. Therefore, the role of 
this protein in the γ-secretase complex is necessary for the proteolytic activity of the 
enzyme; dominant negative mutant forms of nicastrin, in fact, produce a drop in the 
formation of Aβ (Chen et al., 2001).  
 
 
 
 
Figure 1.32. The -
secretase complex 
and domains 
involved in the 
processing of APP. 
(From: http://www. 
biochemie.abi.med.u
ni-muenchen.de/ 
haass/gamma-
secretase/index.html) 
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1.6.5 Causes of AD 
 
AD is a complex disease that produces a pathological phenotype deriving from 
concomitant interaction of environmental factors and genetic background. 
Only a limited amount of mutations in the APP, PS1 and PS2 genes have full 
penetrance autosomal inheritance leading to AD (Table 1.5). These alterations usually 
produce the early-onset familiar forms of AD (EOFAD), which affects about 5% of 
the total number of AD cases and which develope clinically explicit AD condition by 
the age of 65. To date about 160 mutations in these genes have been associated to 
EOFAD, although most of them (~140) have reported in the PS1 gene. These 
modifications produce direct alterations of the biochemical processing of APP that 
lead to increased levels of Aβ with preferential production of Aβ42. Mutated forms of 
PS1 have also been related to anomalies in the activity of protein kinases such as 
glycogen synthase kinase 3β (GSK-3β), protein kinase A (PKA), mitogen-activated 
protein kinase (MAPK) and cyclin-dependant kinase 5 (cdk5). These enzymes seem 
to be involved in the alteration of the architectural structure of the cytoskeleton by 
modifying the phospshorylation state of tau, which can aggregate in tangles and 
destabilize the microtubules when present in the hyperphosphorylated form. This 
process leads to the degeneration of the axon and to the loss of the synapses deriving 
from it (Maccioni et al., 2001, Mandelkow et al., 2003).      
 
Table 1.5. Genes mutated in the familial forms of AD 
Gene Location Described mutations Biochemical alteration 
APP 21q21 16 Increased Aβ generation and aggregation 
Increased Aβ42/Aβ40 ratio  
PSEN1 14q24 140 Increased Aβ42/Aβ40 ratio  
PSEN2 1q42 10 Increased Aβ42/Aβ40 ratio  
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The analysis of the pedigree of late-onset cases of AD (LOAD) by segregation or twin 
study allowed the identification of more that three dozen genes that were mutated in 
AD. However, most of the genetic anomalies described are considered as risk factors 
rather than as primary cause of the disease. In fact, these alterations are considered 
neither necessary nor sufficient for the development of the disease (Table 1.6), unlike 
the mutations described in EOFAD. The most significant association to AD in this 
group is considered the polymorphism of the apolipoprotein E (APOE) gene on 
chromosome 19q13. The role of this protein in the pathogenesis of AD is still not 
clear, although some reports suggested that Aβ is able to bind the lipoprotein receptor 
on the cellular surface by interacting with the low-density lipoprotein receptor-related 
protein (LPR) (Figure 1.33). The interaction of extracellular APOE with the 
lipoprotein receptor produces the internalization of the complex and its translocation 
to the lysosome, where it undergoes a degradation process (Shibata et al., 2000). 
Other hypotheses, instead, suggest a specific role for APOE in binding Aβ in the 
extracellular space and in facilitating its removal from the deposition site. Each APOE 
allele seems to have peculiar capacity for Aβ clearance: the variant ε2, for example, 
has been associated to a more efficient clearance of the β-amyloid, while the presence 
of the ε4 allele seems related to the accumulation of the insoluble fibers (Hone et al., 
2005, Tanzi, 2005).  
Table 1.6. Risk factors genes for AD (sporadic form) 
Gene Location Biochemical dysfunction  
A2M 12p13 Aβ clearance 
ADAM9 8p11 α-secretase 
ADAM10 15q21 α-secretase 
ADAM17 2p25 α-secretase 
APH1A 1q21 γ-secretase 
BACE1 11q23 β-secretase 
BACE2 21q22 β and α-secretase 
IDE 10q23 Aβ/AICD clearance 
LRP1 12q13 Aβ clearance 
NCSTN 1q23 γ-secretase 
NEP 3q25 Aβ clearance 
PEN2 19q13 γ-secretase 
PLAT 8p11 Aβ degradation (via plasminogen) 
PLAU 10q22 Aβ degradation (via plasminogen) 
PLG 6q26 Aβ degradation (via plasminogen) 
ECE2 3q27 Aβ clearance 
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Other LOAD-associated genes are instead associated  to different steps of the Aβ 
metabolism ranging form biosynthesis (e.g., α-secretase, β-secretase, elements of the 
γ-secretase such as PEN2, APH1A and Nicastrin) to the degradation (e.g., insulin 
degrading enzyme, neprilysin, urokinase-type plasminogen activator). However, these 
genes are still considered functional and/or positional candidates due to contrasting 
data about their role in the pathogenesis of AD.  
 
As mentioned, LOAD is a multifactor disease in which non-genetic elements 
contribute to the development of the condition besides the genetic background. In 
fact, several studies reported that factors including level of education (Evans et al., 
1997), dietary habits (Mayeux and Sano, 1999), exposure to heavy metals, head 
injuries (Lye and Shores, 2000)or history of cardiovascular diseases such as 
hypercholesterolemia, hypertension or stroke have an important role in AD etiology.  
   
 
 
Figure 1.33. Mechanism of action of different APOE isoforms on the clearance of 
extracellular amyloid. Extracellular amyloid (A) bind preferentially some forms of APOE such 
as 3. This process allows the internalization of the APOE-Acomplex in the cell and its 
degradation. Other isoforms of APOE and in particular 4 have lower affinity for Ab. This 
produces an increased content of extracellular A that can accumulate in plaques and that activates 
the astrocytes inducing production of APOE in order to facilitate the removal of free A. (From: 
LaDu, 2000) 
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1.6.6 Ca2+ alteration in AD 
 
An interesting aspect of most of the proteins involved in AD is their involvement in 
the regulation of Ca2+ signaling. 
The secreted form of APP, for example, seems to have a role in the protection of the 
cell against toxic increases of intracellular Ca2+, which are induced by injury or by 
overstimulation with glutamate in the neurons. This activity is thought to be mediated 
through the activation of the guanylate cyclase and the subsequent increase of cGMP. 
Therefore, any perturbation to the normal maturation of APP could lead to the 
accumulation of Ca2+ and to apoptosis. This process is further aggravated during 
deposition of Aβ, mainly because the fibers seem to infiltrate the lipid layer of the 
membranes forming cation pores that allow uncontrolled diffusion of Ca2+.  
A second hypothesis on the regulatory role of APP in calcium signaling has been 
related to a direct involvement of the AICD fragment, similarly to what observed with 
the NICD fragment deriving from proteolysis of notch (Leissring et al., 2002).  
 
The mechanisms of action of the presenilin on the Ca2+ regulation, instead, have not 
been completely clarified. In particular it seems that some mutation of PS1 and PS2 
can interact indirectly on the inositol-3-phosphate (Ins-3P) receptor on the ER 
inducing a increased release of Ca2+ (Chan et al., 2000). According to recent theories, 
these mutations are related to a loss of the intrinsic capacity of the PSs to form low-
conductance divalent cation channels. This event leads to an overload of Ca2+ in the 
ER and to a significantly increased release during the opening of the Ins3P-regulated 
channels (Tu et al., 2006) (Figure 1.34). 
PSs seem also to control Ca2+ levels in the cell through indirect pathways involving 
several calcium-related proteins related to ER free Ca2+ binding (calsenilin and 
calmyrin) (Stabler et al., 1999) and Ca2+ release from the ER (sorcin, RyR) (LaFerla, 
2002, Stutzmann et al., 2006).  
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1.6.7 Vascular defects associated to AD 
 
In the last decade cardiovascular diseases have been related to cognitive impairment, 
showing in particular the correlation between AD and hypertension or CAD. 
Neuropathological analysis of the brain of non-demented individuals affected by 
critical CAD (cCAD, i.e., occlusion of one coronary artery greater than 75%) often 
revealed significant deposition of Aβ in the brain compared to same age controls 
(Sparks et al., 1990). These data have been confirmed by animal studies in which the 
deposition of Aβ was induced by administration of a high cholesterol diet and 
reverted by the deprivation of cholesterol. The mechanism underlying this process is 
still unclear but it seems to involve the activation of microglia and alteration in the 
insP3R
Serca
PS
insP3
Wild type Mutant PS
 Figure 1.34. Proposed effects of PS mutation on the InsP-3 pathway. In wild type cells the Ca2+ 
internalized by the ER through SERCA normally leaks through a constitutive channel formed by 
the PSs. Mutations of the PS genes block the Ca2+ leaking from the ER leading to an overload of 
Ca2+ in the ER that results in an abnormal release upon opening of the InsP-3-regulated channels on 
the ER. (From: Tu, 2006) 
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metabolism of cholesterol. These affect the normal cleavage of APP, shifting the 
secretase activity from α to β cleavage (Sparks, 1996, Urmoneit et al., 1998). 
The reports showing correlation between cCAD and deposition of Aβ were able to 
show the occurrence of intracellular fibrils of tau only in a limited number of cCAD 
patients. The study of brain damages in hypertensive heart disease, instead, revealed 
the concomitant presence of Aβ and tangles (Prince et al., 1994, Sparks et al., 1995, 
Petrovitch et al., 2000) that is probably due to the increased possibility of generating 
of silent brain infarcts and thrombosis, two risk factors that have been linked to AD 
(Qiu et al., 2003, Cechetto et al., 2008).  
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Aims 
 
In the last few years an increasing number of previously unrelated disorders have 
been associated to adverse effects deriving from the accumulation of non-functional 
aggregates of unfolded proteins forming amyloid fibers (Selkoe, 2003). These 
aberrant deposits can arise from point mutations destabilizing the polypeptide 
structure or perturbation of the normal homeostasis of the cell.  
Several studies have investigated the correlation between formation of β-sheeted 
structures and alterations of the Ca2+ homeostasis: molecules such as amylin, prion 
protein and Aβ42 seem able to randomly create cation pores in the membranes 
(Mirzabekov et al., 1996, Lin et al., 1997, Kawahara and Kuroda, 2000), producing 
non-regulated ion migration. However, this cause-effect relationship is still 
considered controversial since some groups reported evidences of Ca2+ dysregulation 
in the brain before the detectable formation of amyloid fibers. In addition Ca2+ 
dysregulation was also observed in non-neural tissues normally not affected by the 
presence of Aβ42 (Yoo et al., 2000).  
As previously discussed, DCM hearts are characterized by a marked Ca2+ handling 
impairment that may be sufficient to disturb the correct post-translational 
modification of the protein chains in the sarcoplasmic reticulum. In fact, most of the 
enzymes involved in these processes –including the chaperones GRP78 and GRP94- 
are totally functional only when Ca2+ concentrations are kept within specific ranges. 
For this reason the SR in normal cardiomyocytes is spatially sub-compartmentalized 
in different regions for calcium cycling and protein folding, respectively enriched in 
pumps and ion channels or chaperones and calcium buffering proteins (Papp et al., 
2003).  
The potential deleterious effects of anomalies of the UPR system and of the presence 
of unfolded proteins in HF have been confirmed by an increasing number of reports in 
the last few years.  Activation of the UPR system have been described both in humans 
and in rodent models of HF (Okada et al., 2004, Dally et al., 2009), which showed 
sensitive increase of GRP78 levels and initiation of the CHOP-regulated ER-mediated 
apoptotic pathway. Similar conclusions were reached by Hamada et al. (Hamada et 
al., 2004), which investigated the development of dilated cardiomyopathy in 
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transgenic animals with compromised UPR quality control system. These 
observations are consistent with ultrastructural morphological findings suggesting 
increased extension of the ER network in failing cardiomyocytes (Maron et al., 1975) 
and with other studies showing incapacity of the cell to efficiently degrade the 
peptides accumulation in a time-effective manner, which eventually leads to 
accumulation of poly-ubiquitinated proteins including  the pro-apoptotic factor p53 
(Birks et al., 2008).  
Interesting confirmations of the role of the UPR in the etiology of HF derive from a 
recent paper showing clear correlation between pharmacologically-induced inhibition 
of the proteasome and heart failure (Voortman and Giaccone, 2006, Hacihanefioglu et 
al., 2008): in these studies Giaccone and Gonullu’s groups confirmed that tumor 
patients treated with bortezomib (i.e. a pharmacological proteasome inhibitor used for 
triggering accumulation of  unfolded proteins and therefore death of the metabolically 
hyperactive cancer cells) develop HF. This process has been successfully attenuated 
in vitro by Fu et al., who showed that the overexpression of endoplasmic reticulum-
resident chaperone GRP78 in rat neonatal cardiomyocytes protects from the damages 
induced by proteasome inhibitors (Fu et al., 2008). 
 
Further crucial observations associating protein folding and cardiac failure derive 
from the work of J. Robbins and colleagues, which demonstrated the active role of 
proteins prone to the formation of amyloid structure in the degeneration of the organ 
to a failing condition (Pattison et al., 2008). In particular the authors showed the 
deleterious effects of an exogenous pro-amyloigenic peptide (poly-Q Huntintin) on 
the cardiac function in transgenic mice. These results generate the intriguing 
hypothesis for the findings of Li et al (Li et al., 2006), which reported the presence of 
mutations in the PS1 and PS2 genes in families affected by the genetic forms of 
DCM. In fact, alterations in the γ-secretase complex may produce degeneration of the 
APP processing pathways, leading to increased production of pro-amyloigenic Aβ42. 
 
Based on these previous studies, we hypothesize that in idiopathic DCM the 
subnormal post-translational processing of proteins may lead to the accumulation of 
unfolded species in the cardiomyocytes and, eventually, to cell damage and death. 
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To verify our hypothesis we propose the following specific aims: 
 
1. Verify the presence of unfolded proteins in idiopathic DCM samples. 
 
2. Characterize the unfolded protein response in these samples. 
 
3. Investigate the levels of AD-related proteins.  
 
4. Identify the protein(s) involved in the formation of the aggregates. 
 
5. Identify the pathways specifically altered in idiopathic DCM using high 
throughput analysis 
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2.1 Human samples 
The diseased human heart samples used in this study were collected at Massachusetts 
General Hospital with patient informed consent under a protocol approved by the 
Institutional Review Board. The organs were explanted from patients undergoing 
cardiac transplantation at the time of the operation and immediately stored in ice-cold 
low-potassium University of Wisconsin cardioplegic solution (100 mM potassium 
lactobionate, 25 mM KH2PO4, 5 mM MgSO4, 30 mM raffinose, 5 mM adenosine, 3 
mM glutathine, 1 mM allopurinol, 5% w/v hydroxyethyl starch, 8 mg/l 
dexamethasone, 40 U/l insulin, 2x105 U/l penicillin, pH 7.4 (Desrois et al., 1999)).  
The hearts classified as non-failing were instead obtained under family approval from 
the National Disease Research Interchange (NDRI) program. These organs only 
included hearts considered not suitable for transplantation because of age of the donor, 
blood transfusion while in the emergency room or absence of compatible recipient 
within reasonable distance from the site of explant. The organs were delivered in cold 
University of Wisconsin cardioplegic solution for the transport.  
Upon arrival in the lab the hearts were immediately dissected and processed with 
different protocols compatible with the downstream analysis planned. In particular, 
approximately 1 cm3 of myocardium from the anterior wall of the left ventricle was 
saved for RNA isolation and immediately snap frozen to prevent RNA degradation 
and 1 mm3 was stored in a 2.5% solution of grade II glutaraldehyde (Sigma, MO - Cat 
# G6257) for electron microscopy analysis. For these two critical applications we 
carefully selected areas with no macroscopic presence of adipose and/or fibrotic tissue. 
An additional part of the front wall (2-3 cm3) surrounding a branch of the left anterior 
descending coronary artery was isolated, washed with phosphate-buffered saline (PBS, 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4 pH 7.4) + heparin 
and perfused with PLP solution (4% paraformaldehyde- 75 mM lysine - 10 mM 
sodium metaperiodate in 0.1M Na2PO4). The remaining tissue was instead divided in 
the four chambers, cut in small pieces and snap frozen as above.  
Biopsy samples for early-stage DCM were instead collected with patient informed 
consent and directly stored in glutaraldehyde 2.5%. 
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All the cardiac samples collected were catalogued in a database including information 
such as age, gender, race, diagnosis or cause of brain death, clinical history, 
medications at the time of tissue harvesting, heart functional assessment, pathological 
analysis of the explanted organ, etc. This allowed us to divide the individuals used in 
these studies basing our selection, when possible, on sex, age and race for matching 
case and controls. 
Strict confidentiality on all the information and data was maintained to protect the 
privacy of all donors and patients. 
 
2.2 Congo red staining 
Snap-frozen cardiac tissue was cut with a cryostat (temperature of the chamber: -18° 
C, temperature of the piece holder adjusted between -18° and -23° C to obtain 
wrinkle-free, non-cracked sections) at 8 μm thickness. The slices were collected on 
superfrost plus glass slides (Fisher Scientific, GA) and immediately stored at -80° C. 
The slides were then processed using a commercial congo red staining kit (Sigma, 
MO – Cat # HT60) based on Puchtler’s modification of the original protocol (DC 
Sheenhan, 1980). Briefly, the samples were fixed in paraformaldehyde 4% for 10 min, 
washed 3 times in ddH2O (10 min each wash) and counterstained in hematoxilin for 3 
min (Gill #3 formulation). The excess of dye was washed as above and the slides were 
incubated in alkaline sodium chloride solution (NaCl-saturated SD 3A alcohol 
80%:NaOH 1% 1:100) for 20 min and stained in alkaline congo red solution (0.2% 
congo red in NaCl-saturated SD 3A alcohol 80%:NaOH 1% 1:100) for 20 min. The 
slides were then washed three times in ethanol 100%, clarified in xylene and mounted 
in xylene-based mounting media. The samples were then analyzed in polarized and 
bright light.  
 
2.3 Thioflavin-S staining 
Tissue slides were prepared as described in chapter 2.2. The frozen sections were 
fixed in paraformaldehyde 4% for 10 min, washed 3 times in ddH2O (10 min each 
wash) and immersed for 5 min in thioflavin-S staining solution (1% thioflavin-S in 
H2O) as previously described (Guntern et al., 1992). Starting from this step, the entire 
procedure was performed in controlled light conditions to avoid the degradation of the 
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fluorochrome and photobleaching effect. The slides were then differentiated for 5 min 
in ethanol 70%, rinsed in ddH2O twice (5 min each) and mounted using a 
fluorescence-compatible mounting media (DAKO, Denmark). The slides were then 
imaged on a confocal microscope (Leica TCS) using an excitation wavelength of 430 
nm and detection at 550 nm. 
 
2.4 Electron microscopy 
The samples were processed and analyzed by the PMB Microscopy Core at MGH 
following a modification of a previously described protocol (Burghardt and Droleskey, 
2006). Briefly, 1 mm3 fragments of cardiac tissue were fixed in glutaraldehyde 2.5% 
solution for at least 2 hours. The excess of fixative was removed by three 5 min 
washes with tyrodes-cacodylate buffer (0.1 M NaCl, 2.5 mM KCl, 5 mM MgCl2·6 
H2O, 12 mM NaHCO3, 5 mM glucose, 10 mM Na(CH3)2AsO2·3 H2O 0.2 mM 
CaCl2·2 H2O pH 7.4) and the tissue fragments were dehydrated in crescent 
concentration of ethanol (25%, 50%, 75%, 95%, 100%, 100%, 5 min each) and 
incubated in two changes of propylene oxide (respectively 50% in ethanol and 100%) 
for 10 min. The specimens were then infiltrated with Epon 812 resin (50% in 
propylene oxide for 1 h and two changes of 100% respectively for 1 h and 24 h at 
60°C) and polymerized for 7 h. The polymerized blocks were cut in 100 nm slices 
with an ultramicrotome and collected on formvar-coated grids. The samples were post 
stained in uranyl acetate for 5 min followed by immersion in lead citrate for 5 min. 
The excess of staining solution was removed by washing the grid in NaOH 20 mM 
and water. The samples were then observed in a transmission electron microscope at 
80 kV. 
 
2.5 Immunofluorescence  
Snap frozen cardiac tissue was cut at 5 μm thickness and stored as described in 
paragraph 2.2. The samples were then fixed in paraformaldehyde 4% w/v for 15 min, 
washed 3x (10 min each) in PBS and blocked in PBS + bovine serum albumin (BSA) 
5% w/v for 1 h at RT. The primary antibody was diluted in PBS + BSA and incubated 
on the slides for 90 min at RT. Specific dilutions and conditions for the antibodies 
used are summarized in Table 2.1 and will be listed in the relative chapters. The 
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samples were then washed twice in high salt PBS (PBS + NaCl 2.7 g/L), rinsed in 
PBS and incubated 45 min at room temperature with fluorochrome-conjugated 
secondary antibody in dark conditions (Invitrogen, CA, Alexa 633-cojugated anti-
mouse, anti-rabbit or anti-goat 1:1000 in PBS+BSA). All the following steps were 
conducted in controlled light to avoid degeneration of the fluorescent signal. The 
slides were washed as described above and incubated in PBS + DAPI (1 μg/ml). The 
excess of DAPI was removed by two washes with PBS. The slides were finally 
Antigen Source Cat # Application (dilution) 
 
19S rpt 3 Biomol Int. PW8765 Wb (1:1000) 
19S rpt 5 Biomol Int. PW8770 Wb (1:1000) 
20S α6 Biomol Int. PW8100 Wb (1:1000) 
20S β2 Biomol Int. PW8895 Wb (1:1000) 
20S β5 Biomol Int. PW8210 Wb (1:1000) 
Aβ Covance SIG-39300 IF (1:200) 
APP Abeta W02 Wb (1:1000) 
Sigma A8717 Wb (1:1000), IF (1:1000) 
ATF6 Imgenex IMG-273 Wb (1:500) 
Calsequestrin Thermo PA1-9*13 Wb (1:1000) 
Caspase 12 Abcam AB18766 Wb (1:1000) 
Chop Biolegend 643601 Wb (1:500) 
E2Fα-P Cell Sygnaling 119A11 Wb (1:1000) 
GADPH Zymed 39-8600 Wb (1:1000) 
IgG (Gt) Alexa 633-
conjugated 
Invitrogen A-21082 IF (1:200) 
IgG (Ms) Alexa 
633-conjugated 
Invitrogen A-21050 IF (1:200) 
IgG (Ms) Alexa 
633-conjugated 
Invitrogen A-21070 IF (1:200) 
IgG (Ms) HRP-
conjugated 
GE Lifescience RPN4201 Wb (1:2000) 
IgG (Rb) HRP-
conjugated 
GE Lifescience RPN4301 Wb (1:2000) 
Oligomers Invitrogen AHB0052 EM (1:400), IF (1:400), IP (1:100) 
PS1 Millipore A5308 IF (1:200), Wb (1:1000) 
PS2 Thermo MA1754 IF (1:200), Wb (1:750) 
PS2-P Calbiochem PC235 IF (1:200) 
Serca 2a Abcam AB3625 IP (1:100), Wb (1:1000) 
Ubiquitin Sigma U5379 Wb (1:500) 
XBP-1 Santa Cruz SC7160 Wb (1:200) 
Table 2.1. Commercial antibodies and conditions. 
Abbreviations: Wb: Western blot, IF: immunofluorescence, EM: electron microscopy-immunogold 
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mounted using fluorescence-compatible mounting media (DAKO, Denmark), sealed 
and observed with a confocal microscopy (Leica TCS). 
 
2.6 Immunogold staining 
1 mm3 of PLP-fixed cardiac samples was dehydrated in crescent serial ethanol 
solutions (25%, 50%, 75%, 95%, 100%, 100% v/v, 5 min each) and embedded in 
inclusion resin – medium grade (EMsciences, PA) at 50° C overnight. The 
polymerized blocks were cut in 100 nm slices with a Reichter Ultracut E 
ultramicrotome and collected on formvar-coated grids. The samples were then 
rehydrated to PBS with ethanol serial dilutions (100%, 95%, 75%, 50%, 25%, 5 min 
each) and processed the PMB Microscopy Core at MGH as previously described 
(Burghardt and Droleskey, 2006). Briefly, the sections were blocked in PBS+5% 
normal goat serum (NGS). The primary antibody (anti-oligomers A11 produced in 
rabbit, Invitrogen AHB0052 1:400) was labeled with colloidal gold (10 nM in DAKO 
antibody diluent) for 1 h at RT and applied to the slides. The hybridization was 
performed for 1 h at RT in continuous agitation. The unbound antibody was removed 
with 3x PBS washes (5 min each) and the grids were counterstained with 2% aqueous 
uranyl acetate for 5 minutes. The excess of staining solution was removed by washing 
the samples in NaOH 20 mM and water. The slides were then dried and observed in a 
transmission electron microscope (JEOL 1011) set at 80 kV. 
 
2.7 Laser capture microdissection 
Snap frozen cardiac tissue was cut as described in chapter 2.2 and collected on 
different types of slides. These included:  
 Regular glass (Fisher Scientific, GA) 
 Positively charged glass (Fisher Scientific, GA) 
 Plastic (Fisher Scientific, GA) 
 Plastic film-coated glass (Alphametrix Biotech, Germany)  
 Polyethylene terephthalate membrane frame slides (Alphametrix Biotech, 
Germany) 
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The frozen sections were rehydrated in PBS 1x for 5 min, stained with thioflavin-S (5 
min in thioflavin-S 1% in PBS followed by a differentiation step in ethanol 70% for 5 
min, ethanol 95% for 5 min, two 5 min incubations in absolute ethanol and a final 5 
min step in xylene) and dried o.n. at RT (Burghardt and Droleskey, 2006). This 
protocol was slightly modified by removing the final xylene step for the slides 
containing plastic material due to the solvent incompatibility of the support.  
Three different instruments were tested for this the laser microdissection: 
 
 Leica LMD 6000 
 Zeiss P.A.L.M. 
 Leica LMD 7000 
 
In particular the polyethylene terephthalate membrane frame slides were exclusively 
used with the last system. 
In all the cases the controlling software was programmed to automatically detect the 
Thioflavin-S signal (excitation 430 nm-detection 550 nm) and to isolate the positive 
fibers with a UV laser pulsed microbeam. The cell dissected on the Leica LMD 6000 
apparatus were collected on CapSure collection cups (Invitrogen, CA) and transferred 
to regular 1.5 ml tubes, while the samples excised on the Zeiss P.A.L.M. were 
transferred directly to the tube by pressure catapulting. The cell selected with the 
Leica LMD 7000, instead were dropped by gravity directly in a 1.5 ml tube. 
The collected Thioflavin-S positive material was resuspended in lysis buffer (tris HCl 
10 mM, 7M urea, 2M thiourea, 2% chaps, 2% chapsO, 1% NP-40, 10% glycerol, 
0.1% C8E12, 7 μg/ml calpain inhibitor, 1x Roche Complete proteinase inhibitor 
cocktail, pH 7.4) before further analysis. 
 
2.8 Sarcoplasmic reticulum isolation 
SR membrane-enriched isolation was performed as described by Hajjar et al. (Hajjar 
et al., 1997). 30 g of frozen of tissue in small chunks were resuspended in 300 ml of 
0.3 M sucrose, 1 mM phenylmethylsulfonyl fluoride, 20 mM pipes pH 7.4 and 
homogenized at 4° C with a polytron PT10-35 homogenizer. The homogenates were 
clarified by centrifugation (500 g for 20 min at 4° C). The resulting supernatant was 
Materials and Methods 
  
 
 99
collected and centrifuged at high speed (25000 g) for 60 min at 4° C to pellet the SR-
enriched membrane fractions. The supernatant from this step was disposed and the 
pellet was incubated in 5 ml of 600 mM KCl, 30 mM sucrose, 20 mM pipes on ice for 
30 min. The reconstituted material was homogenized as above, aliquoted and snap-
frozen in liquid N2.   
 
2.9 Western blot 
~500-1000 mg of cardiac tissue were lysed and quantified as described in paragraph 
2.5. 50 μg of protein lysate were mixed with 6x Laemmli loading buffer (380 mM tris 
HCl, 60% v/v glycerol, 12% w/v sodium dodecyl sulfate (SDS), 0.015 % w/v 
bromophenol blue), denaturated at 55° C for 10 min and loaded on 4-20% poly 
acrylamide gel (PAGE) and run at 34 mA for 1.5 h in 25 mM tris, 192 mM glycine, 0.1%. 
At the end of the electrophoresis step, the proteins were transferred at 400mA to a 
Hybond-ECL nitrocellulose membranes (supported, 0.22 μm pore) for 1.25 h at 4° C 
in 25 mM tris, 192 mM glycine, 20% methanol, pH 8.3,. The membranes were 
quickly rinsed in tris-buffered saline-tween 20 (TBS-T, 150 mM NaCl, 25 mM Tris-
HCl, pH 7.6 + Tween 20 0.1%), blocked in TBS-T + non-fat dry milk 5% w/v for 1 h 
at room temperature and incubated over night at 4° C using unlabelled primary 
antibodies diluted in TBS-T + non-fat dry milk 5% w/v. Specific dilutions and 
conditions for the antibodies used are summarized in Table 2.1 and will be listed in 
the relative chapters. The membrane were washed 3x in TBS-T (5 min each) and 
hybridized with horseradish peroxidase-labeled secondary antibodies (DAKO anti- 
mouse, rabbit or goat IgG 1:2000) for 1 h at RT in TBS-T + non-fat dry milk 5% w/v. 
The membrane was detected with ECL reagent (GE lifescience, NJ) following the 
guidelines indicated by the manufacturer. The results were standardized to the content 
of GADPH (Zymed, 1:1000) for cytosolic proteins or calsequestrin (Upstate, 1:1000) 
for SR proteins using ImageJ software (NIH) and MS Excel for data analysis.   
 
2.10 Immuno-precipitation 
~500-1000 mg of cardiac tissue were crushed in liquid nitrogen and homogenized in 
RIPA buffer (50mM tris-cl pH 7.4, 150mM NaCl, 1% NP40, 0.25% w/v Na-
deoxycholate, 1mM phenylmethanesulfonylfluoride (PMSF), 1x Roche complete mini 
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protease inhibitor, 1x Sigma phosphatase inhibitor). The lysates were centrifuged 10 
minutes at 14000 rpm in a tabletop microcentrifuge at 4° C to eliminate detergent-
insoluble fractions, the supernatant was collected and the protein content was 
quantified using a commercial Bradford protocol (Biorad, CA)(Bradford, 1976). 500 
μg of protein were diluted in tris-buffered saline (TBS, 150 mM NaCl, 25 mM Tris-
HCl, pH 7.6) and incubated with continuous agitation for 1 h at 4° C with 5 μg of 
antibody (see Table 2.1 for a complete list of sources and dilutions) to allow the 
formation of the immunocomplexes.  Following the incubation 20 μl of protein G-
coated sephadex G100 suspension (GE Bioscience, NJ) were added to capture the 
immunocomplexes and incubated overnight at 4 C in gentle continuous agitation. The 
next day the sephadex-immunocomplex particles were pelleted for 5 min at 14000 
rpm in a tabletop microcentrifuge at 4° C, the supernatant removed and the pellet was 
resuspended in IP washing buffer (150 mM NaCl, 50 mM hepes, 0.1% triton X-100, 
pH 7.6 + proteinase inhibitors). This step was repeated three times to remove 
contaminations from unbound and aspecific proteins; the pellet was then resuspended 
in 30μl of 1x Laemmli loading buffer and denaturated at 95° C for 3 min to promote 
the dissociation of the sephadex-immunocomplex bonds. The released Sephadex was 
removed by pelleting for 3 min at 14000 in a tabletop microcentrifuge, while the 
supernant (~25 μl) was loaded on 4-20% PAGE and processed as described in chapter 
2.9. 
 
2.11 DADT/PAGE  
Snap frozen cardiac tissue was cut on a cryostat (temperature of the chamber: -18° C, 
temperature of the piece holder: variable between -18° and -23° C) at 20 μm thickness 
and collected in staining baskets. The basket containing 20-30 slices were immersed 
in PBS for 5 min and then incubated for 5 min in 1% thioflavin-S; the tissue was then 
differentiated in EtOH 70% for 5 min and rehydratated with two 5 min washes of PBS. 
The slides were transferred to a 1.5 ml tube and centrifuged at full speed for 30 s. The 
excess of PBS was removed and replaced with RIPA buffer (50 mM Tris-cl pH 7.4, 
150 mM NaCl, 1% v/v NP40. 0.25% w/v Na-deoxycholate, 1mM PMSF, 1x Roche 
Complete mini protease inhibitor, 1x Sigma phosphatase inhibitor). The lysates were 
incubated on ice for 30 min and centrifuged 10 min at 14000 rpm in a tabletop 
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microcentrifuge at 4° C to eliminate detergent-insoluble fractions, the supernatant was 
collected and the protein content was quantified using the Bradford protocol. 50 μg of 
whole cell protein lysate were mixed with 6x Laemmli loading buffer, denaturated at 
37° C for 1 h and loaded on a DADT/PAGE gel composed by a stacking portion 
(2.56% acrylamide, 0.45% diaminedithiol (DADT), 0.1 M tris pH 6.8, 10% glycerol, 
0.1% SDS, 0.06% ammonium persulfate, 0.5% tetramethylethylenediaminide) 
overlaid on the separating gel (10% w/v acrylamide, 0.5% w/v bis-acrylamide, 0.375 
M tris HCl pH 8.6, 10% v/v glycerol, 0.1% w/v SDS, 0.067% w/v ammonium 
persulfate, 0.067% w/v tetramethylethylenediaminide) (Fritz et al., 1989). The gel 
was run at 15 mA for 2 h and then the thioflavin-S signal was detected on a Typhoon 
9400 high-resolution gel laser scanner (GE lifescience, NJ) set at 430/550 nm 
(excitation/detection). 
 
2.12 Agarose gel for protein separation 
1 g of frozen cardiac tissue was ground in liquid nitrogen and homogenized in RIPA 
buffer (50 mM tris-HCl pH 7.4, 150 mM NaCl, 1% v/v NP40. 0.25% w/v Na-
deoxycholate, 1mM PMSF, 1x Roche complete mini protease inhibitor, 1x Sigma 
phosphatase inhibitor). The lysates were centrifuged 10 minutes at 14000 rpm in a 
tabletop microcentrifuge at 4° C to eliminate detergent-insoluble fractions. The 
supernatant was collected and the protein content was quantified using the Bradford 
protocol (Bradford, 1976). 500 μg of protein lysate were mixed in a 1:1 ratio with 2x 
tris-glycine loading buffer (125 mM tris HCl pH 6.8, 15% v/v glycerol, 4% w/v SDS, 
0.002% w/v bromophenol blue, 1.25 M β-mercaptoethanol), denaturated at 95° C for 
5 min and loaded on 2% SeaPlaque GTG agarose gel (Lonza, ME) prepared in 1x 
running buffer (90 mM tris base, 90 mM boric acid, 0.1% SDS) and placed in a 
horizontal submarine apparatus. No stacking gel was present. The gel was run at 80 V 
for 2 h and stained in Sypro Ruby® gel stain (Invitrogen, CA) following the 
instructions suggested by the manufacturer (Berggren et al., 2002). In particular, we 
selected to proceed following the longer basic protocol due to the higher thickness of 
the gel compared to a acrylamide one. Briefly, the gel was fixed in 50% v/v methanol, 
7% v/v acetic acid (2 changes of 100 ml, 30 min each), stained with the staining 
solution o.n. and washed for 30 min in 100 ml of 10% v/v methanol, 7% v/v acetic 
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acid. All the steps were performed at RT in continuous agitation and, after the 
addition of the Sypro reagent, in controlled light conditions. Particular attention was 
focused on avoiding keratin contamination from the operator by using disposable 
sterile containers and tools for this step and the following. At the end of the staining 
process the gel was stored in fresh wash solution and imaged on a Typhoon 9400 
high-resolution gel laser scanner (GE lifescience, NJ) with excitation set at 450 nm, 
emission at 650 nm and photomultiplier at 500 V.  
 
2.13 Detergent extraction of amyloid fibers 
The separation of hydrophobic amyloid structures was based on a modification of the 
protocol previously described by Ramsby et al. (Ramsby and Makowski, 1999). Snap-
frozen cardiac tissue (~1 g) was crushed in liquid nitrogen and immediately 
transferred in TBS 1x + 1x Complete® proteinase inhibitor cocktail (Roche, CH) in 
round bottom 14 ml tubes. The samples were homogenized with a PT10-35 Polytron 
homogenizer with 3 cycles of 30 s each intercalated with 1 min of incubation on ice to 
prevent excessive protein degradation. The suspension was processed with a Branson 
250 sonicator at 40% of power for 10 times for 10 s each. Each sonication cycles was 
followed by 1 min on ice to prevent overheating of the samples. 1 ml of sample was 
transferred to an Eppendorf tube and ~100 μl of glass beads (500 μm in diameter) 
were added. The tubes were vortexed at full speed for 1 min and centrifuged at 14000 
g for 10 min at 4° C to remove the insoluble debris and the beads. The protein content 
of the supernatant was evaluated with a commercial Bradford protocol (Biorad, CA) 
and saved for SDS-PAGE analysis. The insoluble residue from the centrifugation was 
resuspended in 200 μl of TBS 1x + triton-X 1% v/v + 1x Complete® proteinase 
inhibitor cocktail (Roche, CH), vortexed, incubated on ice for 30 min and centrifuged 
as above. The Triton-X-soluble phase was collected and the protein concentration was 
evaluated using a Lowry method-based commercial kit (RC-DC, Biorad, CA)(Lowry 
et al., 1951). The triton-X-insoluble material was resuspended in 200 μl 1x TBS+ 
SDS 2% w/v + 1x Complete® proteinase inhibitor cocktail (Roche, CH) and 
processed as above. The supernatant was loaded on a SDS-PAGE 4-20% and stained 
with coomassie blue at the end of the run (Meyer and Lamberts, 1965). 
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The insoluble residue from the SDS extraction was resuspended in 1 ml of 1x TBS + 
formic acid 70%, vortexed, incubated 30 min at RT and centrifuged to remove the 
insoluble material. The supernatant was transferred to a new tube and the pH was 
neutralized by slowly adding ~120 μl of 1 N NaOH while incubating on ice. The pH 
of the solution was tested on pH paper and the solution was dialyzed with 3 kDa-pore 
centrifuge concentrators (Millipore, MA). 
 
2.14 Oligomer immunoprecipitation and PAGE separation 
Snap-frozen cardiac tissue (~1 g) was processed and quantified as in paragraph 2.20 
and 500 μg of total proteins were used for the following analysis. The lysates were 
diluted with TBS + 1x Complete© proteinase inhibitor cocktail to 500 μl and 
incubated with the anti-oligomer antibody A11 (Invitrogen, CA – AHB0052 1:100) 
for 1 h at 4° C in continuous agitation. The immunocomplexes were isolated using 20 
μl of protein G-coated sephadex G100 particles (GE lifesciences, NJ), which were 
incubated overnight in the solution in continuous agitation at 4 C. The sephadex-
immunocomplex particles were precipitated by centrifugation for 5 min at 14000 g at 
4° C, the supernatant removed and the pellet was resuspended in TBS + 1x 
Complete© proteinase inhibitor cocktail. This step was repeated three times; the pellet 
was then resuspended in 30 μl of 1x Laemmli loading buffer and denaturated at 95° C 
for 3 min to promote the dissociation of the sephadex-immunocomplex bounds. The 
released sephadex was removed by pelleting for 3 min at 14000 rpm in a tabletop 
microcentrifuge at RT, while the supernant (~25 μl) was loaded on 4-20% PAGE and 
run at 34 mA for 1.5 h in 25 mM tris, 192 mM glycine, 0.1% SDS. The gel was removed 
form the cassette and stained in Sypro Ruby® gel stain (Invitrogen, CA) as described 
in chapter 2.12. The acquired image of the gel was transferred to a Non-Linear 
workstation and analyzed using the TotalLab v.2005 software to automatically 
identify the bands in each lane. The automatic recognition was manually monitored 
and, when necessary, corrected by analyzing the densitometry profile of the lane. The 
bands showing statistically different intensity between DCM and non-failing (p<0.05) 
were isolated by band excision on a regular UV transilluminator and stored for 
subsequential analysis in 10% v/v methanol, 7% v/v acetic acid. 
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2.15 Differential sedimentation of unfolded structures 
Density-based separation of amyloid fibers was performed by modification of a 
previously described protocol for protein aggregates extraction from E. Coli (Schrodel 
and de Marco, 2005). 1 g of frozen tissue was ground in liquid nitrogen using a pestle 
and collected in a 15 ml tube on ice. The sample was stained with 5 ml of thioflavin-S 
solution (0.125% thioflavin-S, 1% triton-X) and homogenized 60 s with a PT10-35 
Polytron homogenizer at full speed. The tube was incubated 10 min on ice to allow 
the thioflavin-S to infiltrate the amyloid structure of the unfolded proteins. The excess 
of dye was removed by centrifuging the sample for 10 min at 15,000 g at 4° C and the 
pellet was washed by resuspending in ethanol 50% v/v and centrifuging 10 min at 
15,000 g at 4°C. The ethanol was eliminated and the pellet was washed in deionized 
H2O and recentrifuged in the same conditions. The supernatant was removed and the 
pellet was resuspended in lysis buffer (150 mM NaCl, 20 mM Tris pH 7.6, 1 mM 
CaCl2, 1% NP-40, 1% triton-X, 10% glycerol, 1% SDS, Complete proteinase 
inhibitors (Roche, CH)) and sonicated with a Branson 250 apparatus at 40% power 
with 15 cycles of 10 s sonications/1 min on ice. The sample was centrifuged 10 min at 
full speed at 4° C in a regular tabletop centrifuge. The soluble and insoluble phases 
were separated and loaded on different sucrose step gradients (0%, 30%, 50%, 70%, 
80% in 20 mM tris pH 8.0). The tubes were centrifuged for 18 h at 4° C at 180,000 g 
and the thioflavin-positive bands were detected by using a UV light source and 
isolated by needle aspiration. Each band was then loaded on appropriate continuous 
gradients (25→60%, 45→75% or 60→80% depending on the level where the band 
was isolated) and centrifuged 18 h at 180,000 g at 4° C. The tubes were unloaded and 
observed under UV line to identify thioflavin-positive bands that were collected by 
needle aspiration and saved for further analysis. A small aliquot of each band was 
separated to evaluate the relative aggregation index. This parameter was calculated as 
ratio between Abs280 and Abs340, accordingly to what has been previously described 
(Schrodel and de Marco, 2005). 
 
 
 
 
Materials and Methods 
  
 
 105
2.16 Mass spectrometry 
The protein extracts were analyzed by ion trap - liquid chromatography tandem mass 
spectrometry (LC-MS/MS) by the Proteomics Resource Center at the Harvard School 
of Public Health (Boston, MA). Briefly, the samples were desalted using Centricon 
concentrators (Millipore, MA – membrane cutoff size 5 KDa) and re-constituted in 
0.1% formic acid. The extracts were transferred in Eppendorf tubes, denatured with 6 
M guandine hydrochloride, 50 mM NH4HCO3 at RT for 30 min and concentrated with 
Centricon concentrator. The guanidine hydrochloride was diluted by refilling the top 
cup with 50 mM NH4HCO3 and the sample was re-concentrated. This step was 
repeated three times to achieve almost complete removal of guanidine HCl (<15 μM 
final). The samples were collected from the concentrator and reduced in dithiothreitol 
(DTT) 10 mM final at 37° C for 15 min, followed by addition of iodoacetamide 50 
mM final at RT in dark. DTT and iodoacetamide were removed by concentrator as 
described for guanidine HCl. The samples were digested by adding 50 U/ml trypsin 
(1/50 of the total volume) and incubating overnight at 37° C. The reaction was 
stopped with formic acid (0.2% v/v final), loaded on the liquid chromatography 
apparatus and finally transferred to the MS instrument (LTQ Orbitrap, Thermo 
Scientific), which was controlled by the Xcalibur software. The results were analyzed 
using Bioworks 3.0 (Thermo Scientific). 
 
2.17 Oligomer in-vitro production 
Oligomer solution was obtained using Aβ42 purified peptide (Sigma, MO) as 
described by Kayed et al. (Kayed et al., 2003). The lyophilized peptide was 
reconstituted with a mix of H2O:acetonitrile 1:1 and diluted to a final concentration of 
2 mM in hexafluoroisopropanol. The diluted solution was sonicated for 30 s and 
added to ddH2O in a siliconized container. The hexafluoroisopropanol was removed 
by evaporation and the water-based solution was continuously stired for 96 h. 
Aliquots were sampled at 6 and 12 h and every 12 h afterwards in order to verify the 
correct formation of the pre-amyloid molecular species. This process was monitored 
by blotting the samples on a sheet of Hybond-ECL nitrocellulose membrane 
(supported, 0.22 μm pore). The membrane was dried, quickly rinsed in TBS-T, and 
processed as described in chapter 2.9 using a primary antibody specifically 
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recognizing the three-dimensional structure of oligomers (Invitrogen, CA – 
AHB0052). This protocol produces mostly oligomers in the spherical conformation. 
More complex structures (annular protofibrils and pores) were instead obtained 
adding 5% of hexane. 
At the end of the process the mature fibrils were separated from the solution by 
centrifugation (14000 g at 4° C for 20 min) and their conformation was verified by 
electron microscopy analysis.  
 
2.18 Cardiomyocyte isolation  
Murine cardiomyocytes were isolated as previously described by Liao et al. (Liao and 
Jain, 2007). B6 normal mice (Charles River Labs, MA, age: 4-8 weeks) were injected 
with 0.2 ml of heparin (2 mg/ml) and sacrificed by cervical dislocation; the heart was 
immediately removed and placed in ice-cold sterile saline. The heart was cannulated 
through the aortic valve, secured to the catheter with 3.0 silk suture, connected to a 
perfusion pump and placed in a thermostated glass jacket set to maintain the 
temperature of the organ around 37° C during the perfusion process. The heart was 
perfused for 3 min at 3 ml/min with Ca2+-free perfusion buffer (137 mM NaCl, 4 mM 
KCl, 1 mM MgCl2, 10 mM hepes, 0.33 mM NaH2PO4, 10 mM glucose, 5 mM taurine, 
10 mM 2,3-Butanedione monoxime (BDM) pH 7.4) and then perfused with enzyme 
buffer (perfusion buffer + 360 mg/L collagenase B (Roche, CH), 480 mg/L 
collagenase D (Roche, CH), 60 mg/L protease XIV (Sigma, MO)) until the tissue was 
soft (7-10 min). Both the solutions were equilibrated at 37° C before use and 
continuously oxygenated during the whole process to prevent ischemic degeneration 
of the tissue. The heart was removed from the perfusion apparatus and placed in a 
sterile Petri dish containing transfer buffer (perfusion buffer + bovine serum albumin 
0.5 mg/ml), in which the tissue was mechanically dissociated using two sets of 
forceps. The cell suspension was filtrated through strainers and pelleted by gravity in 
transfer buffer with increasing concentration of Ca2+ (0.06 mM, 0.24 mM, 0.6 M, 1.2 
mM, 15 min each). The cell pellet obtained from the 1.2 mM Ca2+ was isolated and 
used for the following experiments.      
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2.19 Cardiomyocyte contractility analysis 
Mouse cardiomyocytes isolated as described above were incubated 5 min in Fura-
2AM (Invitrogen, CA) at RT and seeded in a flow chamber placed on an inverted 
microscope as previously described (del Monte et al., 1999). The cells were allowed 
to attach to the surface of the chamber for 5 min without any flow and successively 
superfused with Tyrode solution (137 mM NaCl, 4 mM KCl, 1 mM MgCl2, 10 mM 
hepes, 0.33 mM NaH2PO4) at 37° C. External stimulation was applied with a biphasic 
pulse (frequency: 50 Hz, V: 50% above threshold). Due to the presence of damaged 
cells in the suspension, the myocytes used in this study were selected based on their 
aspect: cells without a clear striation pattern and showing presence of sarcolemmal 
blebs or granulation were excluded. The cells characterized by acceptable appearance 
were analyzed up to 12 h after the isolation. After obtaining stable contraction and 
Ca2+ transient, the baseline was recorded. The cardiomyocytes were then exposed to 
0.5 or 5 μg of oligomers by rapid cell-focused administration of the solution through 
an Octaflow apparatus (ALA Scientific, NY). 
Control cells were treated in the same conditions replacing the oligomer solution with 
plain PBS. The cardiomyocyte contraction amplitude and rate of contraction were 
monitored using a camera and a system equipped with Ionoptix software (Ionoptix, 
MA), which has embedded edge detection. The intracellular Ca2+ content of the cells 
was monitored in real time by recording the excitation ratio of fura-2 at 340 and 380 
nm with a dual-excitation spectrophotometer. All these experiments were performed 
in controlled light environment to minimize external interference from ambient light. 
 
2.20 Genetic analysis  
Genomic DNA was extracted from 200 mg of frozen cardiac tissue using Qiagen 
DNeasy kit (Qiagen, Germany) according to the guidelines suggested by the 
manufacturer. The genomic DNA was eluted in 30 μl and quantified with a Nanodrop 
spectrophotometer (Nanodrop, DE). In order to sequence the entire codifying and 
promoter regions, we used sets of primers selected at a distance of at least 20-30 bp 
from the extremity of each exon or of the promoter. The primers were kindly provided 
by the Genetic and Aging Research Unit at Massachusetts General Hospital. 
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The PCR was performed using Phusion® polymerase (NEB, MA). The following 
conditions were used for the amplification of each primer set: 
 
Genomic DNA 100 μg 
Buffer HF 5x 10 μl 
Primer mix 10 μM each 2.5 μl 
dNTPs 2.5 mM each 4 μl 
ddH2O Up to 50 μl 
Enzyme 2 U/μl 0.5 μl 
 
Initial denaturation: 98° C for 30 s 
35 cycles: 98° C for 15 s 
      annealing† for 15 s 
      72° C for 20 s 
Final extension: 72° C for 7 min 
 
†: the annealing temperature (Ta) for each primer set was obtained calculating the 
annealing temperature of each primer (= [(a+t) x 2 + (g+c) x 4] – 4) and setting the 
lower temperature of the pair as Ta for the reaction. 
 
An aliquot (5 μl) of the PCR products was verified on an agarose gel and the 
remaining was purified by spin-column (PCR purification kit, Qiagen, Germany) 
following the instructions suggested by the manufacturer. The purified products were 
sequenced and the resulting electropherograms from DCM samples were compared to 
gene sequences published in Genebank (http://www.ncbi.nlm.nih.gov/, NCBI Build 
36.1), in the University of California-Santa Cruz Human Genome Database 
(http://genome.ucsc.edu, The March 2006 Human Reference Sequence) and to a 
database of genomic sequences isolated form lymphoblasts of AD patients and normal 
controls and conserved at the Genetic and Aging Research Unit at Massachusetts 
General Hospital. The analysis was performed using Genecode Sequencher 4 
(Genecode, MI). 
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2.21 PSEN1 Promoter variant expression level evaluation 
Genomic DNA was extracted from normal and mutated samples and quantified as 
above. The promoter regions 72672641-72673058 and 72673065-72673530 of the 
PSEN1 gene (including respectively the mutation position -92 and -21) were 
amplified by PCR using Phusion® polymerase (NEB, MA) and the following primer 
sets, which included restriction enzyme-recognized sequences for easier cloning and a 
short poly-a to facilitate the restriction enzyme processing (in parenthesis): 
  
 PSEN1-92 FWD: 5’-(AAAGCTAGC)GCCTCTAGGCAAGCAATTTTG Tm 
62° C 
 PSEN1-92 REV: 5’-(AAACTCGAG)TATGTCCATCTTTCCATGT 
GAATAC Tm 66° C 
 
 PSEN1-21 FWD: 5’-(AAAGCTAGC)TGTTACCTGGAAGAAGC Tm 60° C 
 PSEN1-21 REV: 5’-(AAACTCGAG)AAATCTCATCTTGAATTGATTG Tm 
58° C 
 
The following conditions were used for the amplification: 
 
Genomic DNA 100 μg 
Buffer HF 5x 10 μl 
Primer mix 10 μm each 2.5 μl 
dNTPs 2.5 mM each 4 μl 
ddH2O Up to 50 μl 
Enzyme 2 U/μl 0.5 μl 
 
Initial denaturation: 98° C for 30 s 
35 cycles: 98° C for 15 s 
      58° C (PSEN1-92) or 54° C (PSEN1-21) for 15 s 
      72° C for 20 s 
Final extension: 72° C for 7 min 
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The normal and mutated fragments (-92C, -92delC, -21G and -21A) were purified by 
spin-column (PCR purification kit, Qiagen, Germany) following the instructions 
suggested by the manufacturer and digested o.n. with NheI and XhoI (NEB, MA). 
The digested fragments were separated on a 0.8% w/v agarose gel, excised, gel 
purified with a gel extraction kit (Qiagen, Germany) and ligated into the promoterless 
vector  (Promega, WI, Figure 2.1) preventively digested with the same restriction 
enzyme set and gel purified. The following conditions were used for the ligation: 
 
Insert 90 fmol 
Backbone 30 fmol 
Ligase 1 U/μl (Invitrogen, Ca) 1 μl 
Ligase buffer 5x 4 μl 
ddH2O Up to 20 μl 
 
The reaction was performed for 1 h at RT and the ligase was inactivated at 65° C for 
15 min. The ligated product was diluted 1:10 in ddH2O and 2 μl of the dilution were 
used to transform 40 μl of electrocompetent One Shot E.Coli (Invitrogen, CA) 
Figure 2.1. Map of pGL2-basic. (From: http://www.promega.com) 
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at 1800 V. The bacteria were allowed to express the ampicillin resistance gene for 1 at 
37° C in super optimal broth with catabolite expression media (2% w/v bacto-tryptone, 
0.5% w/v bacto-yeast extract, 8.56 mM NaCl, 2.5 mMKCl) and then plated on Luria 
broth (LB)-agar plates (1% w/v tryptone, 0.5% v/w yeast extract, 1% w/v NaCl, 1.2% 
v/w agar) + 75 μg/ml of ampicillin. The colonies were screened by restriction analysis 
and then sequenced to verify the correct amplification using the same primers used for 
the initial amplification (PSEN1-92 FWD and REV and PSEN1-21 FWD and REV). 
The clones matching the desiderated sequence were selected for the following 
experiments.  
To verify the activity of the promoter fragments cloned, we plated 8x104 H4 naïve 
neuroglioma cells (gift of Dr. Tanzi at Massachusetts General Hospital) in 24-well 
tissue culture plates using 500 μl/well of Dulbecco’s modified Eagle’s medium 4.5 
g/L glucose (Sigma, MO) supplemented with 9% heat-inactivated fetal calf serum 
(Sigma, MO), 100 units/ml penicillin (Sigma, MO), 100 μg/ml streptomycin and 2 
mM L-glutamine (Sigma, MO). The day following the plating the cells were 
transiently transfected with lipofectamine-2000 (Invitrogen, CA) following the 
protocol suggested by the manufacturer. As an internal control for the efficiency of 
transfection a second plasmid constitutively expressing Renilla luciferase (pRL-CMV, 
Promega, WI) was co-trasfected with the different forms of pGL2-PSEN promoter 
under investigation as previously described (Yang et al., 2004). Briefly, 0.4 μg of 
endotoxin-free pGL2 and 0.4 μg of pRL-CMV were diluted in 50 μl of Optimem 
media (Invitrogen, CA). In a different tube 2 μl of lipofectamine 2000 were mixed to 
50 μl of Optimem media and incubated at RT. After 10 min the two tubes were mixed, 
incubated for 20 min at RT and distributed on a well. After 48 h the cells were washed 
and the expression levels of the two reporter genes activity was assayed using a dual 
luciferase reporter assay (Promega, WI) as indicated by the manufacturer. Briefly, 
each well was harvested in 65 μl of passive lysis buffer 1x, the cell debris removed by 
centrifugation in a tabletop microcentrifuge (5 min at 14000 rpm at RT) and 10 μl of 
the supernatant were dispensed into a black 96-well assay plate. The plate was 
analyzed with a Victor 5 plate reader (Perkin-Elmer, MA) equipped with automated 
dual injector and programmed to dispense 100 μl of LARII reagent buffer (Promega, 
WI), followed by 2 s incubation and 5 s of firefly luciferase-emitted light detection. 
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The firefly luciferase reaction was blocked by addition of 100 μl of freshly prepared 
Stop and Glow reagent, which also provides the substrate for Renilla luciferase. 
Incubation and detection for this second step was performed as above. The activity of 
the promoter was calculated as the ratio between the Firefly and Renilla activities. 
pGL2 promoterless activity was used to estimate the background of the process. The 
result for each variant was indicated as percentage of the wild-type construct. Each 
comparison was performed in triplicate and statistical significance was calculated 
using Student’s t-test. 
 
2.22 Population analysis 
The single nucleotide polymorphisms (SNP) identified by sequence analysis were 
compared with the allele frequency and heterozygosity for the Caucasian normal 
population collected in the International HapMap database (http://www.hapmap.org) 
and in the NCBI SNP database, using the CEPH collection, which includes genomic 
information from Utah residents with Northern and Western European ancestors 
(Murray et al., 1994, Frazer et al., 2007).  
Allele frequency for AD patients was kindly provided by Genetic and Aging Research 
Unit at Massachusetts General Hospital. 
 
2.23 RNA purification 
RNA from patient samples was prepared as recommended by Affymetrix guidelines 
Rev. 5. 500 mg of frozen tissue was crushed using a mortar and a pestle in liquid 
nitrogen and collected in a round bottom 14 ml tube. 5 ml of cold TRIzol (Invitrogen, 
CA) were added and the suspension was homogenized with a Polytron homogenizer 
for 30 s at full speed keeping the tube on ice. The tube was placed on ice for 1 minute 
before repeating the procedure to avoid overheating the sample. The Polytron probe 
was rinsed after each sample with diethylpyrocarbonate (DEPC) water, cleaned with 
ethanol and rinsed again in fresh DEPC water. The excess of DEPC water was 
removed using sterile gauze before processing the next sample. Each sample was 
divided in 5 RNAse-free 1.5 ml microcentrifuge tubes and centrifuged 10 min at 
12,000 g at 4C to remove remaining insoluble material. The supernatant was 
transferred to a new microcentrifuge tube, incubated at RT for 5 min and mixed with 
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200 μl of chloroform. The organic and the aqueous phases were mixed by vortexing 1 
minute at full speed, incubated 3 min at RT and centrifuged 15 min at 12,000 g at 4C. 
After this spin the aqueous phase formed a clear layer on top of the pink organic 
phase. The aqueous phase was transferred to a fresh tube trying not to perturb the 
organic phase in order to avoid carryover and contamination that could compromise 
the downstream reactions. 500 μl of cold RNAse-free isopropanol were added to 
precipitate the nucleic acids, the tubes were incubated 10 min on ice and the nucleic 
acids were pelleted at 12,000 g for 10 min at 4C. The isopropanol was removed and 
the pellets were washed with 75% v/v RNase-free ethanol. The tubes were re-
centrifuged as above and the ethanol was totally removed by aspiration. The pellets 
were dried on ice for 10 min to allow complete evaporation of the residual ethanol 
and resuspended in nuclease-free non DEPC-treated water (Sigma-Aldrich, MO). 
Total RNA was further purified from protein contaminations using RNeasy Mini Kit 
colums (Qiagen, CA) following the guidelines suggested by the manufacturer and 
eluted in a total volume of 50 μl. 1.5 μl of the samples were analyzed on a Nanodrop 
(Nanodrop, DE) spectrophotometer to evaluate concentration and purity (i.e., Abs 
260/280 ratio). The integrity of the RNA and presence of RNase contamination were 
then assayed using a 2100 Bioanalyzer microfluidistic station (Agilent Technologies, 
CA) equipped with RNA nano chips.  
 
2.24 cRNA preparation  
Only the RNA samples showing no signs of degradation, appropriate 260/280 ratio 
(>1.8) and with concentration higher than 1 μg/μl were selected for further analysis as 
described in the Affymetrix guidelines Rev. 5. 20 μg of total RNA from each sample 
were mixed with 2 μl of T7-Oligo(dT) primer (50 μM) and with a combination of 
exogenous PolyA mRNA. The reaction controls included a set of polyadenylated 
RNA messengers for B. subtilis genes that are absent in eukaryotic samples: lys, phe, 
thr and dap. The volume was adjusted to 11 μl with RNase-free non DEPC-treated 
water. The secondary structures of the RNA were resolved by incubating the reaction 
mixes at 70° C for 10 minutes and then cooled to 4° C for 2 min. The RNA was 
reverse transcribed to cDNA by adding 2 μl of DTT 0.1 M, 1 μl of dNTPs (10 mM 
each) and 4 μl of 5x 1st strand reaction mix (Invitrogen, CA). The reaction mix was 
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preincubated 2 minutes at 42°C before adding 2 μl of Superscript II reverse 
transcriptase and incubating for 1 h at 42° C. The reverse transcription was stopped by 
incubating at 4° C for 2 min. The second strand of cDNA was synthesized by adding 
91 μl of RNAse-free non DEPC-treated water, 30 μl of 5x 2nd strand reaction mix, 3 
μl of dNTPs (10 mM each), 1 μl of E. coli DNA ligase, 4 μl of  E. coli DNA 
polymerase I. The RNA present in the reaction mix was degraded by adding 1 μl of 
RNAse H. The samples were incubated at 16° C for 2 hours before adding 2 μl of T4 
DNA polymerase and incubating 5 min at 16° C. The reaction was stopped by adding 
10 μl of 0.5 M EDTA and the double stranded cDNA was purified using cDNA 
cleanup spin columns (Qiagen, CA). The samples were mixed to 600 μl of cDNA 
binding buffer. The pH was checked using the pH indicator present in the binding 
buffer before loading the solution in the column. The column was spinned at full 
speed for 1 min and the flow-through was discarded. The column was washed by 
adding 750 μl of cDNA wash buffer and spun at 8,000 g for 1 min. The flow-through 
was discarded and the column was centrifuged for 5 min at full speed to remove any 
contamination from the ethanol present in the wash buffer. The cDNA was then eluted 
in a fresh tube by pipeting 14 μl of cDNA elution buffer directly on the membrane, 
incubating 1 min in upright position and centrifuging at full speed for 1 min.    
6 μl of the eluate were transcribed in vitro and labeled with biotin by adding 4 μl of 
10x in-vitro transcription (IVT) labeling buffer, 12 μl of IVT labeling NTP mix and 4 
μl of IVT labeling enzyme mix. The volume of the reaction was adjusted to 40 μl with 
RNase-free non DEPC-treated water (14 μl) and the samples were incubated for 16 
hours at 37° C. The biotinylated cRNA was purified using cRNA cleanup spin 
columns (Qiagen, CA). 60 μl of RNase-free non DEPC-treated water, 350 μl of IVT 
cRNA binding buffer and 250 μl of ethanol were added to the IVT reaction mix. The 
solution was loaded in a column and centrifuged at 8,000 g for 15 s. The flow-through 
was discarded and the filter was washed with 500 μl of wash buffer. The column was 
re-centrifuged as above and the flow-through was discarded. This step was repeated 
with a final wash of 500 μl of 80% ethanol. The flow-through was discarded and the 
residual ethanol removed by centrifuging for 5 min at full speed (14000 rpm in a 
tabletop centrifuge). 21 μl of RNAse-free non DEPC-treated water was added to the 
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membrane and the labeled cRNA was eluted in a fresh tube by spinning at full speed 
for 1 min.  
The cRNA was quantified using a Nanodrop spectrophotometer and diluted to a final 
concentration between 0.5 and 1 μg/μl. 
 
2.25 Hybridization 
The biotinylated cRNA was fragmented to 50-200 nucleotide fragments using a 
protocol based on a metal-induced reaction. 20 μg of cRNA were adjusted to 32 μl 
and mixed to 8 μl of 5x fragmentation buffer (Affymetrix, CA). The solution was 
incubated at 94°C for 35 min and then kept at 4° C. An aliquot (1 μl) of the reaction 
was assayed on an Agilent Bioanalyzer 2100 using a Pico RNA chip in order to verify 
the fragmentation pattern of the samples. 
The fragmented cRNA (20 μg in 39 μl) was mixed with 150 μl of 2x hybridization 
buffer (Affymetrix, CA, pre-equilibrated at RT), 3 μl of herring sperm DNA (10 
mg/ml prewarmed at 40°C), 3 μl of BSA (50 mg/ml pre-warmed at 40°C), and two 
exogenous controls: oligonucleotide B2 (Affymetrix, CA, 5 μl of 3 nM solution pre-
warmed at 40°C) and a 20x solution of bioB. bioC, bioD, cre. The hybridization 
cocktail was heated at 99°C for 5 min, cooled to 45°C for 3 min and centrifuged at 
full speed for 5 min to remove any insoluble material. In the meantime the U133 plus 
2.0 microchip arrays (Affymetrix, CA, one per sample) were equilibrated at room 
temperature for 15 min, preconditioned with 1x hybridization buffer and incubated at 
45°C for 10 min in a rotation oven. The preconditioning solution in the chips was 
removed and replaced with the hybridization cocktail. The cartridges were placed in 
the hybridization oven and incubated for 16 h at 45°C with rotation.  
After the incubation the chips were washed and stained on a Genechip Fluidistic 
Station 450 (Affymetrix, CA) according to the following protocol: 42 min in buffer A 
(300 μl of 2x stain buffer, 24 μl of BSA (50 mg/ml), 6 μl of phycoerythrin-conjugated 
streptavidin (Molecular Probes, CA), 270 of RNase-free non DEPC-treated water), 10 
min in Buffer B (300 μl of 2x stain buffer, 24 μl of BSA (50 mg/ml), 6 μl of goat IgG 
(Sigma-Aldrich), 3.6 of biotinylated anti-goat IgG Ab (Vector Laboratories) and 266 
of RNase-free non DEPC-treated water), followed by 27 min in Buffer A. 
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The cartridges were analyzed by eye to confirm the absence of bubbles in the reading 
area and scanned on a Genechip Scanner 3000 (Affymetrix, CA). 
 
2.26 Microarray analysis 
The data were exported as .cel file and normalized by global scaling. All the quality 
control parameters were calculated by the Affymetrix GeneChip Operating Software 
(Dumur et al., 2004). In addition the scanned images were examined to verify the 
absence of spotted, bleached or damaged area on the hybridization plates 
(Quackenbush, 2002). Data from different chips were normalized using the GeneChip 
Robust MultiChips Analysis algorithm (GCRMA), performed with R in Bioconductor 
(Cope et al., 2004, Wu and Irizarry, 2004). 
 
2.27 Statistical analysis and selection of differentially expressed probes 
A probe was considered absent in a group when the absolute intensity recorded for all 
the patients belonging to that group was lower than 8 fluorescence units as suggested 
by the manifacturer. This threshold was selected based on previous experience from 
the consultants that collaborated in this study. The expression of a particular probe in 
a determined group was indicated as the average of all the samples belonging to that 
group. Statistical significance was calculated using Spotfire DecisonSite 8.0 software 
by applying ANOVA and 2-tail unpaired t-test for unknown variance and multiclass 
analysis (Golub et al., 1999). mRNA levels were considered altered when either their 
content between two different groups was at least 2 (arbitrary value) fold up- or 
down-regulated. Any difference in expression was considered statistically significant 
only when the p value calculated by ANOVA and t-test was lower or equal to 0.05. 
The differentially expressed genes matching the parameters mentioned above were 
grouped in the following three categories: 
 DCM-specific genes: concurrently significantly up- or down-regulated both in 
DCM vs. controls and DCM vs. amyloidosis, but not significantly altered 
between amyloidosis and controls. 
 Amyloidosis-specific genes: concurrently significantly up- or down-regulated 
both in amyloidosis vs. controls and DCM vs. amyloidosis, but not 
significantly altered between DCM and controls. 
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 Failing-related genes: concurrently significantly up- or down-regulated both in 
amyloidosis vs. controls and DCM vs. controls. 
 
2.28 Clustering and self organizing maps 
K-means clustering and Self-organizing maps were used to group the genes identified 
as altered by similarity of profiles on the normalized average of the subgroups of 
samples (Tamayo et al., 1999). Hierarchical clustering on median normalized samples 
was performed on all samples using SpotFire DecisionSite 8.0 for Functional 
Genomics. The analysis was performed applying cosine correlation with complete 
linkage (Eisen et al., 1998, Datta, 2003). 
 
2.29 Functional analysis 
The genes which were significantly differentially expressed from the microarray 
analysis were further examinated to identify specific pathways involved in the 
diseases considered as previously described (Huang da et al., 2009a, Huang da et al., 
2009b). The data were respectively submitted to the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov/home.jsp), to the Kyoto Encyclopedia of Genes and 
Genomes (KEGG, http://www.genome.jp/kegg) and to the Biocarta database 
(http://www.biocarta.com) using the EASE software. The results from the algorithms 
were limited to association involving at least 2 genes with p<0.05.    
 
2.30 Data validation 
The data from the microarray analysis were confirmed by selecting a limited number 
of altered probes and evaluating their alteration by quantitative real-time PCR (qRT-
PCR). 
cDNA for the reaction was obtained by reverse transcribing 2 μg of total RNA from 
the same preparations used for the Genechip analysis using Omniscript RT Kit 
(Qiagen, CA). 
The RNA was mixed with 4 μl of 10x reverse-transcriptase buffer, 4 μl of dNTP mix 
(5 mM each dNTP), 4 μl of oligo-dT9 primer (10 μM), 20 units of RNAseOut RNAse 
inhibitor (Invitrogen, CA) and 8 units of Omniscript reverse transcriptase. The 
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volume was adjusted to 40 μl with RNAse-free non DEPC-treated water. The reaction 
mix was incubated 1 h at 37° C and the obtained cDNA was aliquoted in 3 μl single 
use aliquots to avoid repeated freeze/thaw cycles which could compromise the quality 
of the samples. 
The qRT-PCR was performed using an ABI Prism 7000 Thermocycler (Applied 
Biosystems, CA). Each sample was assayed in triplicate to minimize the experimental 
error. 1 μl of cDNA was mixed in 10 μl of QuantiTect SYBR Green PCR Kit (Qiagen, 
CA), 1 μl of primer mix containing 10 μM of the forward and reverse gene-specific 
primers and 8 μl of PCR grade water. The following gene-specific primer sets were 
used in the reactions: 
 
 ApoE F: 5’-CCAATCACAG GCAGGAAGAT-3’; R: 5’-CTGTCTCCAC 
CGCTTGCT-3’.  
 ANP F: 5’-GCCTAGGGAC AGACTGCAAG-3’; R: 5’-ATCACAACTC 
CATGGCAACA-3’. 
 BNP F: 5’-CCGCCTTTGA AGTGACTCAT-3’; R: 5’-ACCGTGGAAA 
TTTTGTGCTC-3’. 
 DSCR1 F: 5’-AGGGGCCACT CTCTACTGGT-3’; R: 5’-TTGCTGCTGT 
TTTCACAACC-3’. 
 Nestin F: 5’-CACCCTCAGA AAAGGAGGAG-3’; R: 5’-CAGGAAGAAA 
AGGTGCCTCA-3’. 
 RARRES1 F: 5’-CAACTGAAAA ACCCCTTGGA-3’; R: 5’-
GAAAGCCAAA TCCCAGATGA-3’. 
 STNC F: 5’-ATTCCCACCA ACAAAATCCA-3’; R: 5’-GGAAAAACAT 
GGCAGAGGAA-3’. 
 TNN1 F: 5’-GTGAGCATG GTGTGTATGC-3’; R: 5’-AGAGCATCTG 
GGAGGCACTA-3’. 
 
Each primer set was designed using Primer3 (http://frodo.wi.mit.edu/primer3/) using 
specific settings to minimize the possibility of hairpin secondary structures and primer 
dimer formation (maximum self complementarity = 8.00, maximum 3’ self 
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complementarity = 3.00). The optimal Tm for each primer was set at 60° C. The total 
length of the amplicons was 200±25 bp. When possible the primers were designed to 
match a junction region between 2 exons in order to minimize the possibility of 
amplification of genomic DNA contaminating the samples.  
The thermocycler was set to perform an initial step (2 min) at 50° C to allow the 
uracyl-N-glycosylase degradation of carryover DNA contamination from previous 
reactions. The Taq Polymerase was then activated for 15 min at 95° C before starting 
the cycling step consisting of denaturation at 94° C for 15 s, annealing at 60° C for 30 
s and extension at 72° C for 30 s. The data were acquired during the last step. The 
cycling step was repeated 40 times and was followed by a melting protocol to confirm 
the absence of secondary structures and/or dimerization of the primers. Only one gene 
was assayed on a single plate containing the cDNAs from all the patients 
simultaneously in order to minimize the experimental variability. Contamination from 
genomic DNA was evaluated performing an additional reaction using a set of intronic 
primers (F: 5’-CTGTCCTCCA ACTGTCAGCA-3’; R: 5’-CTCTTCCAAG 
GGGATCATCA-3’) 
The data were analyzed with the 7000 SDS 1.1 RQ application (Applied Biosystems, 
CA). The threshold for each gene was automatically calculated by the software. The 
automatic analysis was manually corrected in case the threshold was located in a non-
linear segment of the amplification trace. The CT of each gene was automatically 
calculated and the content of messenger RNA was standardized to the level of 18S 
rRNA (evaluated by qPCR using the primer set F: 5’- 
TCATGTGGTGTTGAGGAAGC -3’; R: 5’- GGCGTGGATTCTGCATAATG -3’).  
 
2.31 Statistical analysis 
Statistical analysis was generally performed by Student’s t-test using Excel software 
(Microsoft, WA). Results were considered significant when p<0.05. Specific 
statistical methods used for particular sets of data are described in the relevant 
Material and Methods sections.   
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3.1 Introduction 
 
 
In the last decade increasing attention has been focused on the role of unfolded 
protein material in the etiology and the progression of several diseases even 
traditionally non related to the presence of amyloid fibers, including Parkinson’s 
disease, Creuzfeldt-Jacob disease, diabetes, obesity and cancer (Hosoi and Ozawa). 
The first report showing correlation between a pathological condition and the 
presence of unfolded protein dates back to the beginning of last century when Alois 
Alzheimer presented to the scientific community a case of early age onset dementia 
characterized by the presence of aggregates resulting positive to silver staining. Later 
characterization of these aggregates allowed the identification of two distinct types of 
deposits, which are referred as senile plaques (extracellular) and neurofibrillar tangles 
(intracellular) and are respectively due to the accumulation of amyloid β (Aβ) and tau 
(Tanzi and Bertram, 2005).  
This condition (later named after its discoverer) is characterized by a large majority of 
sporadic cases with no clear genetic inheritance (~95%) (Bertram and Tanzi, 2004). 
However, several genetic studies performed on the remaining portion of the patients 
led to the identification of a significant number of fully penetrant mutations that are 
inherited following the classical Mendelian rules (Blacker and Tanzi, 1998). These 
mutations are all related to three specific genes codifying the Amyloid precursor 
protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) and mapping respectively on 
chromosome 21, 1 and 14. 
 
These three genes have been extensively characterized in the central nervous system, 
mainly due to their association with Alzheimer’s Disease (AD). However, a recent 
study suggested the presence of a correlation between heart failure and the presenilin 
genes by performing a linkage analysis on early-onset familial forms of dilated 
cardiomyopathy (DCM) (Li et al., 2006). In particular, Li et al reported two unknown 
mutations (D333G in PSEN1 and S130L in PSEN2) which where present in 0.9% of 
the families included in the study (3/325). PS1 and PS2 are highly conserved 
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polytopic proteins which are considered the catalytic core of the γ-secretase complex, 
an enzymatic complex that is involved in the cleavage of several cellular proteins 
such as notch (Zhao et al.) and, mainly, of APP with consequent production of Aβ (De 
Strooper, 2003).  
The function of these proteins in the heart hasn’t been completely elucidated. 
However studies conducted on knock-out mice for the presenilins showed their 
importance at a cardiac level even at very early developmental stages (Donoviel et al., 
1999, Nakajima et al., 2004).  An interesting function of the γ-secretase complex that 
has been observed in the brain is related to its capacity of interacting with sorcin, one 
of the major inhibitors of the ryanodine receptor (Lokuta et al., 1997, Pack-Chung et 
al., 2000, Farrell et al., 2003). 
If this last regulatory mechanism is confirmed in the cardiac muscle, PS1 and PS2 
could represent important molecules in the excitation-contraction coupling.  
 
The mentioned observations by Hershberger’s group on familial DCM (Li et al., 2006) 
open an innovative and interesting field of investigation for better understanding the 
non-familial forms of the disease. Only 35% of the cases of DCM can be directly 
correlated to genetic causes including in particular sarcomeric and cytoskeletal 
components as well as proteins associated to the regulation of the Ca2+ homeostasis 
(Schonberger and Seidman, 2001, Olson, 2004).  The majority of DCM cases are 
instead related epigenetic causes including exposure to toxic substances, infection or 
underlying presence of autoimmune diseases; however in a significant number of 
patients the disease cannot be associated to a specific causative agent. Therefore it is 
possible that some of these cases can be related to malfunction of the γ-secretase 
complex which may lead to dysfunction in Ca2+ homeostasis and eventually creates 
appropriate conditions for the accumulation of misfolded peptides. In general 
alterations in Ca2+ homeostasis in DCM lead to the extensively described contractility 
impairment typically observed in cardiomyocytes deriving from subjects affected by 
this condition. However, Ca2+ has several other important roles in eukaryotic cells 
beside the regulation of the contraction, including regulation of the apoptotic process, 
signaling and protein folding.  This last process, in particular, occurs mostly in the 
ER/SR, involving several proteins which are considered Ca2+-dependent. Therefore 
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the depletion of sarcoplasmic Ca2+ characterizing late-stage DCM cardiomyocytes 
might produce impairment on the post-translational folding of the polypeptide chains, 
leading to the progressive accumulation of unfolded peptides forming β-sheeted 
structures.  
 
At the moment only three forms of cardiac degenerative conditions leading to heart 
failure have been related to the accumulation of unfolded protein fibers: light chain 
amyloidosis, transthyretin (TTR) cardiomyopathy (Kelly and Strauss, 1994) and 
desmin cardiomyopathy (Bova et al., 1999, Li et al., 1999). However, only the latest 
is specifically related to folding dysfunction in the cardiac cells. Amyloidosis and 
TTR cardiomyopathy, instead, originate in the immune system and in the liver 
respectively as consequences of immunoglobulin-overexpressing lymphomas 
(Buxbaum, 2004) or expression of mutated insoluble forms of prealbumin (Hesse et 
al., 1993). The presence of unfolded insoluble fibers in the circulation and their 
deposition in the cardiac muscle leading to increased stiffness and impaired 
contractility of the organ has been considered the only reason for cardiac dysfunction 
for several years (McCarthy and Kasper, 1998). On the other side, recent findings 
suggest that the devastating effects of unfolded protein accumulation in the heart may 
be also mediated at least in part by the presence of soluble precursors of the amyloid 
fibers which do not have any effect on the alteration of the mechanical property and 
stiffness of the organ. These molecules, called oligomers, are β-sheeted protein 
aggregates formed by a limited number of peptides (3 to 12) commonly detectable in 
all the form of foldopathies and usually present in large amount in the proximity of 
mature fiber formations. This hypothesis is supported by several studies conducted on 
isolated neurons suggesting that the deleterious effects of the accumulation of Aβ in 
AD are not mediated (at least totally) by the presence of the insoluble amyloid fibers 
but are instead related to the presence of the intermediates of the fibrillogenesis 
process (Gong et al., 2003, Klyubin et al., 2004, Walsh and Selkoe, 2004, Cleary et al., 
2005).  
 
In this chapter we will focus our attention on the determination of the role of AD-
related proteins in the etiology of idiopathic DCM: our results show interesting 
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dysregulation of the levels of APP, PS1 and PS2 that can be related to the altered 
calcium homeostasis commonly observed in late-stage DCM. Additionally, we report 
and characterize two novel mutations in the promoter regions of PS1 and PS2, which 
led to significant decreased expression of the two proteins.  
Because of the role that PS1 and PS2 have in the regulation of the RyR and calcium 
release from the sarcoplasmic reticulum, we will evaluate the impairment in the 
protein folding process. According to our data DCM cardiomyocytes show 
intracellular deposits of β-sheeted fibers and high levels of oligomers, which exhibit 
the capacity of impairing the mechanical property of the cell.   
In addition we will address the effects that the accumulation of unfolded peptide has 
on the cell by evaluating the levels of key components of the unfolded protein 
response (UPR). 
 
 
3.2 Results 
 
3.2.1 Detection of Protein Aggregates 
 
The detection of β-sheeted aggregates is normally achieved in clinical practice for the 
diagnosis of AD or other amyloid-related diseases using histochemical approaches 
based on the use of dyes such as Congo Red and Thioflavin-S (Figure 3.1). These 
3.1. Molecular structure of Congo 
Red (top) and thioflavin-S (bottom). 
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dyes are characterized by the capacity of specifically binding β-sheeted deposits 
independently of the amino-acid sequence, respectively giving red-orange staining in 
bright light associated with apple-green birefringence under polarized light (Congo 
Red) and intense fluorescence in the green spectrum after UV exposure (Thioflavin-S). 
 
Samples from idiopathic DCM hearts (n=23) and non-failing donors (n=14) were 
stained using Congo Red. The staining protocol was validated using cardiac muscle 
samples from systemic amyloidosis (n=6) as positive controls. As expected all the 
positive controls showed diffused red-orange staining in the extracellular matrix, 
while no signal was detectable in the cardiomyocyte fibers. 17 out of 23 (74%) of the 
idiopathic DCM samples we tested showed intense signals (Figure 3.2). However, the 
distribution of the dye was significantly different from what observed in the 
amyloidosis samples: the staining signal was concentrated within the cardiomyocytes, 
while no evident staining was observed in the extracellular matrix. Instead, most of 
the donor samples didn’t show any Congo Red positivity, except for 2 out of 14 
(14%). Interestingly both these two samples derived from 75 year-old subjects, which 
were the oldest included in the donor group. 
These data were confirmed using thioflavin-S staining as an alternative protocol in 
order to minimize the possibility of false positives due to the unspecific binding of 
d
a
b d
c
f
e
3.2. Congo red staining of non-failing (a: transversal, b: longitudinal), amyloid (c: 
transversal, d: longitudinal) and DCM (e: transversal, f: longitudinal) samples. Congo red 
analysis shows the presence of congophilic materials in the cytoplasm of DCM cardiomyocytes. 
This observation is in contrast to what observed in systemic amyloidosis, in which the deposition of 
congophilic material is diffused in the extracellular matrix. 
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Congo Red to proteins characterized by periodic structure such as collagen (Figure 
3.3).  
 
Further verification of the findings deriving from the histochemical staining was 
obtained from the ultrastructural evaluation of the idiopathic DCM hearts (n=5). The 
samples analyzed were specifically selected in order to avoid interference and 
presence of false positives associated to the severe degeneration of the cellular 
functions in late-stage DCM and the physiological accumulation of aggregates 
observed in the aging process. Early-stage idiopathic DCM sample were obtained 
from explanted organs (n=5) from subjects with an average age of 52 years old (range 
31-65) or from biopsies (n=2) deriving form subjects with an average age of 45 (range 
24-65). The electron microscopy analysis of these samples clearly showed the 
presence of large areas of disorganized high-contrast material of proteic nature mainly 
in the cytoplasm and partially in the extracellular compartment (Figure 3.4), 
resembling the distribution of tau-originated tangles and β-amyloid plaques in AD 
(Kayed et al., 2003). These aggregates don’t present any similarity with physiological 
fibers such as collagen. In addition they seem to be more abundant in proximity of the 
myofilaments and appear to induce a disorganizing effect on the filament itself 
(arrows). The deposits were observed in all the subjects analyzed, which included 
biopsies from early-stage DCM (Figure 3.5, arrows). This suggests the presence of 
strong relationship between the presence of these structures and the onset and 
progression of idiopathic DCM. 
b ca
3.3. Thioflavin-S staining. Thioflavin staining of non-failing (a), amyloid (b) and DCM patients 
(c) clearly showed the presence of intracellular amyloid aggregates in the DCM samples, while the 
amyloid patient used as positive control showed the presence of aggregates in the extracellular 
matrix. 
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3.2.2 Evaluation of the levels of AD-related proteins 
 
In the last decade increasing interest has been focused on the relationship between γ-
secretase and the regulation of Ca2+ content in the cell. This process is apparently 
mediated by several mechanisms including direct (Hayrapetyan et al., 2008) and 
sorcin-mediated (Lokuta et al., 1997, Pack-Chung et al., 2000, Farrell et al., 2003) 
modulation of the RyR and direct interactions between presenilins and SERCA (Jin et 
al.). To elucidate the role of presenilins in the regulation of the cardiac isoform of 
SERCA, we first evaluated the presence of interaction between the two molecules by 
coimmunoprecipitation. As expected SERCA2a behaves similarly to SERCA2b and 
coimmunoprecipitated with PS1 in almost all the samples analyzed (SERCA2a 
antibody: Thermo, MA dil 1:1000, α-PS1: for IP: Millipore, MA dil 1:100, for WB: 
Millipore, MA, dil 1:1000, Figure 3.6). These data suggest that alterations of the 
3.4 Electron microscopy analysis of DCM 
samples. The sample analyzed showed 
presence of indistinct protein material (circles 
in a, higher magnification in b) in proximity of 
the contractile apparatus (arrows). These 
deposits appear to be associated to disruption of 
the fibers. In c low magnification of 
amyloidosis sample in which amyloid deposits 
are located in the extracellular space. 
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content or of the activity of the components of the γ-secretase complex might be 
sufficient to generate anomalies in the calcium homeostasis that can lead to the 
formation of the unfolded peptide deposits previously described and can contribute to 
the development of a failing condition at least in part.  
In order to verify whether our observations were related to altered content of the γ-
secretase components, we evaluated the levels of the catalytic subunit of the complex 
(i.e., presenilin 1 and presenilin 2) by performing Western blots on pooled 
sarcoplasmic reticulum preparations from non-failing and DCM samples (antibodies: 
α-PS1: Millipore, MA dil 1:1000, α-PS2, Thermo, MA dil 1:750). Interestingly, our 
results showed undetectable levels of PS2 in DCM samples (Figure 3.7) associated 
with a moderate increase of the content of full length PS1 (50 kDa band), which 
averaged 46% according to densitometry ratio quantification. As presenilins are 
3.5 Electron microscopy of 
biopsies from DCM 
patients. All the samples 
analyzed showed the 
presence of aggregates in 
the extracellular space 
(panel a) and in the cytosol 
(d, f). Magnifications of the 
highlighted areas in a are 
shown in panels b and c. e 
and g show instead 
magnifications of the 
intracellular deposits 
highlighted in d and f. The 
unfolded fibers of 
proteianceous origin are 
indicated with arrows. 
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usually synthesized as full-length inactive proteins, they need to undergo an 
endoproteolytic step to reach the functional state. During this process the amino- and 
carboxyl-termini are cleaved by a complex including nicastrin, anterior pharynx 
defective 1 and presenilin enhancer 2, in order to create a substrate docking region 
inbetween the two subunits (Xia, 2008). The primary antibody we used for detecting 
PS1 was developed against an epitope mapping in the amino-terminus of the protein, 
thus allowing the visualization of the cleaved fraction by western blot as a band with 
molecular weigh of 28-30 kDa. Our results showed no significant alteration of this 
fragment in DCM compared to non-failing (Figure 3.7, lower band).   
The alteration of PS levels was confirmed by immunofluorescence analysis in which 
DCM cardiac samples were compared to non-failing and AD hearts were used as 
reference (Figure 3.8). As expected, PS1 showed increased content in DCM (+377%). 
Instead we couldn’t observe any significant variation in the levels of PS2, although 
Non-
Failing
DCMC+
Serca2a
PS1
 
3.6 Detection of Serca2a following immunoprecipitation of PS1. PS1 and Serca2a co-
precipitate, suggesting direct interaction between the two proteins. C+ = PS1-overexpressing CHO 
cells. 
3.7. Presenilin1 and 2 levels in SR preps from DCM (n=6) and non-failing (n=4) hearts. Left 
panels show Western blot analysis of the content of PS2 (top) and PS1 (bottom). Interestingly, PS2 
shows massive decrease in DCM patients, while PS1 shows moderate increase of the full length 
form. An additional band relative to the N-terminus of the protein after proteolytic activation was 
visible around 30 kDa, with no significant difference between normal and DCM samples. Right 
panel shows the densitometric analysis of the full length forms of the two proteins tested. CS= 
calsequestrin. 
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3.8. Immunofluorescence 
detection of PS1 and PS2 in 
Non-failing (n=4), Alzheimer 
(n=2) and DCM (n=6) heart 
sections. The DCM samples in 
average showed an increased 
signal/noise ratio for PS1 and for 
the phospshorylated form of PS2 
(PS2-P). No significant difference 
was instead observed in the PS2 
content between non-failing and 
DCM. Alzheimer samples showed 
increased content for all the 
proteins assayed. In order to 
determine the autofluorescence of 
each sample, the small panel on 
the bottom right corner of each 
picture shows a mirror sample 
treated following the same 
protocol with the exclusion of the 
secondary antibody incubation. 
The quantification of the signal of 
each sample examined was 
calculated as signal/background 
ratio. The graphs represent the 
averages of each group. 
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we were able to detect a significant increase of its phosphorylated form (antibodies: α-
PS1: Millipore, MA dil 1:200, α-PS2: Thermo, MA dil 1:200, α-Phospho-PS2: 
Calbiochem, MA 1:200, secondary: Alexa 655, Invitrogen, CA dil 1:200). We 
attributed our incapacity of detecting any change in these last proteins due to a 
technical limit of the technique or of the antibodies used. 
 
Although γ-secretase interacts and cleaves several proteins, the main substrate of the 
enzyme complex is APP. In order to verify any alteration of the levels of APP in 
DCM, we performed Western blot analysis of APP in pooled sarcoplasmic reticulum-
enriched preparations. These experiments showed decreased content of APP in DCM 
samples, both in the native and mature forms (Figure 3.9). The results were confirmed 
using two different commercially available antibodies (α-APP: Sigma, MD dil 1:2000, 
Abeta, Germany dil 1:1000). However, these findings resulted in contrast with our 
analysis based on immunofluorescence, in which we could observe an increased 
signal/noise ratio in DCM samples compared to non-failing (+ 214%, antibodies: α-
APP Sigma, MD dil 1:1000, secondary: Alexa 655, Invitrogen, CA dil 1:200, Figure 
3.10). This discrepancy can be attributed to the presence of APP in several cellular 
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3.9. APP levels in non-failing (n=4) and DCM hearts (n=6). Left panel shows Western blots 
probed for APP using two different commercial antibodies. In the right panel, densitometric 
analysis of the amount of mature and immature APP. C+ = APP overexpressing CHO cells. CS= 
calsequestrin. 
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compartments such as the plasma/sarcolemma, which are not included in the 
sarcoplasmic reticulum preparations used for Western blots.  
As Aβ is considered the final product of APP after presenilin-operated processing, we 
assayed the levels of the peptide by immunofluorescence (antibodies: α- Aβ 6E10 
Covance, secondary Alexa 655 α-Rb, Invitrogen, CA dil 1:1000, Figure 3.11). Our 
results didn’t show any significant difference between non-failing and DCM patients. 
No additional confirmation of the Aβ levels by Western blot was possible due to the 
unsatisfactory performance of the antibody for this technique.  
Non-Failing AD DCM
brighfield
- 2ary
+ 2ary
A
PP
 
3.10. Immunofluorescence detection 
of APP on Non-failing (n=4), 
Alzheimer (n=2) and DCM (n=6) 
heart slices. DCM samples in average 
showed an increased signal/noise ratio, 
while AD samples didn’t show any 
alteration. In order to determine the 
autofluorescence of each sample, the 
small panel on the bottom right corner 
of each picture shows a mirror sample 
treated following the same protocol 
with the exclusion of the secondary 
antibody incubation. The 
quantification of the signal of each 
sample examined was calculated as 
signal/background ratio. The graph 
represents the averages of each group.  
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3.2.3 Genetic analysis of PSEN1 and PSEN2  
 
Most of the alterations of the levels and activity of the γ-secretase complex in AD 
patients have been related to specific mutations in the genes encoding PS1 (PSEN1) 
and PS2 (PSEN2) (Tanzi and Bertram, 2001). We therefore analyzed the promoter 
and the coding exons of the two genes in order to identify anomalies that can be 
associated to the anomalies reported above. Genomic DNA isolated from 20 
idiopathic DCM cases was sequenced and compared to the corresponding fragments 
deposited in public databases. This analysis led to the identification of two 
unpublished and two previously reported mutations (Table 3.1). In particular patient 
14 carried a deletion in position -92 (-92delC) upstream of the alternative 
transcription initial exon 1A (Rogaev et al., 1997) (corresponding to position 
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3.11 Immunodetection of Aβ in DCM samples. DCM patients (n=23) do not seem to have 
increased content of Aβ compared to non-failing samples (n=14). This limits the possibility that Aβ 
is actively involved in the formation of protein deposits detected by histological and EM-based 
analysis. The analysis was confirmed with two different fluorochromes to limit the interference due 
to autofluorescence of the tissue. 
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72672839 on the University of Californa – Santa Cruz (UCSC) Genome Chr 14 
Database); a different mutation (-21G→A, corresponding to position 72673257 on 
UCSC Genome Chr 14 Database) was instead found in patient 4 upstream of the 
alternative transcription initial exon 1B. Patient 4 showed an additional previously 
reported missense mutation in the coding region of PSEN1 in position 953 (A→G) 
(Sandbrink et al., 1996), leading to the substitution of glutamate318 with a glycine 
residue. A second previously reported mutation (Cruts et al., 1998) was instead 
observed in the coding region of PSEN2 (G185A, corresponding to position 
225138072 in the UCSC Chr 1 Database and leading to a substitution of an arginine 
residue with a histidine in position 62 of the polypeptidic sequence) in patients 1 and 
14. It is interesting to observe that the three patients showing mutations in the regions 
analyzed (#1, 4, 14) were female with Caucasian background. 
 
The two novel mutations were characterized in vitro to evaluate their functional 
effects on the expression of PS1. We cloned the regions of the PS1 promoter ranging 
from 72672641 to 72673058 and 72673065 to 72673530 (according to UCSC 
Genome Chr 14 Database), which respectively include the two mutations -92delC and 
-21G→A and the corresponding TATA boxes. The DNA fragments were cloned 
upstream to the coding region in a vector containing a reporter gene (Renilla 
Luciferase, FLuc) and transfected into H4 human neuroglioma cells to verify the 
expression of luciferase. Our results showed a significant reduction (75%, p=10-7) of 
the FLuc activity for the construct containing the -92delC mutation when compared to 
the wild type allele (Figure 3.12, left). Similarly, we observed a decrease (32%, 
3.1 Presenilin mutations detected in iDCM patients. 
The genotype frequency is relative to the total number of DCM cases analyzed (n=20). 
Gene Mutation UCSC Genome Sequence 
 Database Position 
 
Minor allele  
Frequency 
Genotype 
Frequency 
PSEN1 -92delC Chr14:72672839 0.025 CC 
(95%) 
C- 
(5%) 
PSEN1 -21G→A Chr14:72673257 0.025 GG 
(95%) 
GA 
(5%) 
PSEN1 A953G/E318G Chr14:72742931 0.025 AA 
(95%) 
AG 
(5%) 
PSEN2 G185A/R62H Chr1:225138072 0.05 GG 
(90%) 
GA 
(10%) 
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p=0.015) of the luciferase activity in the comparison between the -21G→A mutation 
and the wild type allele (Figure 3.12, right).   
Interestingly, the wild type variant of the promoter showed significantly increased 
expression for exon 1A versus exon 1B (5-fold). 
Further confirmation of the inhibited transcriptional activity associated to the 
mutations in the PSEN1 promoter derived from the evaluation of PS1 levels by 
Western blot (Figure 3.13). Although we observed increased PS1 levels in all the 
DCM samples, the three patients carrying the mutations (marked by squares) showed 
decreased PS1/SERCA ratios compared to the average of the DCM group. Because of 
the central role of the presenilin in APP processing, we investigated whether this 
alteration was producing modifications in the content of Aβ by immunohistochemistry. 
 
3.12 Analysis of the two novel mutations identified in the PS1 promoter. The activity of the 
mutated promoter was assayed using Renilla luciferase as a reporter gene. Both the alterations 
showed significantly impaired expression (-92delC: -75%, p<0.003; -21G→A: -32%, p<0.05). 
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Our results didn’t show any significant change between the mutation carriers and the 
other DCM patients (Figure 3.14). No additional information regarding the content of 
Aβ is available due to the unsatisfactory performance of the antibody used for 
Western blot application. 
  
3.2.4 Population analysis 
 
It is possible that the mutations we describe in this chapter are not specifically 
involved in idiopathic DCM and they can be associated to other diseases and, in 
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3.13 Analysis of PS1 levels in DCM samples. The content of PS1 appeared increased in DCM 
samples when compared to non-failing controls (0.93±0.25 vs. 0.56±0.24, p=0.01 from Krustal-
Wallis test). The carriers of the newly identified mutations (marked by an arrow in the Western 
blot) showed lower levels of PS1 than the patients without any variants (0.79±0.18), although our 
results didn’t reach statistical significance. All the values were standarized to GAPDH content.  
C+= PS1-overexpressing CHO cells. 
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particular, AD. In order to investigate this aspect we performed single nucleotide 
polymorphism (SNP) analysis on existing sequencing data from genomic DNA 
isolated from AD patients stored in the Massachusetts General Hospital Institute for 
Neurodegenerative Disorders.  
Our analysis showed that none of the AD patients analyzed was showing the mutation 
-21G→A in PSEN1(Table 3.2); the second mutation in the PSEN1 promoter (-92delC) 
was instead found in 8 out of 1632 chromosomes analyzed (allele frequency 0.005). 
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3.14. Immunodetection of Aβ in patients carryng mutations in the Presenilin genes. The 
alterations of the presenilin genes we described did not induce any significant detectable alteration 
of the Aβ processing pathway compared to regular DCM samples. The analysis was confirmed 
with two different fluorochromes to limit the interference due to autofluorescence of the tissue. 
Identification of Protein Aggregates and Activation of the Unfolded  
Protein Response in Idiopathic Dilated Cardiomyopathy 
 
 
 141
The two mutations we found in the coding regions of PSEN1 and PSEN2 were 
respectively showing allele frequency equal to 0.02 (PSEN1 E318G, found in 12/596 
chromosomes) and 0.016 (PSEN2 R62H, 5 chromosomes out of 320 analyzed). The 
data relative to these last two alterations were in line with previous reported analyses 
(Sandbrink et al., 1996, Cruts and Van Broeckhoven, 1998, Albani et al., 2007). The 
evaluation of the segregation of these mutations in identified AD families didn’t show 
any significant association between these mutations and the development of the 
neurodegenerative condition. 
 
3.2.5 Effects of oligomers on cardiomyocyte function 
 
In the past the presence of amyloid fibers has been closely related to cytotoxicity. 
However, recent discoveries in the AD field are limiting and reevaluating the role of 
mature fibers in the perpetration of adverse effects on the cell: according to the most 
recent theories oligomers have a major role in this process, while the deposition of 
amyloid fibers could simply represent a defensive mechanism to limit the 
accumulation of the toxic soluble species in the neurons (Walsh and Selkoe, 2004, 
Cleary et al., 2005). These observations raised the possibility that similar properties of 
the oligomers may be valid also in non-neural cell types, including the 
cardiomyocytes.  
The mechanism(s) involved in the cytotoxic effect has still not been completely 
elucidated: some groups proposed that the presence of oligomers alters the Wnt 
pathway ultimately leading to significant decrease of the content of β-catenin 
(Hedgepeth et al., 1997, Inestrosa et al., 2005). Other theories, instead, suggested a 
direct involvement of the oligomers in the formation of unregulated cation channel in 
3.2 Population analysis of the mutations detected in DCM samples. 
Gene Mutation Frequency Chromosomes analyzed
 
PSEN1 -21G→A 0 1632 
PSEN1 -92delC 0.005 1632 
PSEN1 E318G 0.02 596 
PSEN2 R62H 0.016 320 
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the membrane, eventually leading to the activation of the apoptotic cascades and 
induction of oxidative stress (Demuro et al., 2005).   
We first evaluated whether the accumulation of unfolded β-sheeted protein fibers in 
the cardiomyocytes was associated to the presence of other species characterized by 
lower molecular complexity, such as oligomers. We based our experimental approach 
on the use of a structural antibody developed by Dr. Glabe’s group, characterized by 
the capacity of specifically recognizing the three-dimensional structure of oligomers 
with no cross reactivity with mature amyloid fibers. This antibody has been proven to 
bind most of the oligomeric species described to date independently from their amino-
acidic sequence (Kayed et al., 2003). 
We examinated 23 cases of idiopathic DCM and compared them with 14 non-failing 
samples by immunohistochemistry. As expected all the DCM showed higher intensity 
staining than non-failing (antibodies: α-oligomers Invitrogen, CA dil 1:400, Figure 
3.15). Of note some of the non-failing samples showed some levels of positive signal 
to this analysis. However the signal/background ratio was significantly higher in the 
DCM group.  
In addition we investigated the presence of oligomeric species in early-stage DCM 
cases before evident unfolded protein deposits were detectable in the cardiomyocytes. 
Due to the limited amount of material, biopsies from the patients (n=2) were stained 
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3.15. Oligomer immunofluorescence. 
Immunofluorescence analysis of DCM 
(n=23) and non-failing n=14) samples 
showed a significant difference in the 
content of oligomers between the two 
groups analyzed. The small box in the 
lower right corner of each image shows the 
background level obtained on mirror slices 
not incubated with the secondary antibody. 
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with the immunogold technique using the structural antibody previously mentioned 
and analyzed by electron microscopy (antibody: α-oligomers, Invitrogen, CA dil 
1:400, secondary: gold-conjugated DAKO, DK dil 1:20). In addition this technique 
presented the advantage of a higher sensibility compared to the immunofluorescence 
approach previously adopted. Interestingly, early-stage DCM showed diffused 
presence of oligomers, similarly to what was observed in the core of myocardium 
deriving from an end stage idiopathic DCM patient removed for left ventricular assist 
device (LVAD) implantation (Figure 3.16). 
This evidence regarding the presence of oligomers in idiopathic DCM heart does not 
necessarily correlate to a toxic effect of the β-sheeted structure on cardiomyocytes 
leading to degeneration of ventricular function. To assess this question we exposed 
isolated adult mouse cardiomyocytes to oligomers generated in vitro from 
commercially available lyophilized Aβ (Figure 3.17a), supporting this choice with 
recent findings suggesting that the adverse effects of oligomer species are exclusively 
mediated by their three-dimensional structure independently of their amino-acid 
sequence (Demuro et al., 2005). Different concentrations of oligomers (0.5-5 μg/ml) 
were administered to the cardiomyocytes while contractility and Ca2+ transient were 
recorded. Our results showed that the release of oligomers on the cell surface 
produced significant increase of peak systolic content of Ca2+ and of the velocity of 
Ca2+ release (Figure 3.17b). These alterations produced consistent anomalies in the 
cell contractility (Figure 3.17c). 
 
3.16 Electron microscopy analysis of DCM samples. Staining with antibodies conjugated with 
colloidal gold particles showed the presence of oligomers in the myocardium (arrows). a = early 
stage DCM, b = end stage DCM before LVAD implantation. 
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3.17 Effects of oligomers on murine isolated cardiomyocytes. The preparations used in the 
experiments were tested by dot-blot at different time points to identify the peak in oligomer content 
(A, top panel). In addition the oligomers were tested by EM for their capacity of forming fibers 
after exposure to hexane (bottom panels, left: insoluble pellet, right: oligomers-containing 
supernatant). The preparations were administered to isolated cardiomyocytes producing alteration 
of the contractility (B, top left panel) and impairment of Ca2+ handling (B, bottom left panel) 
compared     to     PBS  - treated 
cardiomyocytes (B, right panels).  
The quantification  of the   
alterations in Ca2+  content 
showed significant reduction of 
the systolic concentration (C, 
left panel) and of the velocity of 
release (right panel). For 
statistical purposes we repeated 
the experiment in presence of 
oligomers on cardiomyocytes 
derived from three different 
animals. As control we instead 
used cardiomyocytes from two 
animals, which were exposed to 
PBS instead of the 
PBS/oligomers solution. Three 
cells/animal were recorded.    
A
24 hrs 48 hrs 72 hrs 4 days 0Ag, I, II Ab 0Ag, 0 I, II Ab
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3.2.6 Evaluation of UPR-component levels 
 
As the accumulation of β-sheeted unfolded species has toxic effect on the cell, 
eukaryota evolved mechanisms to prevent the formation of oligomers and amyloid 
fibers, which have been grouped as unfolded protein response (UPR).  
In our analysis we selected several key components of the UPR in order to identify 
which pathways are activated following the events we described in this chapter. In 
particular we focused on proteins involved in the control of the folding process 
(chaperones GRP78 and 94), peptides related to the ubiquitin/proteasome pathway 
(Ubiquitin, RTP3 and RTP5 of the proteasome 19S subunit, β2, β5 and α6 of the 20S 
subunit), transcription factors induced or modified during an unfolded protein shock 
response (ATF6, eIF2αP, Chop, XBP1) and a protein regulating the apoptotic process 
(Caspase12). We analyzed the content of the mentioned peptides by Western blot 
using SR-enriched preparations (for SR peptides such as GRP78 and GRP94) or 
whole cell lysates (Figure 3.18). As expected, our results showed significant increase 
in DCM samples for the chaperones GRP78 and GRP94 (respectively +198% and 
+273%, antibodies: not commercially available - generous gift of Dr. A.M. Lompré,  
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Figure 3.17. Continued from previous page 
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dil 1:500), the transcription factors Chop (+134%, antibody: BioLegend, dil 1:500) 
and ATF6 (both in the native (+162%) and active (+158%) forms, antibody: Imgenex, 
dil 1:500) and for Caspase 12 (+165%, antibody: Abcam, dil 1:1000). No significant 
differences were instead observed between non-failing controls and DCM patients for 
ubiquitin (antibody: Sigma dil 1:500), α6 (antibody: Biomol International, dil 1:1000), 
β2 (antibody: Biomol International, dil 1:1000), RPT3 (antibody: Biomol 
eIF2α-P
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3.18 Analysis of UPR-related protein content in DCM (n=9) and non-failing (n=6) samples. 
DCM samples showed significantly decreased levels of 20S-β5 (-60%) and increased content of 
ATF6 (active, +158%, and native, +162%, forms), Caspase 12 (+165%) and Chop (+134%).  
No alterations were instead observed for the phosphorylated 
form ofE2IFα, XBP1, Native ATF6, Ubiquitin, 19S-Rtp3, 
19S-Rtp5, 20S-α6 and 20S-β2. All the levels were calculated 
as ratios of GADPH content. (Continued on next page)  
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Figure 3.18. Continued from previous page
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International, dil 1:1000), RTP5 (antibody: Biomol International, dil 1:1000), XBP1 
(antibody: Santa Cruz, dil 1:200) and eIF2αP (antibody: Cell Signaling dil 1:1000). 
Of note, DCM samples showed lower content of one of the catalytic subunits of the 
20S proteasome (20S β5, -60%, antibody: Biomol International, dil 1:1000).  
   
 
3.3 Discussion 
 
 
In this chapter we focused on the determination of the etiology of idiopathic DCM, a 
common cause of heart failure. The mechanisms responsible for the development of 
this condition and its evolution to heart failure are currently obscure. Our analysis 
allowed us to identify a series of unknown molecular mechanisms which are 
summarized in Figure 3.19. In particular, we described the presence of consistent 
amounts of unfolded protein material in DCM hearts, which were characterized by the 
β structure typically observed in amyloid fiber, as confirmed by staining with 
amyloid-specific dyes such as Congo Red and thioflavin-S. Ultrastructural 
observation of these deposits showed preferential distribution in the cytoplasm of 
cardiomyocytes and no apparent correlation with any known form of aggregates. As 
expected the formation of amyloid fibers was also associated with the presence of 
intermediates still characterized by the β-sheeted structure but with lower molecular 
complexity. In particular we were able to identify a diffuse presence of oligomers in 
the diseased heart of both early and late stage patients. 
The presence of unfolded peptides assuming β-sheeted structures has been associated 
to negative effects on the metabolism of the cell for many years. Therefore, the 
findings we report strongly suggest the existence of substantial relationships between 
the presence of this structurally disorganized material of proteic origin within the 
cardiomyocytes and the development and progression of idiopathic DCM. This 
hypothesis is supported by our results deriving form normal isolated murine 
cardiomyocytes exposed to increasing concentration of artificial oligomers, which 
showed limited tolerance of the cell to these molecules. In particular our observations 
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demonstrated severe alterations in the contractility of the cell and in Ca2+ handling, 
which, eventually, produced cell death. 
In addition our study focused on the characterization of proteins involved in the 
etiology of foldopathies and that have been reported to be related to Ca2+ regulation, 
such as PS1, which showed interaction with SERCA by co-immunoprecipitation. In 
particular we analyzed the levels of PS1, PS2 and Phospho-PS2 in DCM-affected 
hearts, showing critical increase of the first associated with a significant drop in the 
expression of PS2 (that instead appeared to be present mostly in the phosphorylated 
form). Our findings also showed that the principal substrate of the presenilin (i.e., 
APP) was increased as resulted form immunofluorescence analysis of the protein on 
cardiac tissue, although the levels in the SR membranes appeared decreased by 
Western blot. These contrasting observations may be attributed in first place to the 
distribution of APP in the cell (as the molecule processing follows a complex pathway 
involving different cellular compartments than the SR), but also to an artifact due to 
the preferential localization of the transmembrane peptide in lipid rafts, which are 
detergent-resistant structure and, therefore, are removed as insoluble material during 
the preparation of the samples. Further characterization of the γ-secretase system in 
DCM patients showed a series of mutation in the genomic sequence of PSEN1 and 
PSEN2 genes. In particular we were able to identify two previously reported 
alterations in the cds of the genes and two unknown mutations in the promoter region 
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Figure 3.19. Schematic representation of the mechanisms described. 
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of PSEN1 (-92delC and -21G→A), which were characterized in vitro and resulted 
able to induce significant decrease of the expression of the downstream ORF.  
A last interesting group of observation we reported in this chapter was related to the 
characterization of the UPR. In particular our experiments showed increased levels of 
the SR chaperones GRP78 and GRP94 and of the pro-apoptotic factors Chop and 
Caspase 12. 
 
One of the prominent features of idiopathic DCM is the impairment of Ca2+ re-uptake 
in the sarcoplasmic reticulum. This defect leads to increased concentration of the ion 
in the cytosol, followed by activation of the sarcolemma Ca2+ transport systems 
(including Na+-Ca2+ exchanger and Ca2+ ATPase) and, eventually, by progressive 
depletion in the cellular storage compartments and in particular in the SR. As the SR 
is one of the most important locations for protein folding and post-translational 
modification, any major alteration of the microenviroment of the organelle produces 
significant outcomes on several cell functions. In particular, the accumulation of 
unfolded proteins has been largely related to severe impairment of relevant cellular 
functions in several neurodegenerative disorders and other chronic diseases (Gething 
and Sambrook, 1992, Ross and Poirier, 2004, Gorza and del Monte, 2005). In this 
study we report the presence of unfolded protein deposits in cardiac samples deriving 
from idiopathic DCM patients, suggesting the existence of common underlying 
etiologies between this cardiac condition and other amyloid-related pathologies. 
Although we didn’t specifically address the consequences of the presence of β-
sheeted peptides on human cardiomyocytes, we were able to determine the 
devastating effects of unfolded fibers on the mechanical and Ca2+ handling properties 
of cardiac cells isolated from normal adult mice. This evidence considerably supports 
the hypothesis that analogous effects may occur in idiopathic DCM. 
  
The accumulation of unfolded protein is a common characteristic of the aging process 
in several tissues and organs. In the heart these deposits are present as senile plaques 
and are characterized by an amyloid-like structure. Senile plaques have been 
described in normal non-diseased individuals over 60 years old (de Exel Nunes et al., 
2006, Steiner and Hajkova, 2006), with a peak of incidence of 25% in the population 
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over the 8th decade of age (Cornwell et al., 1983). For the first time we report the 
presence of β-sheeted species in relatively younger patients affected by idiopathic 
DCM. Of note, our analysis included a limited number of biopsies deriving from 
subjects in the early stages of the disease that showed results comparable to the data 
obtained in late stage DCM individuals. These findings represent an important 
confirmation of the fact that the unfolded proteins may have an active role in the 
etiology of idiopathic DCM and, additionally, they significantly exclude the 
possibility that their presence is a mere consequence of the aging process or of the 
devastating effects of the late-stage failing condition. Thus, our results propose an 
alternative vision of the idiopathic form of DCM as a premature aging process of the 
cardiac muscle, similarly to how early-occurring neurodegenerative diseases such as 
AD compare to senile dementia.     
 
The presence of β-sheeted protein fibers has been directly associated to negative 
effects on the cell metabolism for a long time. However these insoluble aggregates 
represent only the endpoint of a process during which a monomeric unfolded protein 
reaches progressively higher levels of molecular complexity including oligomers, 
protofibrils and fibrils. The most recent findings in the AD field showed that soluble 
oligomers  are the most prominent mediators of the β-amyloid-associated toxicity on 
neurons (Cleary et al., 2005, Lansbury and Lashuel, 2006). In the current study we 
demonstrated the presence of oligomers in the myocardium of idiopathic DCM 
patients. In addition, we report the effect of this form of molecular aggregates on 
cardiomyocytes, showing for the first time a significant spike in the systolic Ca2+ 
concentration after administration of oligomers to cells, which may lead to metabolic 
alterations and eventually to death (Stevens and Argon, 1999, Chandrashekhar and 
Narula, 2003, Del Monte and Hajjar, 2008). Although our results contribute to the 
improvement of our knowledge about the pathological mechanism associated to the 
degeneration of DCM cardiomyocytes, these data introduce new and intriguing 
hypotheses on the role of these molecule in the etiology of the disease. In fact, we can 
not exclude that the presence of oligomers might be a pre-existing condition to the 
Ca2+ homeostasis alteration mainly associated to non-fully penetrant mutations or to 
the age-related degeneration of the catalytic pathways of the cell. Consequently, the 
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progressive accumulation of these molecular species might be able to produce Ca2+ 
handling alterations which might lead to the well-known alteration of the cell but, in 
addition, also exacerbate the process of formation of oligomers. Although extremely 
interesting, this hypothesis require further investigations that could be performed for 
example on animal models once the protein(s) involved in the formation of the 
oligomers are identified. 
It is interesting to observe that alterations in Ca2+ handling have been investigated also 
in AD in the last decade (LaFerla, 2002). Indeed several studies have reported that γ-
secretase have multiple roles in the regulation of the intracellular Ca2+. These include 
the capacity of forming a cation permeable channel responsible for the vast majority 
of passive Ca2+ leaks from the ER (Tu et al., 2006) and the modulation of the RyR by 
direct interation (Hayrapetyan et al., 2008) or by cleaving sorcin (Pack-Chung et al., 
2000). In addition, the proteins forming the catalytic core of γ-secretase seem to have 
significant interactions with SERCA –one of the key proteins in the excitation-
contraction coupling process-, attenuating its function when the presenilins are 
downregulated (Green et al., 2008). According to our results significant interaction is 
present between the cardiac-specific isoform of SERCA (2a), suggesting that the 
regulation mechanism observed by Green et al. may be valid even in the heart (Green 
et al., 2008). As a consequence, the increase of PS1 we observed in DCM samples 
may be explained not only as a compensatory process to balance the drop in PS2 but 
also as a protective mechanism initiated by cells in order to indirectly stimulate 
SERCA2a activity to prevent Ca2+ accumulation in the cytosol. 
 
The genomic characterization of the presenilin genes led to the identification of two 
novel alterations of the PSEN1 promoter in three patients (-92delC and -21G→A), 
both related to severe downregulation of the expression of the relative genes, 
decreased content of the relative protein compared to other idiopathic DCM samples 
and, most likely, inhibition of SERCA2a activity. Our analysis allowed also the 
identification of two previously described mutations in the coding region of PSEN1 
and PSEN2. In particular PSEN1 E318G produced the modification of a polar acidic 
(glutamate) into a neutral residue (glycine) in the large cytoplasm loop between the 
transmembrane domains 6 and 7. This domain is considered a “hot spot” of the 
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molecule due to the large number of AD-related mutations identified: indeed, 
alterations in this region have been related to altered cleavage of the N- and C-termini 
of PS1 (Thinakaran et al., 1996) with consequent reduced capacity of docking the 
target proteins (Mah et al., 2000, Xia, 2008). Instead, the mutation found in PSEN2 
(R62H) maps in a different “hot spot” located in the N-terminus of the molecule. This 
alteration has been related to increased degradation of the molecule, reduced stability 
and impaired Notch processing in both AD (Cruts et al., 1998) and breast cancer (To 
et al., 2006).  
Although PS1 and PS2 are characterized by high homology, it is interesting to 
observe that the two mutations in the coding sequence we detected map in two of the 
most diverse domains. This suggests that these two regions may have an important 
role in modulating different functions of the proteins in the heart, that, according to 
our results are neither related to alterations in the APP processing nor to altered levels 
of Aβ.         
 
One of the most common cellular responses to the accumulation of unfolded peptides 
consists in the activation of a large array of mechanisms aimed to eliminate the 
amyloid produced and to prevent the formation of new fibers. These mechanisms are 
grouped in the unfolded protein response (UPR). Several studies have described the 
alteration of several components of this system in foldopathies (Lindholm et al., 2006). 
In particular, the presence of Aβ in AD-affected neurons seems to trigger the 
expression of important components of the UPR such as GRP78 and PERK 
(Hoozemans et al., 2005) (which reflects a neuroprotective activity), and, eventually, 
activation of the apoptotic pathway mediated by Caspase 12 (Nakagawa et al., 2000).  
Our characterization of the key components of the UPR revealed a significant increase 
in the levels of several of the tested proteins as an expected cardioprotective reaction 
to the accumulation of β-sheeted deposits. However the substantial increase in Chop 
and Caspase 12 levels suggests that the cardiomyocytes are mostly prone to apoptosis, 
especially in late stage DCM such as the samples we used for this analysis.     
In addition it was interesting to observe that the catalytic subunit β5 of the 20S 
proteasome showed significantly lower expression. As the proteasome seems to be 
actively involved both in processing and degrading presenilin 1 (Honda et al., 1999), 
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we can speculate that the alteration we are reporting may have an primary role in 
determining the increase in PS1 we described in this chapter. This hypothesis is 
supported by several recent clinical observations on the use of the proteasome 
inhibitor bortezomid for different forms of tumors: indeed, administration of this 
chemotherapic agent in patients resulted in the development of severe acute heart 
failure (Voortman and Giaccone, 2006, Hacihanefioglu et al., 2008), which was 
reverted by interruption of the treatment.  
 
In conclusion, the data we present in this chapter considerably support the hypothesis 
of an active role of protein misfolding in the pathogenesis of idiopathic DCM. Our 
results show that the formation of oligomers induces alteration of the Ca2+ handling 
and toxicity for the cell. In addition alterations of the genes encoding the presenilins 
produces modification in the structure and in the expression of the proteins, which 
may lead to exacerbation of Ca2+ mishandling due to the proven interactions of these 
peptides with key elements of the excitation-contraction coupling.  
However, our findings did not completely elucidate whether the aggregates we 
describe have a primary active role in the etiology of the condition leading to the 
well-described Ca2+ alterations or they are merely a consequence of pre-existing Ca2+ 
handling anomalies with deleterious effects on the progression of the disease. As a 
result of these observations, a better elucidation of the proteins involved in the 
formation of unfolded species is critical to the development of early diagnosis marker 
and new approaches for the treatment of DCM.    
 
3.3.1 Limitations 
Although our results open new and intriguing perspectives in the determination of the 
etiology of DCM, we should consider some technical limitations related to the 
experiments presented in this chapter.  
First, the determination of the toxic effects of the oligomers on isolated 
cardiomyocytes was determined administering pre-formed oligomers to the cells in 
the extracellular space. In this chapter we extensively demonstrated the presence of 
intracellular oligomers amyloid deposits in DCM samples, but we obtained only 
marginal evidences of the presence of unfolded proteins in the extracellular space. 
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Therefore, the use of exogenous pre-formed oligomers should be seen as a model in 
which the effects of the intracellular oligomeric species are not specifically 
investigated. However, we consider this approach the best model to our knowledge 
for this type of study. In fact, a solution for this issue could be obtained from the use 
of regulated promoters for the intracellular expression of amylogenic peptides, but the 
technologies currently available for this purpose are still showing consistent 
limitations in terms of elimination of background expression. In addition, the kinetics 
of the activation of these promoters might be incompatible with in vitro studies on 
isolated cardiomyocytes due to the limited survival of these cells.   
A second limitation derives from the incomplete characterization of some of the 
samples used in the experiments. In fact the use of SR preps in some of the Western 
blots presented in this chapter would have required a preliminary evaluation of the 
contamination with membranes deriving from the sarcolemma and other organelles. 
This could have been estimated performing assays for proteins belonging to the SR 
(such as SERCA2a) and for proteins usually non present in the SR (such as Na+/K+ 
ATPase and 5’ nucleotidase) as previously described (Jaqua-Stewart et al., 1979). 
An additional group of limitations of the study we presented is instead associated to 
the possibility of unspecific binding in the techniques involving the use of antibodies. 
Although we tried to control this issue with preliminary blocking steps to saturate 
unspecific binding sites, it is crucial to exclude the possibility that our conclusions 
might derive from erroneous data interpretation. In this regards, the confidence in our 
results might have been improved by adding a series of positive and negative controls. 
For example, the co-immunoprecipitation experiments might have beneficed form the 
evaluation of the capacity of the proteins tested to unspecificallly bind the protein G-
coated sephadex beads in absence of the antibody and/or in presence of a non-specific 
immunoglobulin belonging to the same isotype. Similarly, it would have been 
important to determine the role of unspecific binding in the immunofluorescence 
experiments by verifying the intensity of the signal in absence of the primary antibody, 
while our negative controls were only focused to determine the interference deriving 
from autofluorescence of the tissue.  
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4.1 Introduction 
 
 
Protein aggregation is a common characteristic of several degenerative diseases 
usually affecting the central nervous system (Kopito and Ron, 2000). In the heart the 
formation of amyloid fibers has been related to the occurrence of conduction 
disturbances and deterioration of the contractile function associated to a progressively 
increased stiffness of the cardiac tissue known as restrictive cardiomyopathy 
(Nihoyannopoulos and Dawson, 2009). This process is usually related to alterations 
in plasma proteins such as serum amyloid A (SAA), transthyretin (TTR) or light 
chain immunoglobulins which are not normally synthesized in the heart, but are 
transported to the organ from a remote location by the plasma. More recently, the 
formation of intracellular cardiac-specific amyloid fibers has been described as a 
result of the accumulation of unfolded desmin due to a mutation in the molecular 
chaperone α-β  crystallin (CryAB) (Sanbe et al., 2004).  
In the previous chapter we documented the presence of intracellular non-CryAB-
related unfolded protein aggregates in late-stage iDCM samples and we demonstrated 
their deleterious effects on the normal activities of the cardiomyocyte and, in 
particular, on the contractile function. In addition, we showed a general upregulation 
of several proteins involved in controlling the accumulation of unfolded proteins. 
However, the molecular mechanisms leading to the accumulation of protein 
aggregates in cardiomyocytes remain still obscure.  
 
In the past, the characterization of protein(s) implicated in the formation of amyloid 
complexes represented a critical step in elucidating the pathogenesis of the related 
diseases (Khan and Falk, 2001). One of the most commonly used methods was based 
on the genetic identification of the gene(s) involved by linkage analysis in individuals 
affected by the familial form of the pathological conditions (Tanzi et al., 1987). 
However, this approach has several limitations mainly related to the influence of 
epigenetic factors or to incomplete penetrance of the genetic defects. Therefore the 
purification and biochemical analysis of the amyloid structures represents a valid 
alternative to the genetic characterization for the identification of amyloigenic 
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proteins in those pathologies in which no clear evidence of familial inheritance is 
available, such as iDCM. 
 
The major obstacle related to the biochemical characterization of amyloid consists in 
the remarkable heterogeneity of the peptides forming the structures. To date at least 
20 amyloigenic proteins have been identified with highly different amino-acid 
sequence but with comparable capacity of producing similar three-dimensional β-
sheeted fibers. This leads to significant differences in the chemical and physical 
properties of the amyloid fibers, including different density and different sensibility to 
detergents, reducing and denaturating agents (Kaplan et al., 2003).   
 
All the successful protocols for isolating amyloid fiber described to date are based on 
several methods which have been developed since the beginning of last century. 
These methods can be classified in four large groups:    
 
 Methods based on surface characteristics (such as solubility);   
 Methods based on structural properties (such as size and shape); 
 Methods based on bioproperties (such as affinity); 
 Methods based on net charge. 
 
In this chapter we will develop different biochemical approaches for the purification 
of the unfolded peptides that we localized in the intracellular space of cardiomyocytes. 
As the accumulation of insoluble amyloid fiber is always associated to the presence 
of soluble oligomers with different biochemical characteristics (Glabe, 2008), we 
designed distinct and parallel experimental plans focused on the isolation of either the 
soluble or the insoluble species.  
Most of the experiments presented in this chapter are meant to be considered as pilot 
tests performed on limited numbers of samples mainly because of the uniqueness of 
the samples and the large amount of starting material required by the purification 
steps. 
One of the major challenges for this study is represented by the elevated number of 
proteins expressed in cardiac tissue such as the components of the contractile 
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apparatus, which can easily confuse the interpretation of high throughput analysis for 
the identifications of proteins. In addition, the ER stress conditions of the DCM 
cardiomyopathy may produce further degeneration of the ER folding machinery, 
leading to the accumulation of a large variety of unfolded proteins. In order to enrich 
the content of our sample in the oligomeric species or in the mature fiber content, our 
strategy included a preliminary separation conducted with both well-established 
techniques such as gel electrophoresis, immunoprecipitation, solubility fractionation, 
density gradient separation and more recently developed techniques such as laser 
capture microscopy. The samples obtained from this first step were then processed by 
mass spectrometry to identify the purified proteins. In particular, we gradually 
increased the stringency of our analysis starting from protocols requiring low 
amounts of starting material and progressively moving to approached producing more 
purified material, which also required high amounts of cardiac tissue. 
A second problem associated with this study and, more specifically, to the isolation of 
oligomers is related to the total absence of data regarding their compatibility to 
solvents. This aspect introduces a major limit to the number of protocols that can be 
applied to the identification of this molecular species, since the use of an aggressive 
detergent may lead to the dissociation of the oligomer structure and, consequently, to 
our incapacity of detection.  To overcome this issue we tried to work in non-
denaturating conditions when possible. 
Our work did not result in the isolation of any specific protein with an active role in 
the formation of unfolded molecular species. However, the characterization of the 
unfolded “bodies” described in the previous chapter still remains an objective of 
primary importance for understanding the molecular mechanisms involved in the 
protein aggregation in the failing heart and, eventually, for the development of new 
diagnostic and therapeutic approaches in the following paragraphs. We will therefore 
analyze in detail the limitations which prevented a successful identification using our 
experimental plan and techniques, as a reference for future characterization of the 
aggregasomes.  
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4.2 Results 
 
4.2.1 High molecular weight protein-optimized gel separation 
Gel separation is a common technique for separating proteins based on their size. This 
approach is usually based on the use of polyacrylamide gel electrophoresis, which in 
general achieves successful separation of polypeptides ranging from 4-5 kDa to 250-
300 kDa. However, in our specific case, we expected to identify insoluble fibers with 
higher molecular weight, which can’t easily migrate through this type of gel matrix. 
Our analysis was therefore focused on the use of two different techniques optimized 
for the separation of large proteins. 
The first protocol was based on the use of horizontal agarose gels that were loaded 
with tissue lysate and stained with Sypro-Ruby. Our results showed poor separation 
of the cellular proteins and no specific bands were identifiable for MS analysis 
(Figure 4.1). 
The second technique we adopted was instead based on the addition of diaminedithiol 
(DADT) in vertical acrylamide gels to help the generation of a large-pore matrix. In 
our pilot experiment we were able to obtain a good resolution of the cellular proteins 
and we could isolate 4 bands that appeared differentially present in DCM and non-
failing samples (Figure 4.2). However this protocol was not appropriate for the use in 
combination with MS apparatuses because DADT was not efficiently removed from 
the sample and generated several problems to the equipment including the occlusion 
of the sample loading lines. 
 
+ -
Direction of 
migration
Figure 4.1. Agarose gel electrophoresis of protein extracts. The protein extract from one cardiac 
amyloidosis sample was loaded on an agarose gel to in-gel migration of large molecular weight 
such as amyloid aggregates and fibers.  However the scarce resolution of the gel did not allow the 
visualization of any specific band to isolate for further processing. 
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4.2.2 Laser capture microdissection (LCM)   
A second type of approach we tested was focused on enriching the tissue lysates for 
MS in amyloid-positive cardiomyocytes with concomitant elimination of extracellular 
matrix protein contamination. In the past LCM has been frequently and successfully 
used for the isolation of specific areas/cells from tissue slices for genomic analysis 
and, more recently, the technique has been applied also to the proteomic 
characterization of amyloid plaques in AD. However in our specific case, the 
collection of the isolated cells from the remaining tissue was highly problematic due 
to the high strength-bonds that cardiac tissue appears to produce with the charges on 
the glass surface of the slides. According to our observations, the best slide for LCM 
of cardiomyocytes was the plain, no charge glass slide (Table 4.1), which allowed the 
recovery of 40-60% of the laser-isolated thioflavin-S-positive cardiomyocytes (Figure 
4.3). 
64
98
148
250
DCM AD NF
Figure 4.2. DADT-PAGE. Lysate from 4 DCM, 2 AD and 2 NF samples were loaded on a DADT 
gel. The box indicates the bands that were considered overexpressed and that were excised for 
further analysis. The sample in the 4th lane from the left resulted overloaded and no bands were 
isolated for the following experiments.  
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Unfortunately our results showed that the amount of proteins collected with this 
protocol was extremely low, leading to the necessity of large amounts of starting 
material to allow the subsequential MS analysis.  
 
4.2.3 Differential sedimentation 
Differential sedimentation has been successfully used in the past for the isolation of 
exogenous proteins produced in E.Coli, which in general are stored in the prokaryotic 
cell as unfolded insoluble structures called inclusion bodies. This protocol is normally 
based on the centrifugation of the whole cell lysate on a single multi-step sucrose 
gradient, but in our specific case we added a second step of centrifugation based on a 
linear gradient due to the higher complexity of eukaryotic cells. 
As expected, unbound thioflavin-S was overlaying the gradients at the end of each 
step of centrifugation (Figure 4.4). However, we were able to observe multiple 
thioflavin-S-positive bands both in DCM and non-failing samples. In addition, the 
Slide LCM apparatus Pros Cons 
Regular glass, no 
charge 
Leica LMD 6000 
Zeiss P.A.L.M. 
• Best recovery of the 
captured cells 
• Tissue adhesion was 
sometimes 
unsatisfactory 
Regular glass, 
charged 
Leica LMD 6000 
Zeiss P.A.L.M. 
 Good tissue adhesion • High strength of the 
tissue/glass interaction 
leading to difficult 
recovery of the captured
cells 
Plastic Leica LMD 6000 
Zeiss P.A.L.M. 
• Good tissue adhesion • Low resistance to 
solvents 
• Deformation 
during collection 
Plastic film-coated 
glass 
Leica LMD 6000 
Zeiss P.A.L.M. 
• Good tissue adhesion
• Easy recovery of the 
captured cells 
• Low resistance to 
solvents 
• Plastic film was 
carried over 
Polyethylene 
terephthalate 
membrane frame 
slides  
Leica LMD 7000 • Easy recovery of the 
captured cells 
• Extremely low 
resistance to solvents 
• Plastic film was 
carried over 
 
Table 4.1. Comparison between different slides for LCM 
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distribution pattern of the bands on the gradients was not consistent in the two groups 
analyzed.  
The bands characterized by higher aggregation index (Abs 280/340, Table 4.2) were 
selected for a pilot MS analysis, but the complexity of the samples still resulted in a 
limiting step for the appropriate identification of peptides. 
 
4.2.4 Detergent extraction of amyloid fibers 
Amyloid fibers are generally characterized by low solubility in water-based solutions. 
However in the past the aggregates have been successfully solubilized using high 
concentration of detergents. Based on this background, we performed several steps of 
solubilization using increasing concentrations of detergents to eliminate the water-
soluble material and progressively extract the molecules in the insoluble pellets. Our 
experimental design was based respectively on the use of TBS, followed by 
TBS+Triton-X 1% v/w and TBS+SDS 2% v/w.                           . 
A B
C D
Figure 4.3. LCM of Thioflavin-stained cardiac tissue on Leika LMD 6000. The area of interest 
was delimited manually or recognized automatically by the software of the system (A). After 
confirmation of the area, the apparatus cut around the region with a focused laser beam (red dot) 
(B). The excised fibers were removed (C) by adhesion of a collecting cup (D). This particular 
sequence shows the isolation of two cardiomyocytes. 
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After the extraction, the samples were concentrated and loaded on a SDS-PAGE gel. 
As illustrated in Figure 4.5 our results show abnormal gel migration of the samples, 
which is probably due to interference of residual detergents, as the migration pattern 
seem to be significantly worse in the SDS-treated fractions. 
this protocol. 2 amyloid samples were added to the analysis as positive control. The thioflavin-
positive bands collected at the end of each linear gradient are summarized in B. The protocol did 
not show any consistency of the distribution of the bands across samples belonging to the same 
group. The shaded samples were selected for further pilot characterization. Abbreviations: Amy: 
amyloidosis. 
1 band270NF
1 band270NF
1 band650DCM
1 bandx950DCM
1 band2 bands780DCM
4 bands + diffuse 
signal 
along the tube1 bands3 bands1260DCM
1 band1 band650DCM
1 bandx500DCM
1 band1500DCM
2 bands1 band1 band960Amy
1 bandx350Amy
60-80%45-75%25-60%
Thio-S+ 
Pellet
Starting tissue 
(mg)Diagnosis
B
Figure 4.4. Density-based 
separation on sucrose 
gradients. Tissue lysates 
were loaded on a step 
gradient to separate the 
thioflavins-S positive 
material based on its density. 
The supernatant (mostly 
containing unbound 
thioflavin-S) and any 
eventual thioflavin-S pellet 
were collected and stored 
without further processing 
(A). The bands lying between 
each step of the gradient were 
loaded on linear higher 
resolution gradients in order 
to obtain a better separation 
of the unfolded fibers. A total 
of 7  DCM  and 2  non-failing 
samples were processed  with  
0%
30%
50%
80%
70%
Step G
radient
Step G
radient
Surnatant: no additional 
centrifugation
Linear gradient
25%
60%
Linear gradient
Linear gradient
60%
80%
Linear gradient
Linear gradient
75%
45%
Linear gradient
Linear gradient
Pellet: no additional 
centrifugation
Band 
collection
A
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In addition, we tried to dissolve the insoluble residual material from the TBS+SDS 
extractions using formic acid 70%. However this approach resulted incompatible with 
the downstream analysis because of the impossibility of efficiently removing the 
formic acid without precipitating the molecules in solution. 
 
4.2.5 Oligomer immunoprecipitation 
Immunoprecipitation (IP) is a common technique to enrich a solution in particular 
protein using the specificity of antibodies. Our strategy was based on the use of 
oligomer-targeting immunoglobulins in order to eliminate the vast majority of cellular 
proteins present in the lysates and to obtain samples more compatible with the 
resolution limitations of MS.  
The antibody (Invitrogen, CA, AHB0052) was used at a final dilution of 1:100 in a 
total volume of 500 μl; due to the limited information available on the biochemical 
Table 4.2. Aggregation index of the Thioflavin-S bands isolated from the linear sucrose 
gradient-based separation. The band characterized by the highest aggregation index (i.e. 280/340 
ratio – shaded) among the bands isolated from the DCM and the amyloid samples analyzed were 
selected for further analysis. This experiment represented a validation of the protocol for the 
extraction of amyloid fibers. In fact as AL systemic amyloidosis is due to the overproduction of 
light immunoglobulin chains, we expected to obtain this protein ID from the MS analysis 
performed on the amyloid sample.    
5.7210.0060.035460-80%
9.7140.0020.020360-80%
1.6450.1100.182260-80%
2.1140.0340.072160-80%
2.3570.0160.037145-75%
3.3330.0090.030325-60%
1.5080.0250.038225-60%
1.3560.0820.112125-60%
DCM
2.2590.0350.078260-80%
1.8010.0570.102160-80%
6.5090.0050.035145-75%
2.6570.0040.009125-60%
Amyloid
RatioAbs340Abs280Band Id
Gradient 
rangeSample
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characteristics of DCM-related oligomers, the IP was performed in native conditions 
to inhibit the dissociation of the oligomeric structures. A pilot MS analysis of these 
samples didn’t significantly recognize any specific peptide probably due to the 
incapacity to achieve a significant dissolution of the unspecific bonds and removal of 
the proteins not specifically recognized by the antibody during the wash steps. 
We tried to address this problem by adding a second separation step based on a 
regular SDS-PAGE. The gel was stained to perform a densitometry analysis (Figure 
4.6). We were able to identify 8 bands resulting differentially expressed between the 
DCM and non-failing groups, which were analyzed by MS. 
This analysis led to the significant identification of a peptide belonging to the ankyrin 
repeat domain-containing protein 18A in band G (GI: 283549153), for which no 
biological function has been reported so far. Further database analysis showed that 
the peptide does not belong to the ankyrin repeat domain within the protein, but 
instead belongs to a region with unknown function (Figure 4.7).  
 
 
DCM AD NF DCM AD NF DCM AD NF
A B C
 
Figure 4.5. Detergent extraction of amyloid material. Cardiac tissues from DCM (n=4), AD 
(n=2) and NF (n=2) samples were homogenized in sequential steps using progressively increasing 
detergent strength. The supernatants obtained from each step were run on a SDS-PAGE gel and the 
migration of the different size proteins was visualized by Coomassie Blue staining. While the 
resolution of the gel was satisfactory for the native extraction (TBS, panel A), no satisfactory 
results were observed in the detergent-containing phases (Triton-X 100, panel B and SDS, panel 
C). 
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4.3 Discussion 
 
The assumption that every polypeptide chain can always reach its own functional 
state had been a paradigm in biochemistry and molecular biology for several decades; 
however in the last fifteen years a significant quantity of studies illustrated the 
importance of the protein folding process in the etiology of several degenerative 
diseases. 
In the past the study of genetic transmission in affected families and linkage analysis 
in sporadic cases proved to play a critical role in the identification of most of the 
proteins currently known to be associated to foldopathies (Bertram and Tanzi, 2005, 
Bertram and Tanzi, 2009). However, in some diseases such as idiopathic DCM, the 
presence of genetic aberrations may be of secondary importance to the occurrence of 
particular epigenetic and environmental conditions, resulting in the inability to 
identify the specific cause underlying the pathological condition.  
 
Figure 4.6. Isolation of soluble unfolded aggregates (oligomers) by immunoprecipitation. 
Oligomers from DCM (n=5) and non-failing (NF, n=3) samples were immunoprecipitated in non-
denaturating conditions and loaded on a SDS-PAGE. The band pattern generated by each sample 
was standardized and analyzed (next page, top panel shows an exemplificative densitometry 
profile obtained from a DCM sample). The bands showing significant increase in DCM 
(identified as A, C, D, E, F, G, H in the table) were excised for further processing. 
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An alternative approach to avoid these limitations and identify a putative candidate 
responsible for the development of iDCM consists in the direct characterization of the 
proteins involved in the unfolded protein deposits we described. 
Our approach was based on a first phase of extraction of the proteins, followed by a 
second step focused on the analysis of the extract, based on tandem mass 
spectrometry. 
Tandem mass spectrometry has been considered for several years the best approach 
for the accurate identification of peptides in a complex solution (Gozal et al., 2006). 
In particular increasing attention has been focused on this technique in amyloid 
research due to the interesting perspective of characterizing the peptides involved in 
Figure 4.6 –continued from previous page
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plaques for diagnostic purposes and to develop more effective therapeutic approaches 
(Murphy et al., 2006). However, our results show a substantial incapacity of 
significantly recognizing any known peptide in the protein extract analyzed. We can 
hypothesize that this issue was related to a series of limitations in the extraction 
methods we developed. In particular our strategy was based on several different 
protocols designed to progressively increase the stringency of the protein isolation. 
Although we were aware that low-stringency isolation techniques such as LCM might 
have produced protein extracts excessively complex to be analyzed by mass 
spectroscopy, we considered this step-based approach critical to increase the 
probability of identifying the specific proteins involved in the aggregates. In fact the 
total absence of biochemical information for the deposits such as stability and 
solubility limited our possibilities to use the more aggressive extraction methods 
previously described for the isolation of moderately and strongly detergent-resistant 
fibers (Rostagno and Ghiso, 2009).   
 
In our opinion, the last protocol we described has the highest potential to isolate the 
proteins involved in the aggregates among the different extraction techniques tested 
Region recognized by 
MS with p<0.05
Ankyrin repeat 
domain
 
Figure 4.7. Ankyrin repeat domain-containing protein 18A amino acid sequence and location 
of the peptide recognized by MS.  
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in this chapter. However, some optimization steps are still required to enrich the 
immunoprecipitates with oligomers and to efficiently remove unspecific contaminants.  
We suppose that this goal can be achieved by modifying the immunoprecipitation 
phase of the process: our experiments were performed using a non-denaturating 
washing buffer to preserve the native conformation of proteins and the interactions 
between them. The use of a mild detergent during the washing process could have 
promoted the dissociation of unspecific binding peptides, resulting in a less complex 
protein extract for the downstream analysis. The most critical step for this approach is 
represented by the choice of a safe detergent for the oligomeric structures, which 
should be selected empirically due to the lack of biochemical characteristics as 
mentioned above. This could have been achieved by incubating tissue slides in 
different washing buffer formulations, followed by immunohistochemistry staining 
for oligomeric structures as described in chapter 3. 
This detergent-resistance screening would have improved our knowledge of the 
aggregate properties and addressed us towards more compatible techniques of 
separation. In particular the agarose gel separation we attempted has been previously 
used for the analysis of large proteins or SDS-stable high molecular weight 
complexes (Bagriantsev et al., 2006), since agarose gels are characterized by larger 
matrix pores than acrylamide (Kryndushkin et al., 2003). However, DCM aggregates 
don’t seem to be as SDS-resistant as other amyloid fibers, which in general maintain 
their three-dimensional structures and dissociate from non-amyloid proteins after 
exposure to the detergent. 
Beside these limitations, this protocol allowed us to identify a fragment of the ankyrin 
repeat domain-containing protein 18A as an iDCM-specific peptide. At the moment 
the presence in the cell of this protein has been predicted only by analysis of large 
cDNA clone libraries (Strausberg et al., 2002, Kimura et al., 2006). Therefore, the 
available information about this protein is very limited and represents a major issue 
for further characterization. An additional limitation in the determination of the role 
of this protein in iDCM also derives from the fact that the ankyrin repeat domain 
(which maps in a different region of the polypeptidic chain than the fragment 
recognized by our analysis) is one of the most common motifs found in proteins and 
is apparently related to large variety of biological activity (Sedgwick and Smerdon, 
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1999). Interestingly the ankyrin repeat domain has been recently identified in CARP, 
a small nuclear factor that seems to be mutated in a small subset of DCM patients 
(Moulik et al., 2009). The alteration of this gene in particular produces altered stretch-
induced gene expression and impaired interaction with the mechanosensory system of 
the cell. We can therefore speculate that ankyrin repeat domain-containing protein 
18A may have similar role in the cardiomyocytes, but unfortunately, the absence of 
specific commercial antibodies for the protein restricts the possibility of further 
characterization, including the validation of the data obtained by MS, and prevents 
more informative analysis such as the electromicroscopy-based 
immunocolocalization of the oligomers and the protein. A possible alternative for the 
validation of these results is represented by the evaluation of the transcript by qRT-
PCR, although the data obtained with this technique do not necessarily correlate with 
the actual protein content.   
   
The remaining approaches we considered are instead affected by substantial issues. 
For example, the use of DADT has been applied in the past for the electrophoretic 
separation of large proteins and proteic complexes. However no communications of 
successful combination of this technique and mass spectrometry have been reported 
to our knowledge. This is probably due to an incompatibility between the two 
protocols due to the incapacity of completely eliminating gel residues from the 
samples loaded in the mass spectroscopy apparatus, which in our hand led to 
occlusion of the sample loading lines.    
 
The progressive sedimentation method we propose in this chapter, instead, represents 
an adaptation of a protocol previously described for the purification of unfolded 
inclusion body resulting from overexpression of exogenous proteins in E.coli 
(Schrodel and de Marco, 2005). In order to enhance the separation of the thioflavin-S-
positive fibers and to improve the resolving capacity of the first gradient, we modified 
the protocol by performing an additional sucrose gradient separation for each band 
extracted from the first step. We decided to generate this second gradient as linear 
and we selected the light and heavy solution to mix based on the position of each 
band in the first gradient. However we think that the considerably higher complexity 
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of a eukaryotic cell lysate represented a limiting step for obtaining an appropriate 
separation form this approach specifically developed for prokaryotes. Therefore, in 
our opinion a decrease of the complexity of the initial protein lysate might be 
beneficial for a successful identification of the unfolded peptides. For example, the 
elimination of background generated by the extracellular matrix components could be 
achieved by using cardiomyocytes isolated from DCM cases; however this alternative, 
although attractive, was not feasible at the time when the study was performed mainly 
because of the large amount of starting material required.  
 
The second protocol we proposed for amyloid fiber purification using the 
biochemical properties of the molecules was based on the scarce solubility in water-
based buffers of the aggregates, which can be improved with the addition of 
detergents to the sample buffer. However our findings suggest that the methodologies 
applied are incompatible with the downstream analysis, since our SDS-PAGEs show 
a progressive deterioration of the resolving capacity of the gel with the increase of 
detergent strength and concentration. We hypothesize that this limitation is primarily 
related to large amounts of residual detergents in the samples which interferes with 
the electrophoretic run. To overcome this issue, we considered the possibility to 
dialyze the samples before loading them on the SDS-PAGE. However this process 
could allow the recreation of large insoluble aggregates which are unable to migrate 
through the gel matrix.       
  
The concept of eliminating as many interfering impurities as possible was also the 
rationale behind the LCM-based approach we proposed. However, our observations 
suggest that also the isolation of the single cardiomyocytes does not lead to the 
generation of lysate compatible with the downstream analysis. 
The combination of LCM and mass spectrometry has been successfully employed to 
characterize the peptides involved in Alzheimer’s disease in the past (Gozal et al., 
2006). However we should consider than the studies reported to date focus on large 
extracellular aggregates characterize by low complexity, since the plaques mostly 
contains the amyloigenic peptide. These structures are usually easily isolated from the 
rest of the tissue using conventional LCM protocols. Instead, as we observed in the 
Isolation and identification of unfolded peptides in idiopathic DCM 
 
 
 175
previous chapter, the distribution of the aggregates in DCM is intracellular, affects the 
vast majority of the cardiomyocytes and is not related to specific structures. Therefore 
the isolation of the thioflavin-S positive aggregates doesn’t allow significant 
enrichment in the proteins specifically involved in the fiber formation and a second 
purification step would be necessary. This represents an important limitation 
especially for the amount of material required for the analysis, although the latest MS 
apparatuses can produce high-quality results even from a very low starting amount of 
material (Craven and Banks, 2001, Mustafa et al., 2008).  
 
An additional problem we encountered in all the analysis presented derived from the 
fact that the samples used in this study were obtained from late-stage iDCM. We can 
speculate that the long-term exposure to the unfolded peptides we described in the 
previous chapter leads to progressive saturation of the unfolded protein response 
systems and, eventually, to a degeneration of the capacity of the cell to resolve the 
accumulation of existing unfolded peptides and prevent the misfolding of newly 
synthesized proteins. Therefore, it this plausible that in this context the aggregates are 
not just formed by a single protein or by a limited number of peptides, but they 
include every cellular protein that fails to reach its functional state due to the lack of a 
properly functioning folding apparatus. This hypothesis is supported by recent finding 
in pancreatic β-cells showing that the process of molecular crowding (i.e., the 
continuous accumulation of unfolded toxic proinsulin in the ER) exacerbates the 
defect in protein folding in diabetes (Despa).   
 
In conclusion, the identification of the proteins involved in the intracellular deposits 
in iDCM represents an open challenge for a better understanding of the disease and to 
generate new diagnostic and therapeutic tools. In particular our approach was 
characterized by a series of technical limitations that might be circumvented by using 
early stage-DCM samples in the first place. Additional possible solutions might 
derive from the combination of some of the isolation techniques we proposed in this 
chapter, although we should consider that extensive manipulation are highly 
impractical due to the limited amount of starting material usually available.  
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CHAPTER 5 
GENE EXPRESSION PROFILING 
OF DILATED CARDIOMYOPATHY 
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5.1 Introduction 
 
 
In the previous chapters we described the presence of insoluble protein aggregates in 
cardiac tissue derived from patients diagnosed with DCM. In addition, we 
demonstrated that these deposits and in particular their soluble intermediate molecular 
precursors can produce impairment of the cardiomyocyte activity and alterations in 
the UPR pathway that can lead potentially to apoptosis. The identification of peptides 
specifically involved in the formation of these amyloid fibers still represents a 
challenging procedure for the technologies currently available for proteomics analysis. 
Therefore in this chapter we will approach the characterization of altered cellular 
pathways in DCM by evaluating the alterations in the messenger RNA (mRNA) levels 
performing a high throughput analysis based on the microarray technology. This 
technique present several advantages compared to the traditional approaches for the 
identification of proteins and genes related to a certain pathological condition. In 
particular, the last generation of microarray allows the analyses of thousands of genes 
at the same time with high reliability and reproducibility. In addition, microarrays 
represent a faster and technically easier alternative compared to other genomic and 
proteomic techniques (Asakura and Kitakaze, 2009).  
 
In the past decade a considerable number of studies have been based on the use of 
microarray to elucidate new genes and pathways related to the etiology of DCM.  
In 2000 a paper from Yang et al (Yang et al., 2000) reported alteration of a total of 17 
genes from a limited number of patients (2 non-failing, 1 DCM, 1 ischemic 
cardiomyopathy). Among these messengers, 12 mRNA showed differential 
expression between non-failing and failing samples and 5 instead were expressed only 
in DCM hearts. The authors categorized these genes in 5 main gene ontology groups: 
structural, metabolic, cell stress-related, protein synthesis-related and related to the 
degradation of myocardial proteins.  
The main limitation of this study consisted in the limited number of patients analyzed. 
Different publications appeared in the following years with larger pools of samples 
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included in each study group (Barrans et al., 2002, Hwang et al., 2002, Tan et al., 
2002, Grzeskowiak et al., 2003, Steenman et al., 2003, Kaab et al., 2004, Yung et al., 
2004, Kittleson et al., 2005, Colak et al., 2009). In addition, these studies could take 
advantage of technological improvements in the microarray technology, which led to 
increased number of messengers analyzed in a single chip and to higher reliability of 
the data. In these papers the authors generally showed alterations in several genes 
encoding for sarcomeric and cytoskeletal proteins, transcription factors, stress 
response proteins and Ca2+ handling, extracellular matrix components, proteins related 
to fatty acid metabolism, and apoptosis.  
 
Additional interesting data on the transcriptosome of DCM heart have become 
available from other groups that investigated specific aspects of DCM: Haddad et al 
(Haddad et al., 2008) focused on the determination of genre-specific transcriptional 
alterations, showing differential deregulation of genes related to contractility 
(specifically deregulated in male patients), energy metabolism and transcription and 
translation (specifically altered in female samples). Dr. Léger’s group, instead, 
determined chamber-specific differences in DCM samples, detecting a relatively 
limited number of alterations between left and right ventricles (Steenman et al., 2003).  
An alternative approach to the determination of the molecular pathways alterated in 
DCM was instead explored in a paper by Hannenhalli et al (Hannenhalli et al., 2006): 
the authors analyzed the promoter regions of the genes found to be deregulated in 
order to determine which transcription factor binding sites were over-represented.  
 
It is interesting to observe that neither of these publications showed results 
overlapping similar studies performed by different authors. Factors that may 
contribute to the discrepancies include the quality of the samples (and therefore of the 
RNA) and the limited availability of age and sex-matched samples. Further variability 
can also arise from the use of terminal heart failure patients as source of samples for 
these studies: in 2003 Grzeskowiak et al were successfully able to obtain a 
homogeneous fingerprinting of early stage DCM patients (Grzeskowiak et al., 2003), 
showing deregulation of genes related to intracellular signaling at early stages, while 
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in the late stages of the disease deregulation of apoptosis and cell cycle regulation 
gene levels seem to be predominant.  
Additional obstacles for successful comparison of the previously published data are 
related to the fact that all the analyses published to date were performed using 
different chips and/or different platforms for the analysis. A study from Barth et al 
(Barth et al., 2006) recently showed the integration of 4 independently-run microarray 
datasets, leading to the identification of a set of 27 genes and minimizing the 
overinterpretation of each single set of data.  
 
The majority of the microarray profiling for DCM published to date were performed 
comparing normal non-failing with failing DCM hearts. However in some cases the 
authors introduced ischemic hearts as an additional group of study in order to isolate 
the gene specifically modified by ischemia (Yang et al., 2000, Hwang et al., 2002, 
Steenman et al., 2003, Kittleson et al., 2005). 
The present study, instead, is focused on the identification of a subset of messengers 
that are specifically altered in DCM and not related to the adverse remodeling 
commonly occurring in failing heart independently of the etiology. Our approach is 
based on an innovative three-way comparison of the transcriptome in non-failing, 
DCM and systemic amyloidosis. Amyloidosis is a systemic pathology affecting 
several organs and, in particular, kidney, liver and heart (Selkoe, 2003). The most 
common form of systemic amyloidosis is associated with multiple myelomas and 
malignant lymphomas, which are often characterized by uncontrolled overexpression 
and secretion of immunoglobulin chains in B lymphocytes. These proteins are 
delivered to the peripheral organs where they form amyloid deposits that affect the 
correct organ functions (Van Geluwe et al., 2006). The presence of these unfolded 
molecular species in the heart produces a restrictive cardiomyopathy that eventually 
leads to a failing condition. The most interesting aspect of this disease for our study 
consists in the localization of the etiology of the disease: although systemic 
amyloidosis doesn’t originate directly in the heart, it is characterized by devastating 
cardiac effects producing activation of the remodeling pathways similarly to what is 
observed in other forms of HF. 
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In addition, the presence of immunoglobulin deposits in the extracellular matrix 
produces alterations of the redox state of the cardiomyocytes leading to impaired 
contractile function and Ca2+ handling (Brenner et al., 2004). As the unfolded light 
chain immunoglobulins assume a β-sheeted three-dimensional structure, we expect 
them to produce effects similar to what we observed in chapter 3 with Aβ oligomers 
on the cardiomyocytes. Therefore, we hypothesize that the inclusion of hearts affected 
by amyloidosis in our study will allow distinguishing the genes involved in the 
etiology and initial phases of DCM from the genes related to the evolution of the 
disease and related to the toxic consequences of the accumulation of unfolded 
products. 
 
The analytical approach we propose resulted in the identification of 10 DCM-specific 
and 41 amyloidosis-specific genes and a total of 118 failing-related genes. While the 
latter were associated to a large array of biological processes, DCM- and amyloidosis-
specific genes mainly clustered in two specific pathways: nervous system 
development and skeletal and tissue remodeling respectively.  
 
 
5.2 Results 
 
This study is based on the comparison between cardiac samples obtained from three 
different groups: patients affected by idiopathic DCM (n=6), patients affected by 
systemic amyloidosis (n=5) and non-failing donor hearts (n=6, Table  5.1). We 
structured our data processing in order to obtain a three-way comparison leading to 
the identification of DCM-specific genes (i.e., significantly altered in the DCM-
amyloidosis and DCM-non failing comparisons, but not altered between amyloidosis 
and non-failing) and amyloidosis-specific genes (i.e., significantly altered in the 
DCM-amyloidosis and amyloidosis-non failing comparisons, but not altered between 
DCM and non-failing). Our analysis also produced the identification of a third subset 
of genes common to amyloidosis and DCM; this group includes the genes that are 
involved in the development of heart failure, independently from the etiology of the 
condition.     
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Table 5.1 Clinical data of the samples used for the microarray analysis 
Pt Diagnosis age Gender 
Cause of 
death Other diseases Medications 
1 Non-failing 56 Male ICH     
2 Non-failing 35 Male GSW (head)     
3 Non-failing 56 Male ICH     
4 Non-failing 62 Female CVA 
HTN, mild LV 
hypertrophy   
5 Non-failing 57 Female N/A 
Legioneer Disease,  
Choliestomy, HTN    
6 Non-failing 75 Female N/A 
HTN, 
hypothyroidism,  
varicous veins   
1 DCM 56 Male N/A 
NIDDM, pulm HTN, 
AF, CRI   
2 DCM 57 Male N/A 
CM, HTN, AF, 
hyperlipemia, 
hyperthyroidism post 
Amio,Obesity  
Diuretics, 
antiarrhythmics, 
anticoagulants,  
nitrates, lipid lowering, 
PDE inhibitors  
3 DCM 25 Male N/A Anemia, asthma 
Beta-blockers, 
antinflammatory 
4 DCM 31 Female N/A Asthma 
Diuretics, beta-
blockers, digoxin, 
ACE  
inhibitors, 
anticoagulants 
5 DCM 65 Female N/A 
COPD, AF ETOH, 
hypothyroidism 
Diuretics, digoxin, 
ACE inhibitors, 
antiarrhythmics, lipid 
lowering, 
levothyroxine 
6 DCM 43 Female N/A Anoxyc brain injury 
Diuretics, beta-
blockers, alpha-
blockers,  
Ca2+ anthagonists 
1 Amyloidosis 61 Male N/A   
Antidepresants, 5HT 
blockers 
2 Amyloidosis 58 Male N/A 
Sleep apnea, NSvT, 
AF,  
obstructive sleep 
apnea,  
Hyperlipemia 
Diuretics, Ca2+ 
anthagonists, albuterol, 
lipid lowering 
3 Amyloidosis 67 Male N/A MI   
4 Amyloidosis 37 Female N/A 
Hypothyroidism, 
kidney stones 
Diuretics, 
antiarrhythmics, PDE 
inhibitors  
5 Amyloidosis 55 Female N/A 
Acute renal failure, 
NSVT Diuretics, colchicine 
List of abbreviation used: NIDDM = Non insulin dependent diabetes mellitus, AF = atrial 
fibrillation, Pulm HTN = pulmonary hypertension, HTN = systemic hypertension, CRI = chronic 
renal insufficiency, COPD+ chronic obstructive pulmonary disease, ETOH= alcohol consumption, 
MI = myocardial infarction, NSVT= non sustained ventricular tachycardia, GSW = gun shot 
wound, ICH=intracranial hemorragia
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5.2.1 RNA extraction 
The RNA samples were quantified on a spectrophotometer by reading the absorbance 
at 260 nm. The concentrations were ranging between 250 and 650 ng/μl. The 
contamination with protein was evaluated by reading the absorbance at 280 nm and 
analyzing the Abs260/Abs280 ratios: all the samples showed values ranging from 1.7 
and 2.0. The quality and the integrity of the RNA were tested by microcapillary 
electrophoresis. The Abs260 profile of each run showed distinct peaks for the tRNAs 
5S, 18S and 28S (Figure  5.1). No signs of accumulation of low molecular weight-
degradation fragments were detected in the area surrounding the 5S tRNA peak. In 
addition the integration of the peaks relative to the 18S and 28S tRNAs showed ratios 
close to 1:2. These results were considered compatible with the Affymetrix guidelines 
for the quality of RNA for the microarray analysis.    
 
5.2.2 Microarray preparation 
The quality of the cRNA prepared was evaluated before the fragmentation process. 
The profile of the samples showed no tRNA peaks and correct distribution of the 
RNAs of different length, consisting in considerable amount of short-medium 
molecules (over 200-250 bases) gradually declining for longer molecules (Figure  
5.2a). The analysis was repeated after performing a random metal-catalyzed 
fragmentation reaction. The Abs260 profile showed a wide peak shifted to the 
beginning of the run and corresponding to 50-200 base-long molecules (Figure  5.2b). 
No evidence of unfragmented cRNA was observed.  
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Figure  5.1. Bioanalyzer 
profiles of a representative 
RNA sample. The graph shows 
the modification of units of 
fluorescence (FU) of the sample 
with the progression of the run. 
This RNA preparation showed 
insignificant presence of 
degradation and neat peaks for 
the tRNAs 5, 18 and 28S, which 
were detected respectively at 
22, 41 and 50 sec after the 
beginning of the run.  
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5.2.3 Microarray analysis 
Quality control of the scanned chip images was performed before further analysis of 
the data. All the normalized images were characterized by comparable high quality. 
The percentage of present calls on each chip ranged between 40.6% and 47.8%, with 
an average of 44%±2.17% (27,125±1,338 probes, Figure  5.3). The overall pre-
normalization variability across the samples did not exceed 15% in term for all the 
following parameters: background, noise, spike-ins, levels of exogenous controls and 
housekeeping genes. A total of 19,357 probe sets (=31.4% of all the probes on the 
chip surface) were identified as present or marginally present in all the 17 samples in 
the study, while 22,316 (=36.2%) were considered absent, i.e. not represented in any 
of the samples. The presence/absence similarity across the samples and the different 
groups considered was equal to 67.6%, indicating good consistency of the results 
obtained.  
The data were processed considering as differentially expressed all the probes 
showing difference in post-normalization signal intensity of at least 2 fold. 
Preliminary 2-group analyses indicated analogue differentially expressed probe 
distribution in the DCM-non failing and amyloidosis-non failing comparisons with the 
majority of the probes significantly up-regulated (DCM-non failing: 312 upregulated 
and 272 downregulated; amyloidosis-nonfailing: 558 upregulated and 215 
downregulated, Table  5.2). The DCM-amyloidosis comparison, instead, showed 197 
probe underexpressed and 40 overexpressed. In addition we observed that most of the 
Figure  5.2. Bioanalyzer 
profile of a representative 
cRNA sample before (a) and 
after (b) fragmentation. The 
graphs show the alterations of 
the fluorescence units (FU) 
against time. The wide bump 
showed in (a) between 21 and 
55 seconds is correlated to the 
presence of several cRNA of 
different length, which were 
successfully disrupted to 50-
200 base-long fragments as 
indicate by the narrow peak 
present between 20 and 27 sec 
in (b). 
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altered probes in the DCM-non failing comparison showed changes between and 0.08 
and 6 fold, while the alterations between amyloidosis and non failing groups were 
distributed within a larger interval (0.04 and 32 folds, Figure  5.4).  
 
Figure  5.3. Amount of probe sets in each microchip image considered present (i.e. 
characterized by normalized intensity higher than 8, labeled as P) or absent (labeled as A). 
All the samples showed comparable number of present probes ranging between 40.6% and 47.8%. 
On average the number of present probes was of 27,125±1,338 or 44%±2.17% of the total. M 
represents the exogenous positive controls introduced during the cRNA syntesis. 
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Table  5.2. Number of probes altered in each 2-group comparison. 
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5.2.4 Group comparison  
The probes that were differentially expressed in our 2-group analysis represent a 
combination of genes specific for the disease and genes that instead contribute to the 
progressive degeneration in the failing process or are altered as an adaptive 
mechanism (Figure 5.5). In order to efficiently discriminate these two categories of 
genes we introduced a more complex analysis based on simultaneous comparison of 
the three different groups used in this study. This analysis allowed the recognition 
respectively of amyloidosis and DCM-specific genes and the separation from the 
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Figure  5.4. Distribution of altered probes 
in 2-group comparisons. Shaded areas 
represent changes in expression inferior to 
the arbitrary fixed value for this analysis (i.e., 
2 folds. The intervals are expressed as log2). 
 
 
 
 
 
 
Figure  5.5. Representation of the 
rationale behind the use of our 
three-group analysis. The probes that 
are commonly altered in DCM and 
Amyloidosis were separated from the 
disease-specific and considered 
failing-associated. 
Amyloid 
specific
n = 52
Failing 
related
n = 200
DCM 
specific
n = 13
Total probes on Affymetrix
U133 plus 2.0          
n=54675
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genes commonly alterated in the two diseases, which were labeled as “failing-
associated”.  
Our approach led to the identification of limited DCM-specific probes (6 upregulated 
and 7 downregulated, Table  5.3) representing a total of 10 known genes (4 increased 
and 6 decreased). The probes specifically altered in amyloidosis totaled 52 
overexpressed sets and none underexpressed (Table  5.4), representing 41 known 
genes. The failure-related probes (i.e., significantly differentially expressend in DCM 
and amyloidosis) included a total of 200 EST (118 increased and 82 decreased, listed 
in Table  5.5) representing 138 known genes (82 increased and 56 decreased). 
The probes resulting DCM-specific, amyloidosis-specific or failing-related were 
organized by hierarchical clustering (Figure  5.6). In particular the DCM-specific 
probes distinctly grouped all the DCM patients and clearly separated them from non-
failing samples (Figure  5.6a), with the exception of the sample indicated as donor 1 
(red arrow), that instead clustered within the DCM group. The amyloidosis samples, 
instead,   were  randomly   interspersed  between   both  DCM   and   non-failing.  The  
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Figure  5.6. Hierarchical clustering of DCM- (panel a), amyloidosis (panel b) and failing 
specific (panel c) genes in the 17 samples analyzed. The samples were distributed on the x axis 
according to their similarities in the expression profile for the probe considered, i.e., samples with 
similar expression profile are close to each other. The color of each probe for each samples indicate 
the variation relative to the median value of all the samples considered. The red arrow indicates 
samples showing dissociation from their respective groups. 
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hierarchical clustering of the amyloidosis-specific probes resulted in a very clear 
distinction between the amyloidosis, DCM and non-failing samples (Figure  5.6b), 
with the exception of donor 1 that showed again an expression profile closer to DCM 
than to non-failing samples. The hierarchical clustering of failing-associated genes 
showed clear separation of the non-failing samples from DCM and amyloidosis 
patients. Only the DCM sample designated as DCM 5 was (red arrow) showed a 
transcriptosome profile closer to non-failing samples. 
The two samples clustering outside of their respective groups were further 
investigated with a more detailed clinical history analysis in order to find the cause of 
the abnormal transcriptome profile. This revealed presence of mild hypertrophy in 
donor 1 and history of increased alcohol consumption in DCM 5. 
With these post-analysis considerations, we can conclude that the results form the 
hierarchical clustering suggested consistency of the analysis performed and clear 
specificity of the EST identified.  
 
5.2.5 PCR validation 
RNA microarrays are based on an extremely powerful technology which allows the 
determination of the levels of thousands of transcripts at the same time. However, this 
expression profiling method is also characterized by high occurrence of false positive 
and false negative due to several causes including cross hybridization of cRNAs with 
similar sequences, artifacts deriving from the preparation of the samples leading to 
preferential enrichment of a subset of transcripts or simply deriving from 
technological limitations of the detection systems. Therefore it is of primary 
importance to validate the data obtained from microchips analyses using alternative 
methods. Currently the most accurate and trusted method for microarray data 
validation is the quantitative real-time-PCR (qRT-PCR). 
qRT-PCR was used in our study to confirm the expression levels of randomly selected 
genes showing differential expression in the groups we analyzed. In particular we 
assayed the levels of nestin (NES) and Down Syndrome Critical Region 1 (DSCR1) 
for the DCM-specific genes and apolipoprotein E (APOE) and stanniocalcin (STNC) 
for the amyloidosis-specific genes (Figure  5.7). In addition we verified four failing-
related genes: atrial natriuretic peptide (ANP), brain  natriuretic peptide  (BNP), slow- 
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twitch skeletal troponin 1 (TNN1) and retinoic acid receptor responder 1 (RARRES1). 
The results were standardized to the content of 18S tRNA of each sample. Our results 
showed accuracy between the microarray and qRT-PCR data in 7 transcripts out of 8 
(87.5%). Only the amyloidosis-specific gene APOE did not show expression levels 
matching with the microchip results. 
  
5.2.6 Gene Ontology analysis 
Microarray studies generate a large amount of data that often becomes excessively 
difficult to analyze in order to identify the pathways involved in certain phenotypes. A 
valid contribution to the analysis of these results and to understand their biological 
meaning derives from the use of Gene Ontology databases. These databases collect all 
the known molecular functions, cellular localization and interactions of gene products. 
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Figure  5.7. qRT-PCR validation of microchip results. The levels of four failing-related genes 
(atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), retinoic acid receptor responder 1 
(RARRES1), slow-twitch skeletal troponin 1 (TNN1)), 2 DCM-specific (DSCR1), nestin (NES)) 
and 2 amyloidosis-specific (apolipoprotein E (APOE), stanniocalcin 1 (STNC1)) were analyzed by 
qRT-PCR and standardized to the content of 18S tRNA. Panel a compares the averages of each 
gene for each group analyzed in the study. Statistically significance between two groups (p<0.05) is 
indicated by the presence of a horizontal bar. In b the data from qRT-PCR are compared to what 
was generated from the microarray analysis.    
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For our study we submitted the lists of significantly altered probes we identified from 
our 3-group analysis to the Database for Annotation, Visualization and Integrated 
Discovery (DAVID). 
According to the database, 123 of the 200 failing-related EST deriving from our 
analysis were significantly associated to biological processes (summarized in Table  
5.6a and visualized in Figure  5.8). No specific correlation was instead detected for 
the remaining 77 probes. The analysis performed using the KEGG database showed 
significant alteration in the complement/coagulation cascades and in the extracellular 
matrix-receptor interaction (Table  5.6b). The biocarta database, instead, suggested 
presence of alterations in the activin like kinase pathway (Table  5.6c). 
 
 
Table  5.6.  List of biological processes and pathways associated to the failing process 
according to DAVID (a), Kyoto encyclopedia of genes and genomes (KEGG) (b) and biocarta 
databases (c). Only processes involving at least 2 genes and p<0.05 were included. Abbreviations: 
Wnt: wingless-type mouse mammary tumor virus integration site ECM: Extra-cellular matrix 
ALK: Activin receptor-like kinase (Bone morphogenetic protein receptor type IA precursor).  
A   
      
Process Count p value 
      
      
Establishment of localization 38 0.001 
Localization 38 0.001 
Transport 35 0.001 
Cell communication 35 0.037 
Development 31 >0.001 
Ion transport 20 >0.001 
Inorganic anion transport 11 0.000 
Anion transport 11 0.000 
Morphogenesis 11 0.012 
Phosphate transport 10 >0.001 
Circulation 6 0.001 
Regulation of cell growth 5 0.012 
Regulation of growth 5 0.015 
Cell growth 5 0.028 
Regulation of cell size 5 0.028 
Wnt receptor signaling pathway 4 0.038 
Blood pressure regulation 3 0.024 
Osmoregulation 2 0.043 
Not classified 77   
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The application of the DAVID algorithm to the 13 DCM-specific probes indicated the 
presence of a group (n=3) of EST involved in the system maturation and, in particular, 
in the nervous system development, while 10 probes were not significantly classified 
in any category (Table  5.7). The consultation of the KEGG and Biocarta database 
could not associate any specific pathway to the identified DCM-specific ESTs.  
B   
      
Process Count p value 
      
      
Complement and coagulation cascades 4 0.018 
ECM-receptor interaction 4 0.039 
Not classified 130   
 
 
C   
      
Process Count p value 
      
      
ALK in cardiac myocytes 4 0.012 
Not classified 134   
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Figure  5.8. Biological processes associated to the failing-specific genes according to the 
Database for Annotation, Visualization and Integrated Discovery (DAVID). 
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The amyloidosis-specific probes resulted involved mostly in processes such as 
development, cell adhesion and tissue remodeling (Table  5.8 and Figure  5.9). No 
significant classification was instead indicated for 20 EST out of the 52 identified by 
our analysis. According to the KEGG database, the amyloidosis-specific probes 
resulted related to cell communication, focal adhesion and extracellular matrix-
receptor interaction pathways (Table  5.8b). In addition, the biocarta database 
identified a cluster of probes involved in the maturation of T lymphocytes from their 
naïve state (Table  5.8c): Thy-1 and CD28. 
 
 
5.3 Discussion 
 
In the previous chapter we attempted to identify unknown myocardial alterations 
involved in the etiology of idiopathic DCM using a proteomic-based approach such as 
mass spectrometry. Unfortunately, several technical limitations associated to the 
technique restricted the possibility of obtaining significant results. In this study we 
propose the use of a second high throughput technique to investigate new causes of 
DCM. In particular we decided to develop a comprehensive picture of the 
transcriptosome of the failing tissue using the microarray technology, which allows 
the detection of the levels of thousand of ESTs. Several limitations have been 
described in the past in relationship to this technique, including the biological 
variability of the samples (especially when deriving from human patients), stochastic 
variability or the incapacity of detecting alterations in the post-translational 
Table  5.7. List of biological processes associated to DCM according to DAVID database. No 
pathways resulted significantly related to DCM according to KEGG and biocarta databases. Only 
processes involving at least 2 genes and p<0.05 were included. 
 
      
Process Count p value 
      
      
Nervous system development 3 0.032 
System development 3 0.032 
Not classified 10   
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Table  5.8. List of biological processes and pathways associated to amyloidosis according to 
DAVID (a), KEGG (b) and biocarta databases (c). Only processes involving at least 2 genes and 
p<0.05 were included. 
A   
      
Process Count p value 
      
      
Organismal physiological process 12 >0.001 
Development 11 >0.001 
Cell adhesion 8 0.001 
Organ development 8 0.001 
Skeletal development 6 0.004 
Tissue development 5 0.005 
Regulation of organismal physiological process 4 0.005 
Biomineral formation 3 0.005 
Bone remodeling 3 0.005 
Ossification 3 0.005 
Phosphate transport 3 0.015 
Tissue remodeling 3 0.022 
Positive regulation of T cell activation 2 0.050 
Not classified 20   
B   
      
Process Count p value 
      
      
Cell communication 5 >0.001 
Focal adhesion 4 0.022 
ECM-receptor interaction 3 0.028 
Not classified 36   
C   
      
Process Count p value 
      
      
T Cytotoxic Cell Surface Molecules 2 0.037 
T Helper Cell Surface Molecules 2 0.037 
Not classified 39   
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modification pathways. However, microarrays are nowadays commonly considered a 
valid and efficient method to analyze multiple pathways simultaneously, significantly 
reducing the problems associated to the inter-experimental variability.  
Our analysis was performed with the most complete human chip available 
(Affymetrix Human Genome U133 Plus 2.0), which contains more than 54,000 EST 
and allowed one of the most detailed characterization of the DCM transcriptome up to 
date.  
The rationale supporting this study consists in separating the transcripts specifically 
expressed in DCM from the messengers involved in the progression of the failing 
condition and, at least in part, from the effects produced by the pharmacological 
treatment of the disease. We therefore propose a 3-group analysis including two 
different causes of HF, idiopathic DCM and systemic-light chain amyloidosis, and a 
control group of non-failing samples. Light chain amyloidosis is a systemic disorder 
associated to malignant lymphomas or myelomas. The uncontrolled expansion of B 
lymphocyte clones in these forms of liquid tumors often produces overexpression of 
immunoglobulin chains, leading to their accumulation in the circulation and, 
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Figure  5.9. Biological processes associated to the amyloid-specific genes according to the 
Database for Annotation, Visualization and Integrated Discovery (DAVID). 
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eventually, to the aggregation in amyloid fibers. The deposition of this molecular 
species in the heart gradually increases the stiffness of the organ and reduces the 
elasticity of the tissue, leading to a restrictive cardiomyopathy and to heart failure. In 
addition, the presence in the extracellular space of β-plated unfolded structures can 
directly impair the cardiomyocyte contractility by altering the redox state and the Ca2+ 
handling of the cell (Brenner et al., 2004). As we demonstrated in Chapter 3, 
idiopathic DCM samples show strong evidences of unfolded proteins not associated to 
any known amyloigenic alteration (Sanbe et al., 2004). We assume that the presence 
of these aggregates produces effects on the cardiomyocytes, which may include 
modifications of the transcription profile of the cell. As systemic amyloid is 
associated with deposition of amyloid aggregates in the whole body, here we 
hypothesize that the exposure to circulating amyloid may be able to produce at least 
part of the transcriptosome alterations normally due to the formation of intracellular 
amyloid fibers in cardiomyocytes. Based on this assumption, we think that the direct 
comparison between systemic amyloidosis and DCM samples also allows increased 
precision in determining a subset of DCM-specific genes by permitting the 
identification of the modifications of the transcriptome due to the potential effects of 
amyloid fibers on the cells.   
 
Our data from gene-ontology analysis show that the genes that we identify as failure-
related mainly group in 4 categories: metabolism (Sack and Kelly, 1998, Tan et al., 
2002, Oyama and Chittur, 2005), ion transport and localization (Barrans et al., 2001, 
Barrans et al., 2002, Hwang et al., 2002, Yung et al., 2004), fibroblast grow and 
activation (Reiss et al., 1995) and extracellular matrix components (categorized as 
response to wounding and development in Table  5.8). We can hypothesize that this 
indicates the activation of a series of mechanisms to counteract the progressive loss of 
cardiac function during the failing process. Although they have beneficial effects in 
the short term by providing structural support and resilience to the organ, these 
mechanisms eventually produce deleterious maladaptive results consisting in 
excessive stiffness of the organ, electromechanical uncoupling and further 
decompensation (Sharma et al., 2005).   
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Some of the genes that we identified as failing-related have been previously proven to 
be associated to the progression of the disease and are currently used as clinical 
markers (Rademaker and Richards, 2005). The detection of overexpression of genes 
such as the atrial natriuretic peptide (ANP) and the brain natriuretic peptide (BNP) in 
both amyloidosis and DCM samples is a confirmation of the validity of our results, 
which demonstrate to be in line with previous studies. ANP and BNP in the past have 
been associated to a compensatory activity aimed to oppose the increasing 
inefficiency in cardiac activity typically observed during the progression of heart 
failure. These genes are acquiring increasing interest both as diagnostic and 
prognostic indicators as well as potential target for the development of alternative 
therapeutic approaches, even if they can not be classified as initial cause of the failing 
process. 
 
Considering the significant differences between amyloidosis and DCM both in term 
of etiologies and features of the diseases, it is interesting to observe that the two 
groups we analyzed share a large majority of common altered genes and are instead 
characterized by relatively small groups of disease-specific messengers (amyloidosis: 
41, DCM: 10). 
 
The analysis of the amyloidosis-related transcripts showed significant alterations in 
genes related to mechanical stress -including the detection of mechanical stress-, 
skeletal development, tissue remodeling, cell-to-cell and cell-to matrix adhesion. The 
continuous accumulation of light immunoglobulin chains produces major alterations 
to the elasticity of the heart that lead to increased pressure on the cardiac walls and 
deposition of extracellular matrix components characterized by higher resistance to 
mechanical stress. Although this process is aimed to protect the cardiac tissue from 
being damaged, in the long term it accelerates the development of restrictive 
cardiomyopathies and the occurrence of heart failure.  
In addition our data suggest the presence of increased levels of two surface markers 
involved in the maturation of T-cells (Thy-1 and CD28), which may be related to the 
presence of lymphocyte T infiltrates in the cardiac tissue or, alternatively, may 
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represent a consequence of the immunosuppressive therapeutic approach involved in 
the treatment of systemic AL amyloidosis. 
Within the amyloidosis-specific genes, STC1 was overexpressed in all the 
amyloidosis samples analyzed. This gene codify for Stanniocalcin 1 (Stc1), an highly 
conserved homodimer glycoprotein involved in the regulation of Ca2+ homeostasis 
and transportation in the intestine (Madsen et al., 1998). The role of Stc1 in the 
myocardium, instead, seems related to the protection of the cardiomyocytes during 
diastole by regulating the Ca2+ currents in order to prevent overload of the ion and 
hypercontracture of the cell (Koizumi et al., 2007). Previous data from Hamad et al 
(Sheikh-Hamad et al.) show no alteration of Stc1 mRNA levels in failing hearts; 
however the authors detected significant increase of the protein levels that can 
apparently be reverted by cardiac unload mediated by left ventricular assist device 
(LVAD).  
In addition to the protective role on Ca2+ overload, that is a common feature of heart 
failure independently from the etiology, STC1 gene overexpression in cardiac 
amyloidosis might relate to the response of cardiac tissue to the accumulation of 
unfolded -pleated protein fibers in the extracellular space. Stc1 shares 61% 
homology with stanniocalcin 2 (Stc2), a protein shown to be overexpressed following 
the administration of -amyloid fibers in the culture media in isolated neuroblastoma 
cells (Kim et al., 2003). Stc2 is also activated following endoplasmic reticulum stress 
by ATF4 and PERK, two molecules of the unfolded protein response pathway (Ito et 
al., 2004). The activation of STC1 in stress condition seems to be achieved 
independently of ATF4 and PERK. However we can not exclude overlapping 
functional roles of these two peptidic hormones and STC1 activation mediated by 
other components of the UPR. 
 
The gene-ontological classification of the DCM-specific genes identified showed a 
limited number of messengers which have ever been related to DCM and which were 
characterized by clear involvement in the development processes and, more 
specifically, in the development of nervous system.  
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Among the genes that were overexpressed we considered of particular interest the 
presence of nestin. Nestin is a protein belonging to the family of the intermediate 
filaments normally expressed in the nervous system during neurogenesis in the 
embryonic development. In adult subjects nestin expression has been observed in the 
pituitary gland and in the subventricular zone of the brain (Kukekov et al., 1999, 
Leonard et al., 2009, Weiss et al., 2009) and, at lower levels, in several stem cell 
niches including the bone marrow (Kachinsky et al., 1995, Fukuhara et al., 2005, 
Wagner et al., 2006). Interestingly, some of these studies also reported the presence of 
nestin positive cells in the cardiac tissue. Different hypotheses have been formulated 
to explain the function of nestin in the myocardium: nestin positive cells can develop 
from neural types normally present in the heart (neural fiber (El-Helou et al., 2005) or 
cells deriving from the activation of dormant multipotent precursors homed in the 
heart but originated from the neural crest during embryogenesis (Tomita et al., 2005)) 
or can relocate to the heart from other tissues such as bone marrow as a protective and 
reparative response to injury or prolonged stress condition (Fukuhara et al., 2005). 
Alternatively, the overexpression of nestin we observed can be related to a 
compensatory process specific to the cardiomyocytes to replace cytoskeletal elements 
previously described to be progressively lost in late stage cardiomyopathies (Hein et 
al., 2000, Kostin et al., 2000) and to increase the mechanical resistance of the 
cardiomyocytes (Capetanaki et al., 1997). 
 
A second DCM-specific messenger we considered interesting was a gene relate to 
Down Syndrome (SD), Down Syndrome Critical Region 1 (DSCR1). This gene was 
identified in 1997 on the chromosome 21 in a highly conserved region (q22.1-2) in all 
the patients affected by Chr 21 trysomy (Fuentes et al.). Although no clear biological 
role for this gene has been described to date, functional analyses classified DSCR1 as 
an “adaptive response stress gene” (Crawford et al., 1997, Leahy et al., 1999).   
DSCR1 encodes for calcipressin, a proline-rich protein normally found at high levels 
in the brain and in the heart at developmental stage. During adulthood this protein 
seems instead to be constitutively overexpressed in pathological conditions such as 
DS (as a result of polyploidy of the region 21q22.1-2) and Alzheimer’s Disease 
(Fuentes et al., 1995, Fuentes et al., 2000, Casas et al., 2001, Porta et al., 2007). 
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Several groups investigated the presence of correlation between the two diseases, 
collecting interesting results: in fact it seems that DS patients develop increased 
cognitive impairment during the 4th decade of life. These forms of dementia are 
similar to what has been observed in AD. In addition post mortem analysis of DS 
brain samples clearly show markers typically associated to AD, such as diffuse 
presence of amyloid plaques (Lemere et al., 1996, Liu et al., 2006). Of note these 
alterations are apparently not related to the presence of an additional copy of the APP 
gene (that maps closely to DSCR1 in region 21q21), since they appear to be present 
even in partial trisomic subjects in which DSCR1 is present in 3 copies, while APP is 
diploid (Korenberg et al., 1989).  
 
The role of calcipressin in AD, instead, seems related to protecting the cell from the 
oxidative stress that is commonly observed in the disease as suggested by the elevated 
levels of oxidized proteins in post-mortem examinations (Subbarao et al., 1990, 
Balazs and Leon, 1994, Lovell et al., 1995, Sayre et al., 1997). Several studies showed 
that calcipressin has beneficial effects in the short term in presence of stress 
conditions originated from accumulation of oxygen radicals (Ermak et al., 2002). 
However the chronic expression of the protein seems to induce irreversible damage 
and therefore to the progression of the degenerative condition (Ermak et al., 2001, 
Ermak and Davies, 2002, Ermak et al., 2002, Ermak and Davies, 2003).  
The DSCR1-mediated cellular response to oxidative stress in AD seems to activated 
by release of Ca2+ in the cytoplasm (Crawford et al., 1997, Leahy et al., 1999). 
Therefore we can hypothesize that the well-described accumulation of Ca2+ in DCM 
hearts triggers the expression of DSCR1 to achieve a transient protective effect for the 
cardiomyocytes. In particular calcipressin seems to directly inhibit the calcineurin 
signal transduction pathway, by blocking the capacity of the protein to allocate in the 
Ca2+-calmodulin-dependent serine/threonine phosphatase holoenzyme (PP2B), in 
which it represents the catalytic subunit (Fuentes et al., 2000).  
The calcineurin A pathway is a highly conserved transduction system in eukaryotes 
(Liu et al., 1991) and seems to have an important function in triggering cellular 
reactions in response to several extracellular stimuli.  In neurons the pathway appears 
to be related to the creation of memory (Barinaga, 1998, Zhuo et al., 1999) and to 
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apoptosis (Asai et al., 1999, Honig and Rosenberg, 2000). The role and the effects of 
the activation of this pathway in the heart are still debated: some reports associated 
calcineurin to cellular growth and to hypertrophy (Molkentin et al., 1998, De Windt et 
al., 2001), while other groups demonstrated the capacity of the protein to induce 
apoptosis of the cardiomyocytes by dephosphorylating BAD (Saito et al., 2000, Wang 
et al., 2002).  
Overexpression of DSCR1 has also been detected in the adult heart as a response to 
mechanical stress conditions such as pressure overload-induced hypertrophy. This 
suggests that DSCR1 might have a  role as a negative feedback mechanism regulating 
the activity of calcineurin (Dorn, 2001, Rothermel et al., 2001, Wang et al., 2002, Ni 
et al., 2006). In fact, transgenic murine models overexpressing DSCR1 showed 
reduced hypertrophic response to exercise and adrenergic stimulation and, in the long 
term, significantly lower probability of progression towards a failing condition. In 
DSCR1(-/-) knockout mice, instead, the absence of the calcipressin aggravated the 
hypertrophic response to the activation of the calcineurin pathway and no significant 
alteration of the development of hypertrophy was observed as consequence of chronic 
adrenergic stimulation and of pressure overload.  
 
According to several studies the cardioprotective role of DSCR1 might be related to a 
chaperon-like function associated to calcipressin (Crawford et al., 1997, Leahy et al., 
1999). Interesting observations on the analysis of the amino acid sequence of the 
protein showed the presence of regions highly homologous to chaperones belonging 
to the glucose-regulated protein (grp) class, which, similarly to DSCR1, have been 
extensively described to be induced by alterations of Ca2+ homeostasis (Leahy et al., 
1999). In addition, calcipressin has been showed to share the same localization pattern 
of grp78, the most abundant of the grps: in absence of stress stimuli the protein is 
concentrated in the perinuclear area and in the cytosol, while during stress conditions 
the protein is translocated to the endoplasmic reticulum, where calcipressin can 
accomplish its hypothetical chaperon activity (Leahy and Crawford, 2000).               
 
Other investigators reported involvement of calcipressin in the regulation of the cell 
cycle and proliferation: the overexpression of DSCR1 has been described to be 
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associated to an arrest in the cell cycle in G1-phase (Leahy and Crawford, 2000) 
which might be mediated by direct action of calcipressin on the proteins involved in 
the progression of cell cycle, i.e., cyclins and cyclin-dependent kinases (CDKs).  
 
In our specific case the upregulation of DSCR1 specifically observed in DCM 
samples might be part of an adaptive response to chronic stress conditions including 
alterations of Ca2+ homeostasis or the accumulation of unfolded peptides we described 
in chapter 3. Alternatively, we can speculate that the upregulation of DSCR1 is a low-
penetrance genetic alteration that produces inhibition of the hypertrophic remodeling 
of the heart normally mediated by calcineurin and downregulation of CDKs in 
presence of stress conditions or other genetic factors. This last hypothesis is supported 
by our experimental data in which we could observe a significant decrease of the 
cyclin-dependent kinase inhibitor 3 (CDKN3), a dual-specificity phosphatase that 
interacts with both cdc2 and CDK2 (Hannon et al., 1994). These two proteins control 
the progression of the cell cycle respectively from G2 to M phase and from G1 to S 
phase (Liao et al., 2001). Their levels are usually elevated during cardiac development 
in the embryonic and neonatal stages; however their expression progressively 
decreases to basal levels during adulthood (Kang et al., 1997) and their role in 
terminally differentiated non-proliferating cell is still unclear. Results obtained from 
different in vitro models including neonatal cardiomyocytes suggested that cdc2 and 
CDK2 are involved in the initiation of the apoptotic process (Meikrantz et al., 1994, 
Hiromura et al., 1999). However other studies reported that CDK activity is required 
in neonatal cardiomyocytes for the hypertrophic response to serum stimulation 
(Tamamori et al., 1998). These data are supported by the analysis of cardiac tissue 
deriving from transgenic mice overexpressing CDK2, in which the heart showed an 
increase in mononucleated cardiomyocytes and exacerbated hypertrophic response to 
pressure overload with no change in the proportion of mononucleated cells. 
Interestingly, the CDK2-mediated apoptosis initiation seems to be related to the 
activation of caspase 3, with no participation of the calcineurin pathway. Therefore 
the downregulation of the CDK2 inhibitor we observed in our results in DCM 
samples might be compatible to increased apoptotic signals that lead to further 
degeneration of the cardiac tissue.        
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An additional interesting observation on the function of DSCR1 was recently reported 
by Dr. Ryeom’s group (Baek et al., 2009). DS patients seem to have lower incidence 
of tumors than the normal population and the cancer protection activity seems to be 
specifically achieved by the overexpression of calcipressin. The occurrence of cardiac 
tumors is usually a rare event. Therefore we can speculate that DSCR1 is 
overexpressed in the heart during the aging process in order to prevent the formation 
of tumor masses in the organ. However the long term overexpression of the gene 
combined with other still unknown factors might lead to the alterations leading to 
DCM. 
 
In conclusion, in the vast majority of the cases DCM is a multi-factorial disease in 
which multiple genetic defects and environmental factors combine producing 
progressive dilatation of the heart and contractile dysfunction. The identification of 
specific factors involved in the etiology of this condition represents an important goal 
for understanding the alterations in that portion of patients that are still categorized as 
idiopathic. This will lead to considerable advancements in the recognition of risk 
factors as well as in early detection of the disease and in the development of new 
therapeutic approaches. The study we performed used high throughput technologies to 
obtain a complete picture of the expression pattern of DCM, focusing in particular on 
the determination of those aspects that specifically characterize DCM from other 
cardiomyopathies. Our results show interesting involvement of genes related to 
neurodegenerative diseases and to the development of the nervous system and suggest 
new intriguing therapeutic possibilities to explore in the future.    
 
5.3.1 Limitations 
Although microarrays represent an attractive method for obtaining the most complete 
and detailed picture of the transcriptome available with current technologies, we have 
to consider some limitations of the technique. First, the alterations detected by 
microarray do not always correspond to actual alteration in protein levels since a 
considerable number of regulatory steps are present between the mRNA maturation 
and the functional protein. These include translational regulation, folding, post-
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translational modification, transport to the correct subcellular location and stability of 
the protein. 
A second limitation of microarrays derives from the significant occurrence of false 
negative and false positive detection. It has been estimated that a good quality 
microarray analysis is biased by at least a 5% intrinsic error due to technological 
limits (Firestein and Pisetsky, 2002, Hindmarch et al., 2006). This percentage is even 
higher in the case when low amount of starting material is available and the 
investigators are forced to introduce an RNA amplification step that might 
preferentially amplify particular subsets of messengers. It is therefore important to 
validate the results obtained from RNA chips using more reliable techniques such as 
qRT-PCR. However the amount of data generated by a microarray analysis is usually 
extensive and the validation step is usually limited to selected genes of interest. In our 
specific study we could confirm 87.5% of the selected genes, even if we obtained 
confirmation of the quality of the analysis from the hierarchical clustering of the 
samples for the genes that we defined as amyloidosis-, DCM- and failing- specific, in 
which we showed a clear separation of the patients in the 3 different groups analyzed.  
Of note our analysis could not confirm the majority of expression alterations 
previously described by other authors in heart failure, with the exception of ANP and 
BNP (Barrans et al., 2002, Chen et al., 2002). This discrepancy might be attributed to 
several factors including the use of different genechip platforms and the strict cut-off 
threshold (2-folds) we adopted for processing the data. The adoption of less restrictive 
parameters (cut-off threshold=1.5 fold) on a limited number of messengers previously 
described allowed the confirmation of earlier reported HF-related genes such as 
lumican. This approach would allow the identification of larger numbers of messenger 
for each group we analyzed, although it would also introduce several technical 
difficulties in term of validation and analysis of the results.  
Further inconsistencies between different microarray-based studies also arises from 
the biological variability between the individuals analyzed and their stage of the 
disease. This represents a major limitation not only for the meta-comparisons, but also 
for the analysis of the data of a single study. To minimize this error we specifically 
selected samples that were matched for the age, gender and, when possible, for 
ethnicity. However further variability was introduced by other factors which we 
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couldn’t verify especially for the non-failing samples, of which limited clinical history 
was available. These include the presence of concomitant pathological conditions and 
social habits such as diet and smoking (Bristow, 2003). 
 
A final limitation affecting microarray-based analyses as well as other high 
throughput studies is related to the extensive statistical processing that is normally 
applied to this type of data (Storey and Tibshirani, 2003). This complex issue, which 
has been referred as multiple testing problem, derives from the intrinsic probability 
that the statistical analysis applied to every gene represented on the microarray chip 
can lead to an erroneous conclusion (Pounds, 2006). While this probability has 
minimal effects on traditional approaches due to the limited amounts of genes 
analyzed, significant issues arise when instead one or more entire pathways are 
considered without the possibility of analyzing multiple biological replicates because 
of the limited material available or the costs associated to the analysis. Although this 
problem can be partially addressed by introducing stricter significance cutoff 
thresholds for each gene considered, the occurrence of false positives and false 
negatives still can not be ignored and several analytic methods have been developed 
to estimate the robustness of a study. Based on these considerations, the results 
obtained from high throughput studies such as the observation we report in this 
chapter should be seen as preliminary data regardless of the statistical method used 
for the analysis and should be followed by more focused functional validation. 
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Final considerations 
 
In some cases cardiovascular diseases can be prevented, but in some others our 
knowledge of the detailed molecular aspects and involved pathways is still 
fragmentary and requires further investigation. 
In the last five years a significant number of publications describing the involvement 
of the UPR in several cardiac conditions have appeared, confirming this pathway as a 
common alteration for a continuously increasing number of human pathologies. 
Evidences of activation of the UPR including increased XBP-1 mRNA splicing and 
overexpression of GRP78 have been clearly demonstrated after inducing hypoxia in 
isolated rat neonatal cardiomyocytes as well as general increased expression of 
several UPR components have been described in cardiomyocytes derived form the 
peri-infarcted area both in humans and in murine models of ischemic heart disease. 
These observations have been related to a protective role of the UPR components 
against the ischemic insult. In particular, recent studies show that the ATF6 arm of the 
UPR seems to have significant effect on the expression of GRP78 and GRP94, with 
consequent beneficial effects on the cardiomyocyte. However, other reports showed 
that longer exposures to the hypoxia activate other pathways of the UPR such as the 
CHOP- and caspase 12-mediated apoptosis and that the survival of the cell depends 
almost completely on the intensity and duration of the ischemic event.  
Similar observations have been reported also for heart failure and DCM, including the 
increase of GRP78 levels and morphological modifications of the ER, which suggest 
the presence of an overload process. Interestingly, studies conducted on mice after 
aortic banding showed the activation of the CHOP signaling pathway only in the 
failing hearts but not in the hypertrophic, which confirms the hypothesis that the 
UPR-induced apoptosis is initiated by persistent ER stress conditions and UPR 
activation.  
It is interesting to observe that the heart seems to be one of the most sensitive organs 
to the negative effects of prolonged activation of the UPR.  In fact, animal studies 
showed that the induction of alterations of the normal vescicular traffic leads to the 
accumulation of ubiquitinated proteins in the ER, producing a situation of stress and, 
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eventually, DCM with no obvious alterations in other organs. Similarly, clinical 
reports showed that the administration of proteasome inhibitors such as bortezomib 
(which are normally used in the treatment of cancer and systemic amyloidosis) 
produce toxic effects on the heart and leads to the development of a severe acute 
failing condition similar to DCM.  
Additional confirmation of the role of the protein folding control has been reported in 
desmin-related cardiomyopathy, in which the work of J. Robbins and collaborators 
elucidated the presence of electron-dense granulofilaments characterized by the β-
sheeted structure typically observed in other amyloid-related pathologies. These 
deposits were associated to anomalies of α-β crystallin, eventually leading to the 
incapacity of this chaperone to control the appropriate folding of desmin and 
progressive impairment in degradation of the aberrant peptides.   
 
In the previous chapters we described our findings related to idiopathic dilated 
cardiomyopathy, one of the main causes of heart failure. In particular our results show 
for the first time the presence of thioflavin-S-positive and electron-dense aggregates 
of proteinaceous material in the cytosol of cardiomyocytes affected by the disease, 
which formed intracellular fibers similar to the structures normally observed in the 
amyloid deposits of several conditions related to the accumulation of unfolded 
proteins. Our experiments demonstrated that the presence of these structures is 
associated to a general activation of the cellular mechanisms involved in the control 
of the accumulation of unfolded peptides including transcription factors (ATF6), 
chaperones (GRP78 and GRP94) and peptides involved in the activation of the 
apoptotic cascade (CHOP and Caspase 12), which may explain the diffuse apoptotic 
process normally observed in late-stage DCM cardiac samples. 
Although in the past the expression of pro-amyloigenic peptides such as polyQ-
huntintin has been positively associated to the development of heart failure, our study 
demonstrated the presence of mature amyloid structures and pre-amyloid precursors 
(oligomers) of endogenous nature, which seem able to produce devastating effects on 
the cardiomyocytes and on the contractile function. Our results from isolated murine 
cardiomyocytes showed that this toxicity seems to be mediated through significant 
alterations in Ca2+ handling, which led to increased velocity of Ca2+ release from the 
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SR and systolic cytoplasmatic Ca2+ content. These data reflect what has been 
observed in amyloid-associated neurodegenerative diseases such as Alzheimer’s 
disease. In fact, several studies in the AD research field demonstrated the presence of 
several interactions between the γ-secretase complex and cardinal molecules involved 
in the intracellular Ca2+ regulation, such as RyR and SERCA. In our study we 
confirmed the presence of direct interaction between the cardio-specific form of 
SERCA and Presenilin 1 by co-immunoprecipitation. In addition, we were able to 
show significant alterations of the presenilin levels in DCM-affected hearts, which 
might be correlated to genomic alterations leading to altered expression levels, 
instability or defective function. In particular the genomic analysis of our sets of 
patients identified two previously described AD-related mutations in the codifying 
sequence (A953G in PS1 and G185A in PS2) and two new polymorphisms in the 
promoter region of the PSEN1 gene (-92delC and -21G→A). We characterized these 
two new SNIPs using an in vitro reporter assay and our results showed that the 
presence of either of these two alterations produces dramatic reduction of the 
expression of the protein encoded downstream (respectively 75% for -92delC and 
32% for -21G→A).  
 
These observations represent interesting and innovative findings in the DCM field. 
Nonetheless, the identification of the protein(s) forming the amyloid species is still of 
primary importance. In this regard our strategy was based on a series of different 
methods to obtain tissue lysates enriched in insoluble aggregates (fibers) or in soluble 
oligomers. Our analysis was structured to start from relatively simple techniques 
involving the analysis of the whole tissue lysates on gels optimized for the separation 
of large protein complexes (DADT-PAGE and agarose). However, this approach did 
not produce any significant result. Therefore, our experiment focused on the 
elaboration of new protocols to isolate amyloid fibers (by taking advantage of the 
specific density of these structures) and oligomers (by co-immunocoprecipitating the 
aggregates with antibodies recognizing their specific three-dimensional structure). 
These techniques were ultimately paired to a mass-spectrometry analysis to identify 
the peptides present in the purified products. In particular the immunoprecipitation of 
the oligomeric forms allowed the identification of a peptide called ankyrin repeat 
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domain-containing protein 18A, which, at the moment, has not been associated to any 
recognized significant biological role. Therefore, additional investigation on the 
functions of this protein in the normal heart needs to be conducted to understand its 
involvement in DCM.    
 
Although we were not able to specifically identify the protein(s) directly involved in 
the amyloid deposition process through biochemical analysis, our findings opened 
new and intriguing perspectives for the analysis of DCM. For example, we proposed 
an innovative analytical approach in which we attempted to focus on DCM-specific 
genes by comparing the DCM transcriptome with the transcriptional profile of 
restrictive heart failure associated to systemic amyloidosis. This analysis led to the 
identification of a limited set of purely DCM-specific genes which are not altered by 
the deposition of amyloid products and are not related to the development and 
progression of the failing condition. 
For this study we adopted a high-throughput method such as RNA microchip, using 
the most comprehensive array currently on the market, which recognized the levels of 
expression of over 50,000 ESTs. The analysis of this vast amount of data led to the 
identification of a very limited set of iDCM-specific ESTs (13 in total, which were 
associated to 10 known genes) and, in parallel, to the identification of 200 failing-
associated EST (representing 138 known genes) and 52 amyloidosis-specific 
sequences (representing 41 known genes).  
Interestingly, the gene-ontological analysis of the DCM-specific ESTs showed that 
the only significantly recognizable cluster of genes included sequences normally 
correlated to the neuro-developmental process, such as nestin and DSCR-1. The latter, 
in particular, seems related to a chaperone-like activity that might be evoked by the 
intracellular Ca2+ dysregulation and by the toxicity produced by the accumulation of 
unfolded peptides. However, several studies showed that overexpression of DSCR-1 
in the long term could have deleterious effects by inhibiting hypertrophy and by 
initiating the degeneration towards the failing process. 
 
Of note, in this study we were able to observe significant and intriguing common 
features between Alzheimer’s disease and iDCM, which included the deposition of 
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amyloid, the alterations in the APP processing pathway and the overexpression of 
DSCR-1. These findings can be interpreted as a consequence of the exponential 
increase in the lifespan of human beings in the last century associated to the 
progressively ameliorating conditions of life. In fact, the occurrence and progression 
of degenerative disease such as AD or DCM might be considered as a degeneration of 
the cellular aging process, which normally become manifest as defects in the cellular 
catabolic processes and accumulation of senile plaques. In fact it is commonly 
accepted that the proteosomal function consistently decreases with age, especially in 
tissues rich in terminally differentiated cells with low regenerative capacity such as 
the CNS and the heart. This process seems to be associated to alterations in the 
subunit composition of the proteasome and/or to post-transtlational modifications, 
with correlates with the progressive accumulation of oxidized proteins. Similar age-
depending degeneration has been observed also in the lysosome, the other major 
catabolic apparatus of the cell. This process seems to be totally due to unknown 
epigenetic reasons and appears to be totally independent from the presence of 
defective lysosomal enzymes. As the lysosome seems to have a significant role in the 
removal of aberrant proteins and, in particular, of proteins prone to the formation of 
aggregates, the progressive degeneration of the organelle activity can produce 
reduction of the autophagy process and gradual accumulation of oligomeric species 
with deleterious effects on the cell. A significant confirmation of this concept in 
cardiomyocytes derives from Nakai et al. recent work, in which the authors showed 
that perturbation of the autophagy process by inhibiting proteins of the Atg family 
produces severe cardiac alterations in animal models eventually leading to the 
development of DCM.  
The degeneration of the lysosomal activity has been visually associated to the 
accumulation of lipofuscin, which are degradation-resistant pigments of 
heterogeneous nature containing portion of proteins linked by aldehyde bridges 
originating from lipid-derive peroxides. However, at the moment several theories are 
still debated regarding whether these molecules have any significant impact on any 
cell function or are completely inert.    
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The role of the catabolic pathways in the heart has been also shown in a series of 
hereditary disease involving lysomal defects, such as Fabry, Pompe or Danon, in 
which heart insufficiency has been described to occur earlier. 
Unfortunately, at the moment our knowledge of the mechanisms involved in these 
processes is very limited although several groups are already investigating these 
different aspects of the aging process in order to find useful clues for deciphering the 
etiology of several diseases that are still not completely understood. However we 
consider that this topic will receive even more attention in the next decades as the 
world population’s life expectancy is supposed to increase even further and aging-
related disease will represent a major social problem in the developed countries. 
 
In conclusion, we can say that our work has shed new light on the etiology of 
idiopathic dilated cardiomyopathy by linking the disease to the accumulation of 
intracellular amyloid species, a process that seems to be involved in several other 
degenerative diseases. Although we were not able to identify a specific candidate as a 
target for an innovative therapeutic approach, our study opens new and intriguing 
topics in DCM-related research. Among these we consider of particular importance 
for future studies the determination of the causative nature of the accumulation of 
unfolded proteins: although our data clearly show the significant degenerative effects 
of oligomer accumulation on cardiomyocytes, we were not able to clarify whether the 
presence of these molecular forms just reflects a general cellular dysfunction due to 
the pre-existence of a different pathological state and/or molecular alteration.   
 
 
6.1 Limitations and future directions 
 
Although we were able to report some innovative findings in the iDCM field, we are 
aware that our analysis is characterized by major limitations mainly due to the 
typology of the samples used in the study and to technical limits of the technologies 
currently available.    
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In fact, during the interpretation of the results presented in this book we should 
consider with particular attention that the samples used for the experiments described 
were mostly derived from late-stage iDCM patients, in which the cellular functions 
are usually significantly compromised. Thus, we can’t exclude that impairment in the 
Ca2+ handling in the cell may be a pre-existing condition with deleterious effects on 
the folding apparatus, eventually leading to the formation of the aggregates we 
reported. Therefore, it would be of interest to investigate the presence of these 
anomalies in early-stage DCM that, unfortunately, were not available in the tissue 
bank from which we obtained our samples. Additional confirmations of the possible 
role of cellular Ca2+ anomalies on the generation of ER stress, activation of the UPR 
and, eventually, formation of amyloid forms may derive from the analysis of 
resections obtained from hypertrophic hearts and chronic valve diseases, which also 
present Ca2+ handling impairment. 
  
We also consider that further significant information on the etiology of DCM and on 
the role of the APP processing machinery in the heart could derive from the analysis 
of cardiac samples from AD patients, as our observations support previous data 
showing DCM-related alterations in the presenilin genes. In fact, no clinical reports 
describing the cardiac characteristics of AD patients have been published to date to 
our knowledge, mostly because the aggravation of the health conditions of these 
subjects is generally clinically associated to the degeneration of the neural function. In 
particular, it would be interesting to evaluate the cardiac function of late-stage 
patients to determine the presence of cardiac alterations and DCM signs, while post-
mortem analysis of the cardiac tissue will reveal the presence of amyloidosis and UPR 
activation.  
In addition, several observations of UPR activation and ER stress have been reported 
in the last few years in patients and animal models of ischemic heart disease and 
cardiac hypertrophy. Therefore, it will be of relevant interest to verify whether any of 
the phenomena we reported in DCM is present in different cardiac conditions or it is 
peculiar to the disease we examined.  
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A second limitation to our study derives from our incapacity to identify the peptides 
involved in the intracellular aggregates mainly due to technical difficulties. We still 
believe that a better understanding of the causes underlying idiopathic DCM could be 
achieved though characterization of the protein(s) involved in the amyloid deposits in 
cardiomyocytes. Therefore, we consider this step a primary goal for future 
developments of the work described in this volume.  
The experimental protocols we investigated showed several technical limitations 
mainly related to the large variety of proteins expressed in the myocardium, which 
could not be resolved by enriching the lysates in the oligomeric and amyloid species. 
In addition, we should consider that the use of late stage-DCM samples implies the 
presence of a terminally compromised folding and quality control processes in the 
cardiomyocytes and, consequently, the accumulation of unfolded protein deposits 
composed by peptides not necessarily amyloidogenic.  
A second major technical limitation derives from our complete lack of information 
regarding the solubility of the peptides involved in the aggregates and their resistance 
to detergents. In fact we think that the high background we obtained from the mass 
spectrometry-based analysis of our lysates is mainly due to the presence of 
contaminants not characterized by amyloid structures, which could have been 
removed form the solution with the use of mild detergents. An alternative approach to 
obtain better resolution of the different proteins present in our lysates is represented 
by the use of 2D gel instead of the linear PAGE we adopted. However at the moment 
this strategy is still highly inconvenient for the large requirements in starting material 
and the costs associated to the post-separation analysis. 
 
Besides the development of methods to resolve the issues we encountered during our 
experimental process, our results opened a new interesting field of investigation 
which will be useful for a more detailed comprehension of iDCM and the aging 
process in the heart and will facilitate the generation of new diagnostic tools and 
therapeutic approaches.   
In particular, one of the major limitations currently limiting iDCM research consists 
in the absence of convenient spontaneous animal models, which still represent critical 
tools for basic and translational research. 
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In the past three decades, several investigators have developed a large number of 
rodent and large animal models which mimic the signs typically observed in the 
human condition. One of the most common models currently available for rodents 
consists of inducing pressure overload by surgical banding of the ascending aortic 
tract, which leads to compensated hypertrophy that eventually degenerates into dilated 
cardiomyopathy. Alternatively, a large number of transgenic and knock-out models 
has been developed and characterized especially in mice.  
Although these models provided invaluable support for increasing our knowledge on 
several aspects and molecular mechanisms involved in iDCM, they represent good 
models only for the study of the clinically manifest phases of iDCM, due to the scarce 
information regarding the etiology of the disease currently available. 
As the results we report in this thesis enhance our knowledge of the possible 
mechanisms involved in the development of iDCM, it will be interesting to evaluate 
the effects of the alterations we report in transgenic models. In particular a large array 
of transgenic mice carrying alterations related to APP processing has been developed 
for Alzheimer’s disease research. The characterization of the cardiac function and 
UPR system in these animals may be able to provide significant confirmation of our 
results and, at the same time, provide new useful tools for iDCM research. 
 
The complete delineation of the molecular mechanisms related to a specific 
pathological condition is a critical step for designing more efficient diagnosis 
protocols and more effected and targeted therapeutic approaches. In particular the 
study we described suggests novel and interesting aspects of iDCM which appear to 
have significant importance for the etiology and the development of the disease. 
More detailed analysis of these characteristics will lead to the identification of new 
non invasive protocols for early diagnosis of DCM and therefore to the possibility of 
early and more effective treatments. In particular the identification of a larger subset 
of DCM-specific mutations such as the PSEN alterations we described in chapter 3 
will allow the development of easy genetic screening, which, as we expect the number 
of mutations to grow, will be excellent candidates for the development of high 
throughput diagnosis techniques such as single nucleotide polymorphism microarrays. 
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In addition, we consider that critical improvements to early diagnosis of DCM will 
also derive from the identification of the specific proteins(s) involved in the formation 
of oligomers and fibers. In fact this will allow the development of ligands which 
specifically bind the aggregating species and which will be of significant utility for 
non-invasive imaging analysis such as magnetic resonance or positron emission 
tomography. 
A second important perspective deriving from the identification of the pro-amyloid 
protein(s) consists of the possibility of developing assays for the detection of the 
involved peptides in the body fluids, as we can speculate that the accumulation of the 
proteins(s) involved in the formation of the oligomeric and amyloid species may be 
associated to the release in the circulation of specific amyloigenic peptides similarly 
to what is currently under debate for plasma Aβ in AD.  
 
Other interesting perspectives deriving from the observations we report in this thesis 
are related to the development of new therapies aimed to limit the accumulation of 
oligomers, by directly downregulating the protein(s) involved in the formation of the 
amyloid prefibrillar forms or by stimulating and enhancing the activation of the 
cellular mechanisms related to the resolution of unfolded protein-induced stress 
conditions. Alternatively, a different approach for the identification of new 
therapeutic approaches could be based on a more detailed characterization of the 
mechanisms involved in the manifestation of the toxic effect related to the 
accumulation of unfolded proteins, in order to identify specific targets to inhibit the 
activation of the UPR cascade steps that lead to cell dysfunction and, eventually, to 
apoptosis.  
As we demonstrated that iDCM presents several common aspects with other forms of 
amyloidosis, we can speculate that the therapeutic approaches in development for this 
group of diseases may present some relevant effects also on iDCM. Unfortunately, no 
efficient therapy is available for most amyloid-based conditions at the moment; 
however the recognition of the molecular mechanisms generating the accumulation of 
oligomers and involved in the toxicity of these molecular species will allow a process 
currently largely adopted by pharmaceutical companies for fast identification of 
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potential new drugs, which is based on the screening of large libraries of small 
molecules to identify the compounds that interfere with specific processes. 
Alternatively, other innovative therapeutic approaches may arise from applications of 
interesting studies emerged in the last few years and showing the importance of 
cutting-edge technologies such as gene silencing for the downregulation of 
overexpressed protein using small interfering (si) RNA. However, at the moment this 
approach is still affected by significant limitations, including the efficiency and 
specificity of the in vivo delivery of the siRNA molecules and the variable silencing 
effect. 
 
 
In summary, the study we presented shows the critical role of unfolded proteins in the 
development of DCM and, in particular, the deleterious effects of the accumulation of 
oligomers on contractility and Ca2+ handling. This process eventually leads to severe 
impairment of the folding apparatus of the cardiomyocyte which appears to activate 
the Chop- and Caspase 12-mediated apoptotic pathway. In addition we identified two 
novel mutations in the presenilin 1 promoter which seem to induce alteration of the 
expression of the gene with possible effects on the recently proposed regulation of 
this protein on SERCA2a. 
On the basis of these observations, we developed an innovative 3-group analysis of 
the global transcriptosome which analyzed simultaneously the expression levels in 
DCM, non-failing and amyloidosis-affected individuals. This approach allowed the 
identification of a very limited number of DCM-specific messengers by distinguishing 
them from transcripts related to the progression of the failing process and mRNA 
induced by the accumulation of unfolded proteins. Interestingly these included 
DSCR1 and Nestin, two genes normally associated to the development of the neural 
system. 
Although these findings creates new and intriguing fields of investigation, further 
analyses are still required to identify the protein(s) involved in the formation of the 
aggregates we reported and to elucidate whether these unfolded structures are 
causative of the Ca2+ dysregulation observed in DCM or if they simply represent a 
consequence of it. 
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